Author Index to Volume 31*

A

Abadi U (see Nagler A et al). 2000;31:641-648
Abe Y (see Kawai H et al). 2000;31:1246-1250
Abergel A (see Pol S et al). 2000;31:1338-1344
Abo T (see Minigawa M et al). 2000;31:907-915
Abrahamsson A (see Axelson M et al). 2000;31:1305-1312
Adams O (see Erhardt A et al). 2000;31:716-725
Adams PC, Kertesz AE, McLaren CE, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: A comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. 2000;31:1160-1164
Agarwal K, Czaja AJ, Jones DEJ, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. 2000;31:49-53
Agellon LB, Walkey CJ, Vance DE, Kuipers F, Verkade HJ. Role of the CDP-choline and the alternative pathway for phosphatidylcholine biosynthesis. 2000;31:543 (Correspondence)
Ahn SH, Han K-H, Park JY, Lee CK, Kang SW, Chon CY, Kim YS, Park K, Kim DK, Moon YM. Association between hepatitis B virus infection and HLA-DR type in Korea. 2000;31:1371-1373
Akagi R, Shimizu R, Furuyama K, Doss MO, Sassa S. Novel molecular defects of the δ-aminolevulinate dehydratase gene in a patient with inherited acute hepatic porphyria. 2000;31:704-708
Akremi R (see Martinot-Peignoux M et al). 2000;31:726-729
Alarcon WH (see Su GL et al). 2000;31:932-936
Albano E (see Carini R et al). 2000;31:166-172
—(see Rolla R et al). 2000;31:878-884
Alberti A (see Calabrese F et al). 2000;31:1153-1159
—(see Belli LS et al). 2000;31:1345-1350
Albillos A (see Pérez-Paramo M et al). 2000;31:43-48
Albrecht J (see Poynard T et al). 2000;31:211-218
Alcalde MP (see Macias RIR et al). 2000;31:975-983
Alderman B (see Ko CW et al). 2000;31:18-23
ALGOVIRC Project Group (see Poynard T et al). 2000;31:211-218
Allen MI (see Hunt CM et al). 2000;31:1037-1044
Alpini G (see Kanno N et al). 2000;31:555-561 (Concise Review)
Alter MJ (see Armstrong GL et al). 2000;31:777-782
Alvarez W (see Brandhagen DJ et al). 2000;31:456-460
Alvaro D (see Kanno N et al). 2000;31:555-561 (Concise Review)
Ames PRJ (see Amitrano L et al). 2000;31:345-348
Ameti DI (see Murphy EL et al). 2000;31:756-762
Aminlari A (see Su GL et al). 2000;31:932-936
Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D'Andrea G, Marmo R, Ames PRJ, Balzano A. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. 2000;31:345-348
Amodio P (see Merkel C et al). 2000;31:324-329
Anbari MA (see Chalasani N et al). 2000;31:7-11
Andreasen F (see Jonassen TEN et al). 2000;31:1224-1230
Andreu V (see Castañeda B et al). 2000;31:581-586
Angeli P, Jiménez W, Veggian R, Fasolato S, Volpin R, MacHenzie HS, Craighero R, Libera VD, Sticca A, Arroyo V, Gatta A. Increased activity of guanosine 3′-5′-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites. 2000;31:304-310
Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. 2000;31:318-323
Ankoma-Sey V, Wang Y, Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. 2000;31:141-148
Ansari AA (see Reynoso-Paz S et al). 2000;31:24-29
Aoyagi Y (see Kawai H et al). 2000;31:1246-1250
Arian CL (see Lee AY et al). 2000;31:1327-1333
Aricó S (see Rolla R et al). 2000;31:878-884
Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. 2000;31:777-782
Arora S (see Jamal MM et al). 2000;31:813 (Correction)
Arroyo V (see Angeli P et al). 2000;31:304-310
Asakura H (see Kawai H et al). 2000;31:1246-1250
Ashihara T (see Ochiai T et al). 2000;31:615-621
Ausina V (see Pardo A et al). 2000;31:858-863
Auster A (see Iraburu MJ et al). 2000;31:1086-1093
Axelson M, Ellis E, Mörk B, Garmark K, Abrahamsson A, Björkhem I, Ericzon B-G, Einarsson C. Bile acid synthesis in cultured human hepatocytes: Support for an alternative biosynthetic pathway to cholic acid. 2000;31:1305-1312
Ayi K (see De Francheschi L et al). 2000;31:997-1004
Ayuso C (see Llovet JM et al). 2000;31:54-58

B

Badve S (see Thiese ND et al). 2000;31:235-240 (Rapid Communication)
Bagnati M (see Carini R et al). 2000;31:166-172
Bakker CTM (see Paulusma CC et al). 2000;31:684-693
Baldwin BH (see Cote PJ et al). 2000;31:190-200
Baluyut A (see Chalasani N et al). 2000;31:7-11
Balzano A (see Amitrano L et al). 2000;31:345-348
Bamford A (see Adams PC et al). 2000;31:1160-1164
Bañares R, Moitinho E, Bosch J. Carvedilol—A new nonselective beta blocker. 2000;31:810-811
Bandi J-C (see Castañeda B et al). 2000;31:581-586
Bannai M (see Minigawa M et al). 2000;31:907-915
Banner BF (see Fontana RJ et al). 2000;31:730-736
Barajas JL (see Lee AY et al). 2000;31:1327-1333
Baratti D (see Perseghin G et al). 2000;31:694-703
Barr R (see Adams PC et al). 2000;31:1160-1164

*January, 1-254; February, 255-554; March, 555-818; April, 819-1036; May, 1037-1206; June, 1207-1426.

Bartoli R (*see* Pardo A et al). 2000;31:858-863
Bass N (*see* Reynoso-Paz S et al). 2000;31:24-29
Bastie A, Castera L, Roudot-Thoraval F, Dhumeaux D, Pawlotsky J-M. Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: A wrong track. 2000;31:547-548 (Correspondence)
Basuni AA (*see* Ireland JH et al). 2000;31:1176-1182
Bauer I (*see* Bauer M et al). 2000;31:937-947
Bauer M, Bauer I, Sonin NV, Kresge N, Baveja R, Yokoyama Y, Harding D, Zhang JX, Clemens MG. Functional significance of endothelin B receptors in mediating sinusoidal and extrasinusoidal effects of endothelins in the intact rat liver. 2000;31:937-947
Baveja R (*see* Bauer M et al). 2000;31:937-947
Bazer FW (*see* Kim H-T et al). 2000;31:1275-1284
Bazzigaluppi E (*see* Perseghin G et al). 2000;31:694-703
Belli LS, Zavaglia C, Alberti AB, Poli F, Rondinara G, Silini E, Taioli E, de Carlis L, Scalamogna M, Forti D, Pinzello G, Idèo G. Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation. 2000;31:1345-1350
Bellomo G (*see* Carloni V et al). 2000;31:131-140
—(*see* Rolla R et al). 2000;31:878-884
Bellon L (*see* Macejak DG et al). 2000;31:769-776
Benedini S (*see* Perseghin G et al). 2000;31:694-703
Bennoun M (*see* de Coupade C et al). 2000;31:371-380
Benvegnù L (*see* Calabrese F et al). 2000;31:1153-1159
Beresford SAA (*see* Ko CW et al). 2000;31:18-23
Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, Weinberg M. The cost of hepatitis A infections in American adolescents and adults in 1997. 2000;31:469-473
Berr F (*see* Wiedman M et al). 2000;31:230-234
—, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, Wittekind C, Hauss J, Mössner J. Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival. 2000;31:291-298
Berson A (*see* Feldmann G et al). 2000;31:674-683
Berthelot P (*see* Pol S et al). 2000;31:1338-1344
Bertolino P, Klimpel G, Lemon SM. Hepatic imflammation and immunity: A summary of a conference on the function of the immune system within the liver. 2000;31:1374-1378 (Meeting Report)
Bezeaud A (*see* Denninger M-H et al). 2000;31:587-591
Bhopal RS (*see* Howel D et al). 2000;31:1055-1060
Bianchi FB (*see* Bogdanos D-P et al). 2000;31:1380 (Correspondence)
Bianchi L (*see* Llovet JM et al). 2000;31:54-58
Bianchi P (*see* Roncalli M et al). 2000;31:846-850
Bilodeau M (*see* Villeneuve J-P et al). 2000;31:207-210
Bissell DM. Brave new millennium. 2000;31:1-2 (Editorial)
Björkhem I (*see* Axelson M et al). 2000;31:1305-1312
Blatt LM (*see* Macejak DG et al). 2000;31:769-776
Blondin D (*see* Erhardt A et al). 2000;31:716-725
Blum HE (*see* Mohr L et al). 2000;31:606-614
Böcher WO (*see* Rahman F et al). 2000;31:521-527
—, Galun E, Marcus H, Daudi N, Terkieltaub D, Shouval D, Löhr HF, Reisner Y. Reduced hepatitis B virus surface antigen–specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse. 2000;31:480-487
Bogdal J (*see* Borras E et al). 2000;31:984-989
Bogdanos D-P, Muratori L, Bianchi FB, Mieli-Vergani G, Vergani D. Hepatitis C virus and autoimmunity. 2000;31:1380 (Correspondence)
Bogner H (*see* Forman L et al). 2000;31:1029 (Correspondence)
Boiocchi M (*see* De Vita S et al). 2000;31:182-189
Bolder U (*see* Paulusma CC et al). 2000;31:684-693
Bolognesi M (*see* Merkel C et al). 2000;31:324-329
Bolondi L (*see* Piscaglia F et al). 2000;31:349-357
Bonelli G (*see* De Miglio MR et al). 2000;31:956-965
Bonkovsky HL (*see* Fontana RJ et al). 2000;31:730-736
Bordas JM (*see* Escorsell A et al). 2000;31:1061-1067
Borràs E, Coutelle C, Rosell A, Fernández-Muixi F, Broch M, Crosas B, Hjelmqvist L, Lorenzo A, Gutiérrez C, Santos M, Szczepanek M, Heilig M, Quattrocchi P, Farrés J, Vidal F, Richart C, Mach T, Bogdal J, Jörnvall H, Seitz HK, Couzigou P, Parés X. Genetic polymorphism of alcohol dehydrogenase in Europeans: The *ADH2*2* allele decreases the risk for alcoholism and is associated with *ADH3*1*. 2000;31:984-989
Borzio M (*see* Roncalli M et al). 2000;31:846-850
—(*see* Roncalli M et al). 2000;31:1381 (Correspondence)
Bosch J (*see* Bañares R et al). 2000;31:810-811 (Correspondence)
—(*see* Castañeda B et al). 2000;31:581-586
—(*see* Escorsell A et al). 2000;31:1061-1067
Bosma PJ (*see* Paulusma CC et al). 2000;31:684-693
Bourlière M (*see* Pol S et al). 2000;31:1338-1344
Boveris A (*see* Cutrin JC et al). 2000;31:622-632
Boyer JL. Hepatology Highlights. 2000;31:i-ii(Jan), i-ii(Feb), i-ii(Mar), i-ii(Apr), i-ii(May), i-ii(June)
Boyer N (*see* Di Martino V et al). 2000;31:1030-1031 (Correspondence)
—(*see* Martinot-Peignoux M et al). 2000;31:726-729
Bradford BU (*see* Iimuro Y et al). 2000;31:391-398
—(*see* Yin M et al). 2000;31:117-123
Brancaccio V (*see* Amitrano L et al). 2000;31:345-348
Brancatelli S (*see* Cacciola et al). 2000;31:507-512
Brandhagen DJ, Alvarez W, Therneau TM, Kruckeberg KE, Thibodeau SN, Ludwig J, Porayko MK. Iron overload in cirrhosis—*HFE* genotypes and outcome after liver transplantation. 2000;31:456-460
Brashear DL (*see* Schmidt WN et al). 2000;31:737-744
Brass EP (*see* Krähenbühl S et al). 2000;31:1217-1223
Bravo A (*see* Macias RIR et al). 2000;31:975-983
Bréchot C (*see* Pol S et al). 2000;31:548-549 (Correspondence)
—(*see* Pol et al). 2000;31:1338-1344
Brenner D (*see* Iimuro Y et al). 2000;31:391-398
Brewer GJ, Johnson VD, Dick RD, Hedera P, Fink JK, Kluin KJ. Treatment of Wilson's disease with zinc. XVII: Treatment during pregnancy. 2000;31:364-370
Briand P (*see* de Coupade C et al). 2000;31:371-380
Briere J (*see* Denninger M-H et al). 2000;31:587-591
Bringuier A (*see* Feldmann G et al). 2000;31:674-683
Broch M (*see* Borràs E et al). 2000;31:984-989
Brown JJ, Parashar B, Moshage H, Tanaka KE, Engelhardt D, Rabbani E, Roy-Chowdhury N, Roy-Chowdhury J. A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2–deficient mice. 2000;31:173-181
Brown RS Jr (*see* Russo MW et al). 2000;31:358-363

Bruch K (see Sarrazin C et al). 2000;31:1360-1370
Brugnara C (see De Francheschi L et al). 2000;31:997-1004
Bruix J (see Llovet JM et al). 2000;31:54-58
—(see Llovet JM et al). 2000;31:1019-1021
Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond. 2000;31:241-246 (Hepatology at the Millennium)
Bryzman SM (see Murphy EL et al). 2000;31:756-762
Buchler N (see Zdilar D et al). 2000;31:1207-1211 (Concise Review)
Burdick MD (see Colletti LM et al). 2000;31:435-445
Burroughs AK (see Piscaglia F et al). 2000;31:349-357
Burt AD (see Reeves HL et al). 2000;31:95-100
Butterworth RF (see Rose C et al). 2000;31:872-877
Byth K (see Khan MH et al). 2000;31:513-520

C

Cabré E (see Pardo A et al). 2000;31:858-863
Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Villari D, de Franchis R, Santantonio T, Brancatelli S, Colucci G, Raimondo G. Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. 2000;31:507-512.
Cai J (see Kobayashi N et al). 2000;31:851-857
Caini P (see Zignego AL et al). 2000;31:474-479
Calabrese F, Pontisso P, Pettenazzo E, Benvegnù L, Vario A, Chemello L, Alberti A, Valente M. Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. 2000;31:1153-1159
Calhoun B (see Ko CW et al). 2000;31:18-23
Calori G (see Perseghin G et al). 2000;31:694-703
Calvisi DF (see De Miglio MR et al). 2000;31:956-965
Calvo A (see Castilla-Cortazar I et al). 2000;31:592-600
Cammilleri F (see Santucci L et al). 2000;31:399-406
Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. 2000;31:840-845
Cannon B (see Fanning L et al). 2000;31:225-229
Canonico PL (see Storto M et al). 2000;31:649-655
Carbone A (see De Vita S et al). 2000;31:182-189
Carini R, De Cesaris MG, Splendon R, Bagnati M, Albano E. Ischemic preconditioning reduces Na^+ accumulation and cell killing in isolated rat hepatocytes exposed to hypoxia. 2000;31:166-172
Carloni V, Pinzani M, Giusti S, Romanelli RG, Parola M, Bellomo G, Failli P, Hamilton AD, Sebti SM, Laffi G, Gentilini P. Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on Ras in human hepatic stellate cells. 2000;31:131-140
Carman WF (see Ireland JH et al). 2000;31:1176-1182
Carpenter HA (see Czaja AJ et al). 2000;31:1231-1238
Carreño V (see Cotonat T et al). 2000;31:502-506
Carrington M (see Thio CL et al). 2000;31:819-827 (Concise Review)
Carru A (see De Miglio MR et al). 2000;31:956-965
Casadevall N (see Denninger M-H et al). 2000;31:587-591
Casini A (see Galli A et al). 2000;31:101-108
Castañeda B (see Escorsell A et al). 2000;31:1061-1067
—, Debernardi-Venon W, Bandi J-C, Andreu V, Pérez-del-Pulgar S, Moitinho E, Pizcueta P, Bosch J. The role of portal pressure in the severity of bleeding in portal hypertensive rats. 2000;31:581-586
Castells L (see Llovet JM et al). 2000;31:54-58
Castelnau C (see Martinot-Peignoux M et al). 2000;31:726-729
Castera L (see Bastie A et al). 2000;31:547-548 (Correspondence)
Castilla-Cortazar I, Garcia M, Quiroga J, Diez N, Diez-Caballero F, Calvo A, Diaz M, Prieto J. Insulin-like growth factor-1 reverts testicular atrophy in rats with advanced cirrhosis. 2000;31:592-600
—, Quiroga J, Prieto J. Insulin-like growth factor-1, liver function, and hypogonadism in rats with experimentally induced cirrhosis. 2000;31:1379 (Correspondence)
Cavallarin G (see Merkel C et al). 2000;31:324-329
Ceni E (see Galli A et al). 2000;31:101-108
Cerenzia G (see Cacciola et al). 2000;31:507-512
Cerny A, Kammer AR, Chisari FV. Hepatitis C and autoimmune hepatitis. 2000;31:811-812 (Correspondence)
Chait Y (see Denninger M-H et al). 2000;31:587-591
Chakrabarti S (see Adams PC et al). 2000;31:1160-1164
Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H. Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. 2000;31:7-11
Chan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. Hepatitis B e antigen–negative chronic hepatitis B in Hong Kong. 2000;31:763-768
Chang KSS (see Tai D-I et al). 2000;31:656-664
Chatauret N (see Rose C et al). 2000;31:872-877
Chatila R, Ferayorni L, Gupta T, Groszmann RJ. Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. 2000;31:572-576
Chaudhary N (see Macejak DG et al). 2000;31:769-776
Chejfec G (see Gaweco AS et al). 2000;31:1183-1191
Chemello L (see Calabrese F et al). 2000;31:1153-1159
Chen J (see Doctor RB et al). 2000;31:1045-1054
Chen Y-M (see Tai D-I et al). 2000;31:656-664
Cheng C-C (see Wong W-M et al). 2000;31:201-206
—(see Yuen M-F et al). 2000;31:330-335
Chiba T (see Marusawa H et al). 2000;31:488-495
Chien R-N (see Yeh C-T et al). 2000;31:1318-1326
Chisari FV (see Cerny A et al). 2000;31:811-812 (Correspondence)
Chon CY (see Ahn SH et al). 2000;31:1371-1373
Choudhury KR (see Fanning L et al). 2000;31:225-229
Chowdhury JR (see Nagler A et al). 2000;31:641-648
Chowdhury NR (see Nagler A et al). 2000;31:641-648
Christ B, Yazici E, Nath A. Phosphatidylinositol 3-kinase and protein kinase C contribute to the inhibition by interleukin 6 of phosphoenolpyruvate carboxykinase gene expression in cultured rat hepatocytes. 2000;31:461-468
Christensen S (see Jonassen TEN et al). 2000;31:1224-1230
Chu C-M (see Yeh C-T et al). 2000;31:1318-1326
Chuang Y-L (see Tai D-I et al). 2000;31:656-664
Ciliberto G (see Kovalovich K et al). 2000;31:149-159
Cimini AM (see Contreras MA et al). 2000;31:446-455
Cirera I (see Sanchez-Fueyo A et al). 2000;31:496-501
Clavien P-A (see Rüdiger HA et al). 2000;31:533-535 (Editorial)
—(see Selzner M et al). 2000;31:35-42
Clemens MG (see Bauer M et al). 2000;31:937-947
Clouet R (see Cotonat T et al). 2000;31:502-506

Clouston AD (*see* Powell EE et al). 2000; 31:828-833
Coggi G (*see* Roncalli M et al). 2000;31: 846-850
Cohen DE (*see* Rigotti A et al). 2000;31: 538-539 (Hepatology *Elsewhere*)
Colletti LM, Green ME, Burdick MD, Strieter RM. The ratio of ELR+ to ELR– CXC chemokines affects the lung and liver injury following hepatic ischemia/reperfusion in the rat. 2000;31: 435-445
Colucci A (*see* Conte D et al). 2000;31: 751-755
Colucci G (*see* Cacciola et al). 2000;31: 507-512
Condreay LD (*see* Hunt CM et al). 2000; 31:1037-1044
—(*see* Villeneuve J-P et al). 2000;31:207-210
Conrad A (*see* Macejak DG et al). 2000;31: 769-776
Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. 2000;31: 751-755
Contreras MA, Khan M, Smith BT, Cimini AM, Gilg AG, Orak J, Singh I, Singh AK. Endotoxin induces structure-function alterations of rat liver peroxisomes: Kupffer cells released factors as possible modulators. 2000;31:446-455
Copani A (*see* Storto M et al). 2000;31:649-655
Coppel RL (*see* Reynoso-Paz S et al). 2000; 31:24-29
Corrocher R (*see* De Francheschi L et al). 2000;31:997-1004
Corvetti G (*see* Cutrin JC et al). 2000;31: 622-632
Costa J (*see* Sanchez-Fueyo A et al). 2000; 31:496-501
Cosulich SC (*see* Roberts RA et al). 2000; 31:420-427
Cote P (*see* Korba BE et al). 2000;31:1165-1175
—, Korba BE, Miller RH, Jacob JR, Baldwin BH, Hornbuckle WE, Purcell RH, Tennant BC, Gerin JL. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. 2000;31:190-200
Cotonat T, Quiroga JA, López-Alcorocho JM, Clouet R, Pardo M, Manzarbeitia F, Carreño V. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody–positive patients. 2000;31:502-506
Couronné B (*see* Godichaud S et al). 2000; 31:922-931
Coutelle C (*see* Borràs E et al). 2000;31: 984-989
Couzigou P (*see* Borràs E et al). 2000;31: 984-989
—(*see* Marschall H-U et al). 2000;31:990-996
—(*see* Pol S et al). 2000;31:1338-1344
Covarrubias-Pinedo A (*see* Iraburu MJ et al). 2000;31:1086-1093
Crabb D (*see* Galli A et al). 2000;31:101-108
Craighero R (*see* Angeli P et al). 2000;31: 304-310
Crawford AR (*see* Sturm E et al). 2000;31: 124-130
Crawford DHG (*see* Powell EE et al). 2000; 31:828-833
—, Hickman P. Screening for hemochromatosis. 2000;31:1192-1193 (Editorial)
Crawford JM (*see* Sturm E et al). 2000;31: 124-130
—(*see* Thiese ND et al). 2000;31:235-240 (Rapid Communication)
Crewe E (*see* Khan MH et al). 2000;31: 513-520
Crispe IN. Do natural T cells promote liver regeneration? 2000;31:1022-1024 (Editorial)
Crofts N (*see* Rodger AJ et al). 2000;31: 1029-1030 (Correspondence)
Crosas B (*see* Borràs E et al). 2000;31:984-989
Curry MP (*see* Golden-Mason L et al). 2000;31:1251-1256
Cutrin JC, Boveris A, Zingaro B, Corvetti G, Poli G. *In situ* determination by surface chemiluminescence of temporal relationships between evolving warm ischemia-reperfusion injury in rat liver and phagocyte activation and recruitment. 2000;31:622-632
Czaja AJ (*see* Agarwal K et al). 2000;31: 49-53
—, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. 2000;31:1231-1238
—, Manns MP, McFarlane IG, Hoofnagle JH. Autoimmune hepatitis: The investigational and clinical challenges. 2000;31:1194-1200 (Meeting Report)

D

D'Andrea G (*see* Amitrano L et al). 2000; 31:345-348
Dack CL (*see* Reeves HL et al). 2000;31:95-100
Dahl RH (*see* Doctor RB et al). 2000;31: 1045-1054
Dahmen A (*see* Rahman F et al). 2000;31: 521-527
Dai Z (*see* Ankoma-Sey V et al). 2000;31: 141-148
Dammacco F (*see* De Vita S et al). 2000;31: 182-189
Danino D (*see* Konikoff FM et al). 2000;31: 261-268
Das A. Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic tiver transplant recipients. 2000;31:311-317
Daudi N (*see* Böcher WO et al). 2000;31: 480-487
Day CP (*see* Reeves HL et al). 2000;31:95-100
de Carlis L (*see* Belli LS et al). 2000;31: 1345-1350
De Cesaris MG (*see* Carini R et al). 2000; 31:166-172
de Coupade C, Gillet R, Bennoun M, Briand P, Russo-Marie F, Solito E. Annexin I expression and phosphorylation are upregulated during liver regeneration and transformation in antithrombin III SV40 T large antigen transgenic mice. 2000;31:371-380
De Francheschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanzial AM, Solero P, Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. 2000;31:997-1004
de Franchis R (*see* Cacciola et al). 2000;31: 507-512
de Grazia U (*see* Storto M et al). 2000;31: 649-655
de Groen PC. Cholangiocarcinoma in primary sclerosing cholangitis: Who is at risk and how do we screen? 2000;31: 247-248 (Editorial)
De Miglio MR, Muroni MR, Simile MM, Calvisi DF, Tolu P, Deiana L, Carru A, Bonelli G, Feo F, Pascale RM. Implication of Bcl-2 family genes in basal and D-amphetamine–induced apoptosis in preneoplastic and neoplastic rat liver lesions. 2000;31:956-965
De Re V (*see* De Vita S et al). 2000;31:182-189
De Vita S, De Re V, Sansonno D, Sorrentino D, La Corte R, Pivetta B, Gasparotto D, Racanelli V, Marzotto A, Labombarda A, Gloghini A, Ferraccioli G, Monteverde A, Carbone A, Dammacco F, Boiocchi M. Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low-grade lymphoma associated with autoimmine disease and in chronic gastritis. 2000;31:182-189
DeAngelis RA (*see* Kovalovich K et al). 2000;31:149-159
Debernardi-Venon W (*see* Castañeda B et al). 2000;31:581-586
Degos F (*see* Di Martino V et al). 2000;31: 1030-1031 (Correspondence)
Deiana L (*see* De Miglio MR et al). 2000; 31:956-965
DeLeve LD (*see* Wang X et al). 2000;31: 428-434
Delvoux B (*see* Dooley S et al). 2000;31: 1094-1106
Demetris AJ, and an International Panel. Update of the international Banff schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. 2000;31:792-799

Demols A (*see* Le Moine O et al). 2000;31:1266-1274
Demoor F (*see* Le Moine O et al). 2000;31:1266-1274
Dennert G (*see* Liu Z-X et al). 2000;31:665-673
Denninger M-H, Chäit Y, Casadevall N, Hillaire S, Guillin M-C, Bezeaud A, Erlinger S, Briere J, Valla D. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors. 2000;31:587-591
Desalle F (*see* Le Moine O et al). 2000;31:1266-1274
Desmoulière A (*see* Godichaud S et al). 2000;31:922-931
Devière J (*see* Le Moine O et al). 2000;31:1266-1274
—(*see* Louis H et al). 2000;31:381-390
Dhar DK (*see* Nagasue N et al). 2000;31:1107-1114
Dhumeaux D (*see* Bastie A et al). 2000;31:547-548 (Correspondence)
—(*see* Hezode C et al). 2000;31:809 (Correspondence)
Di Bisceglie AM. Natural history of hepatitis C: Its impact on clinical management. 2000;31:1014-1018 (Hepatology at the Millennium)
Di Martino V, Thevenot T, Boyer N, Degos F, Valla D, Marcellin P. Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus–infected patients. 2000;31:1030-1031 (Correspondence)
Diaz M (*see* Castilla-Cortazar I et al). 2000;31:592-600
Dick RD (*see* Brewer GJ et al). 2000;31:364-370
Dickson ER (*see* Angulo P et al). 2000;31:318-323
Diehl AK. Cholelithiasis and the insulin resistance syndrome. 2000;31:528-530 (Editorial)
Diehl AM (*see* Guebre-Xabier M et al). 2000;31:633-640
Diez N (*see* Castilla-Cortazar I et al). 2000;31:592-600
Diez-Caballero F (*see* Castilla-Cortazar I et al). 2000;31:592-600
Doctor RB, Dahl RH, Salter KD, Fouassier L, Chen J, Fitz JG. ATP depletion in rat cholangiocytes leads to marked internalization of membrane proteins. 2000;31:1045-1054
Domenico K (*see* Macejak DG et al). 2000;31:769-776
Domínguez-Rosales J-A (*see* Greenwel P et al). 2000;31:109-116
—(*see* Iraburu MJ et al). 2000;31:1086-1093
Donada C (*see* Merkel C et al). 2000;31:324-329
Donald PJ (*see* Reynoso-Paz S et al). 2000;31:24-29
Donaldson PT (*see* Agarwal K et al). 2000;31:49-53
Donati G (*see* Piscaglia F et al). 2000;31:349-357
Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner AM. Modulation of transforming growth factor β response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. 2000;31:1094-1106
Doss MO (*see* Akagi R et al). 2000;31:704-708
Dõtsch KU (*see* Honscha W et al). 2000;31:1296-1304
Drennan DP (*see* Berge JJ et al). 2000;31:469-473
Dubuisson L (*see* Godichaud S et al). 2000;31:922-931
Durand-Schneider A-M (*see* Feldmann G et al). 2000;31:674-683

E

Eagon PK (*see* Tadic SD et al). 2000;31:1135-1140
Edwards-Smith CJ (*see* Powell EE et al). 2000;31:828-833
Einarsson C (*see* Axelson M et al). 2000;31:1305-1312
Ekataksin W. The isolated artery: An intrahepatic arterial pathway that can bypass the lobular parenchyma in mammalian livers. 2000;31:269-279
Elferink RPJO (*see* Paulusma CC et al). 2000;31:684-693
Ellis E (*see* Axelson M et al). 2000;31:1305-1312
Elm MS (*see* Tadic SD et al). 2000;31:1135-1140
Elsing C (*see* Hübner C et al). 2000;31:562-571
Emi Y (*see* Nagasue N et al). 2000;31:1107-1114
Enders G (*see* Terajima H et al). 2000;31:407-415
Engelhardt D (*see* Brown JJ et al). 2000;31:173-181
—(*see* Nagler A et al). 2000;31:641-648
Enomoto N (*see* Iimuro Y et al). 2000;31:391-398
Enomoto N (*see* Nagayama K et al). 2000;31:745-750
—(*see* Tanaka Y et al). 2000;31:890-898
Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, Niederau C, Haussinger D. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. 2000;31:716-725
Ericzon B-G (*see* Axelson M et al). 2000;31:1305-1312
Erlinger S (*see* Denninger M-H et al). 2000;31:587-591
Escorsell A, Bordas JM, Castañeda B, Llach J, García-Pagán JC, Rodés J, Bosch J. Predictive value of the variceal pressure response ot continued pharmacological therapy in patients with cirrhosis and portal hypertension. 2000;31:1061-1067
Everhart JE (*see* Ruhl CE et al). 2000;31:299-303

F

Failli P (*see* Carloni V et al). 2000;31:131-140
Fanning L, Kenny-Walsh E, Levis J, Choudhury KR, Cannon B, Sheehan M, Whelton M, Shanahan F. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: A prospective study. 2000;31:225-229
—, Levis J, Kenny-Walsh E, Wynne F, Whelton M, Shanahan F. Viral clearance in hepatitis C (1b) infection: Relationship with human leukocyte antigen class II in a homogeneous population. 2000;31:1334-1337
Farrell GC (*see* Khan MH et al). 2000;31:513-520
—(*see* Samarasinghe DA et al). 2000;31:160-165
Farrés J (*see* Borrás E et al). 2000;31:984-989
Fasolato S (*see* Angeli P et al). 2000;31:304-310
Fattovich G (*see* De Francheschi L et al). 2000;31:997-1004
Fau D (*see* Feldmann G et al). 2000;31:674-683
Federici B (*see* Santucci L et al). 2000;31:399-406
Felder M (*see* Merkel C et al). 2000;31:324-329
Feldmann G, Haouzi D, Moreau A, Durand-Schneider A-M, Bringuier A, Berson A, Mansouri A, Fau D, Pessayre D. Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice. 2000;31:674-683
Felipo V (*see* Hermenegildo C et al). 2000;31:709-715
Fennekohl A, Lucas M, Püschel GP. Induction by interleukin 6 of G_s-coupled prostaglandin E_2 receptors in rat hepatocytes mediating a prostaglandin E_2–dependent inhibition of the hepatocytes' acute phase response. 2000;31:1128-1134
Fenyves D (*see* Villeneuve J-P et al). 2000;31:207-210
Feo F (*see* De Miglio MR et al). 2000;31:956-965
Ferayorni L (*see* Chatila R et al). 2000;31:572-576
Ferenci P (*see* Kramer L et al). 2000;31:30-34
Fernández-Muixi F (*see* Borrás E et al). 2000;31:984-989
Ferraccioli G (*see* De Vita S et al). 2000;31:182-189
Ferrara JLM (*see* Sturm E et al). 2000;31:124-130
Ferri C (*see* Zignego AL et al). 2000;31:474-479

Fiarman G DL (see Fontana RJ et al). 2000; 31:730-736
Fink JK (see Brewer GJ et al). 2000;31:364-370
Fiorucci S (see Santucci L et al). 2000;31: 399-406
Fischbacher CM (see Howel D et al). 2000; 31:1055-1060
Fitz JG (see Doctor RB et al). 2000;31: 1045-1054
Fontana L (see Iraburu MJ et al). 2000;31: 1086-1093
Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, Levine RA, Fiarman G, Thiim M, Tavill AS, Bonkovsky HL. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial. 2000;31: 730-736
Forman DT (see Iimuro Y et al). 2000;31: 391-398
—(see Yin M et al). 2000;31:117-123
Forman L, Kawut S, Rosen I, Pien G, Bogner H. The impact of diagnosis of hepatitis C on quality of life. 2000;31: 1029 (Correspondence)
Forrest E, Stanley A, Hayes P. Carvediol—A new nonselective beta blocker. 2000; 31:809-810
Forti D (see Belli LS et al). 2000;31:1345-1350
Fouassier L (see Doctor RB et al). 2000;31: 1045-1054
Fox IJ (see Kobayashi N et al). 2000;31: 851-857
Fox-Robichaud A, Kubes P. Molecular mechanisms of tumor necrosis factor α-stimulated leukocyte recruitment into the murine hepatic circulation. 2000;31:1123-1127
Franco-Bronson K (see Zdilar D et al). 2000;31:1207-1211 (Concise Review)
Fraquelli M (see Conte D et al). 2000;31: 751-755
Freile I (see Pérez-Paramo M et al). 2000; 31:43-48
Frey W (see Iimuro Y et al). 2000;31:391-398
Fujikawa K (see Ito T et al). 2000;31:1080-1085
Fujiwara H (see Morikawa H et al). 2000; 31:83-94
Fukumoto M (see Okabe H et al). 2000;31: 1073-1079
Fung JJ (see Totsuka E et al). 2000;31:577-580
Furth EE (see Kovalovich K et al). 2000;31: 149-159
Furuyama K (see Akagi R et al). 2000;31: 704-708

G

Gaiani S (see Piscaglia F et al). 2000;31: 349-357
Galle PR (see Rahman F et al). 2000;31: 521-527
Galli A, Crabb D, Price D, Ceni E, Salzano R, Surrenti C, Casini A. Peroxisome proliferator–activated receptor γ transcriptional regulation is involved in platelet-derived growth factor–induced proliferation of human hepatic stellate cells. 2000;31:101-108
Galmiche J-P (see Gournay J et al). 2000; 31:1239-1245
Galun E (see Böcher WO et al). 2000;31: 480-487
Gao C (see Kobayashi N et al). 2000;31: 851-857
Garcia M (see Castilla-Cortazar I et al). 2000;31:592-600
García-Pagán JC (see Escorsell A et al). 2000;31:1061-1067
García-Trevijano ER (see Iraburu MJ et al). 2000;31:1086-1093
Garmark K (see Axelson M et al). 2000;31: 1305-1312
Gasparotto D (see De Vita S et al). 2000;31: 182-189
Gassull MA (see Pardo A et al). 2000;31: 858-863
Gatta A (see Angeli P et al). 2000;31:304-310
—(see Merkel C et al). 2000;31:324-329
Gaweco AS, Wiesner RH, Porayko M, Rustgi VK, Yong S, Hamdani R, Harig J, Chejfec G, McClatchey KD, Van Thiel DH. Intragraft localization of activated nuclear factor κB in recurrent hepatitis C virus disease following liver transplantation. 2000;31: 1183-1191
Geerts A (see Louis H et al). 2000;31:381-390
Geissler M (see Mohr L et al). 2000;31:606-614
Gendo A (see Kramer L et al). 2000;31: 30-34
Gentilini P (see Carloni V et al). 2000;31: 131-140
—(see Zignego AL et al). 2000;31:474-479
George DK (see MacDonald GA et al). 2000;31:549 (Correspondence)
George J (see Khan MH et al). 2000;31: 513-520
Gerin JL (see Cote PJ et al). 2000;31:190-200
—(see Korba BE et al). 2000;31:1165-1175
Gerlich WH (see Erhardt A et al). 2000;31: 716-725
Gershwin ME (see Reynoso-Paz S et al). 2000;31:24-29
—(see Shimoda S et al). 2000;31:1212-1216
Ghalib R (see Chalasani N et al). 2000;31: 7-11
Giannelli F (see Zignego AL et al). 2000; 31:474-479
Giannini C (see Zignego AL et al). 2000;31: 474-479
Gibbs CS (see Xiong X et al). 2000;31:219-224
Gilg AG (see Contreras MA et al). 2000;31: 446-455
Gillet R (see de Coupade C et al). 2000;31: 371-380
Giusti S (see Carloni V et al). 2000;31:131-140
Glaser S (see Kanno N et al). 2000;31:555-561 (Concise Review)
Gloghini A (see De Vita S et al). 2000;31: 182-189
Glynn SA (see Murphy EL et al). 2000;31: 756-762
Godichaud S, Krisa S, Couronné B, Dubuisson L, Mérillon J-M, Desmoulière A, Rosenbaum J. Deactivation of cultured human myofibroblasts by *trans*-reservatrol, a grapevine-derived polyphenol. 2000;31:922-931
Golden-Mason L, Curry MP, Nolan N, Traynor O, McEntee G, Kelly J, Hegarty JE, O'Farrelly C. Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver. 2000;31: 1251-1256
Goldman M (see Le Moine O et al). 2000; 31:1266-1274
—(see Louis H et al). 2000;31:381-390
Goodman Z (see Poynard T et al). 2000;31: 211-218
Gordon FD (see Malinchoc M et al). 2000; 31:864-871
Gores GJ (see Llovet JM et al). 2000;31: 1019-1021
Gournay J, Masliah C, Martin T, Perrin D, Galmiche J-P. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. 2000;31:1239-1245
Govindarajan S (see Liu Z-X et al). 2000; 31:665-673
Grace N (see Fontana RJ et al). 2000;31: 730-736
Gramantieri L (see Piscaglia F et al). 2000; 31:349-357
Grande L (see Sanchez-Fueyo A et al). 2000;31:496-501
Gray J (see Howel D et al). 2000;31:1055-1060
Green ME (see Colletti LM et al). 2000;31: 435-445
Greenwel P (see Iraburu MJ et al). 2000;31: 1086-1093
—, Domínguez-Rosales J-A, Mavi G, Rivas-Estilla AM, Rojkind M. Hydrogen peroxide: A link between acetaldehyde-elicited α1(I) collagen gene upregulation and oxidative stress in mouse hepatic stellate cells. 2000;31: 109-116
Gregor JC (see Myers RP et al). 2000;31: 834-839
Gressner AM (see Dooley S et al). 2000;31: 1094-1106
Gretch D. Standardization of hepatitis C virus-RNA quantification: Advances and unfinished business. 2000;31: 788-789 (Editorial)
Grimaldi GC (see Roncalli M et al). 2000; 31:846-850

Gross JB Jr (*see* Kim WR et al). 2000;31:807 (Correspondence)
Groszmann RJ (*see* Chatila R et al). 2000;31:572-576
Gruppo Triveneto per l'Ipertensione Portale (GTIP) (*see* Merkel C et al). 2000;31:324-329
Guardascione MA (*see* Amitrano L et al). 2000;31:345-348
Guebre-Xabier M, Yang S, Lin HZ, Schwenk R, Krzych U, Diehl AM. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: Potential mechanism for sensitization to liver damage. 2000;31:633-640
Guillin M-C (*see* Denninger M-H et al). 2000;31:587-591
Gupta T (*see* Chatila R et al). 2000;31:572-576
Gürakan F (*see* Koçak N et al). 2000;31:545 (Correspondence)
Gushima T (*see* Shimoda S et al). 2000;31:1212-1216
Gutiérrez C (*see* Borràs E et al). 2000;31:984-989

H

Habib NA (*see* Mitry RR et al). 2000;31:885-889
Hachiya K (*see* Morikawa H et al). 2000;31:83-94
Hadengue A (*see* Majno PE et al). 2000;31:899-906
Hahn EG (*see* Schuppan D et al). 2000;31:546-547 (Correspondence)
Hakamada K (*see* Totsuka E et al). 2000;31:577-580
Halm U (*see* Berr F et al). 2000;31:291-298
—(*see* Wiedman M et al). 2000;31:230-234
Hamdani R (*see* Gaweco AS et al). 2000;31:1183-1191
Hamilton AD (*see* Carloni V et al). 2000;31:131-140
Hammel JM (*see* Kobayashi N et al). 2000;31:851-857
Hammer C (*see* Terajima H et al). 2000;31:407-415
Han K-H (*see* Ahn SH et al). 2000;31:1371-1373
Hanafusa T (*see* Ito N et al). 2000;31:544-545 (Correspondence)
Haouzi D (*see* Feldmann G et al). 2000;31:674-683
Harada M (*see* Kawaguchi T et al). 2000;31:1285-1295
Harada T (*see* Nagasue N et al). 2000;31:1107-1114
Harding D (*see* Bauer M et al). 2000;31:937-947
Harig J (*see* Gaweco AS et al). 2000;31:1183-1191
Hatakeyama K (*see* Minigawa M et al). 2000;31:907-915
Hauss J (*see* Berr F et al). 2000;31:291-298
Haussinger D (*see* Erhardt A et al). 2000;31:716-725
Havlik R (*see* Mitry RR et al). 2000;31:885-889
Hay JL (*see* Powell EE et al). 2000;31:828-833
Hayashi N (*see* Tanaka Y et al). 2000;31:890-898
Hayashida M (*see* Ito T et al). 2000;31:1080-1085
Hayes P (*see* Forrest E et al). 2000;31:809-810
Heathcote EJ (*see* Villeneuve J-P et al). 2000;31:207-210
—. Management of primary biliary cirrhosis. 2000;31:1005-1013 (AASLD Practice Guidelines)
Hedera P (*see* Brewer GJ et al). 2000;31:364-370
Hegarty JE (*see* Golden-Mason L et al). 2000;31:1251-1256
Heilig M (*see* Borràs E et al). 2000;31:984-989
Heintges T (*see* Erhardt A et al). 2000;31:716-725
Henegariu O (*see* Thiese ND et al). 2000;31:235-240 (Rapid Communication)
Herath NI, Kew MC, Whitehall VLJ, Walsh MD, Jass JR, Khanna KK, Young J, Powell LW, Leggett BA, MacDonald GA. *p73* is upregulated in a subset of hepatocellular carcinomas. 2000;31:601-605
Hermenegildo C, Monfort P, Felipo V. Activation of *N*-methyl-D-aspartate receptors in rat brain *in vivo* following acute ammonia intoxication: Characterization by *in vivo* brain microdialysis. 2000;31:709-715
Hermida RC (*see* Piscaglia F et al). 2000;31:349-357
Herzog-Hauff S (*see* Rahman F et al). 2000;31:521-527
Hezode C, Dhumeaux D, Pawlotsky J-M. Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation. 2000;31:809 (Correspondence)
Hickman P (*see* Crawford DHG et al). 2000;31:1192-1193 (Editorial)
Hijikata M (*see* Marusawa H et al). 2000;31:488-495
Hillaire S (*see* Denninger M-H et al). 2000;31:587-591
Hippeläinen M (*see* Lozeva V et al). 2000;31:336-344
Hiramatsu N (*see* Tanaka Y et al). 2000;31:890-898
Hirsch KR, Wright TL. "Silent killer" or benign disease? The dilemma of hepatitis C virus outcomes. 2000;31:536-537 (Editorial)
Hjelmqvist L (*see* Borràs E et al). 2000;31:984-989
Hoek JB (*see* Pastorino JG et al). 2000;31:1141-1152
Hoen H (*see* Chalasani N et al). 2000;31:7-11
Honda M, Kaneko S, Shimazaki T, Matsushita E, Kobayashi K, Ping L, Zhang H, Lemon SM. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. 2000;31:1351-1359
Honscha W, Dötsch KU, Thomsen N, Petzinger E. Cloning and functional characterization of the bile acid sensitive methotrexate carrier from rat liver cells. 2000;31:1296-1304
Hoofnagle JH (*see* Czaja AJ et al). 2000;31:1194-1200 (Meeting Report)
Höög J-O (*see* Marschall H-U et al). 2000;31:990-996
Hoppel CL (*see* Krähenbühl S et al). 2000;31:1217-1223
Hori M (*see* Tanaka Y et al). 2000;31:890-898
Horikawa S (*see* Ito K et al). 2000;31:416-419
Hornbuckle WE (*see* Korba BE et al). 2000;31:1165-1175
—(*see* Cote PJ et al). 2000;31:190-200
Houghton M (*see* Lee AY et al). 2000;31:1327-1333
Housset C. The dual play of endothelin receptors in hepatic vasoregulation. 2000;31:1025-1026 (Editorial)
Howel D, Fischbacher CM, Bhopal RS, Gray J, Metcalf JV, James OFW. An exploratory population-based case-control study of primary biliary cirrhosis. 2000;31:1055-1060
Huang S-N (*see* Tai D-I et al). 2000;31:656-664
Hübner C, Stremmel W, Elsing C. Sodium, hydrogen exchange type 1 and bile ductular secretory activity in the guinea pig. 2000;31:562-571
Hui A-M, Li X, Shi Y-Z, Torzilli G, Takayama T, Makuuchi M. $p27^{Kip1}$ expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: Association with cancer progression and prognosis. 2000;31:1068-1072
Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. 2000;31:1037-1044 (Concise Review)
Hussain M (*see* Chan HLY et al). 2000;31:763-768

I

Iannaccone L (*see* Amitrano L et al). 2000;31:345-348
Idèo G (*see* Belli LS et al). 2000;31:1345-1350
Igarashi M (*see* Kawai H et al). 2000;31:1246-1250
Iimuro Y, Bradford BU, Yamashina S, Rusyn I, Nakagami M, Enomoto N, Kono H, Frey W, Forman D, Brenner D, Thurman RG. The glutathione precursor L-2-oxothiazolodine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat. 2000;31:391-398
Ikai I (*see* Okabe H et al). 2000;31:1073-1079

Ikejima K (*see* Yin M et al). 2000;31:117-123
Ilan Y (*see* Nagler A et al). 2000;31:641-648
Ilic Z (*see* Rosenberg D et al). 2000;31:948-955
Iraburu MJ, Domínguez-Rosales JA, Fontana L, Auster A, García-Trevijano ER, Covarrubias-Pinedo A, Rivas-Estilla AM, Greenwel P, Rojkind M. Tumor necrosis factor α down-regulates expression of the α1(I) collagen gene in rat hepatic stellate cells through a p20C/EBPβ- and C/EBPδ-dependent mechanism. 2000;31:1086-1093
Ireland JH, O'Donnell B, Basuni AA, Kean JD, Wallace LA, Lau GKK, Carman WF. Reactivity of 13 *in vitro* expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays. 2000;31:1176-1182
Ishibashi H (*see* Shimoda S et al). 2000;31:1212-1216
Ishii M (*see* Ueno Y et al). 2000;31:966-974
Ishii T (*see* Totsuka E et al). 2000;31:577-580
Ishimura Y (*see* Suematsu M et al). 2000;31:3-6 (Concise Review)
Ismail A (*see* Chalasani N et al). 2000;31:7-11
Isokawa O (*see* Kawai H et al). 2000;31:1246-1250
Israel J (*see* Fontana RJ et al). 2000;31:730-736
Itkonen M (*see* Lozeva V et al). 2000;31:336-344
Ito A (*see* Tanaka Y et al). 2000;31:890-898
Ito K, Ozasa H, Sanada K, Horikawa S. Doxorubicin preconditioning: A preotection against rat hepatic ischemia-reperfusion injury. 2000;31:416-419
Ito M (*see* Ito T et al). 2000;31:1080-1085
—(*see* Kobayashi N et al). 2000;31:851-857
Ito N, Kawata S, Tamura S, Nakajima H, Kiso S, Saeki A, Oue T, Hanafusa T, Matsuzawa Y. Amino acid sequence of EC2 domain in CD81 is highly conserved in Japanese subjects. 2000;31:544-545 (Correspondence)
Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. 2000;31:1080-1085

J

Jacob JR (*see* Cote PJ et al). 2000;31:190-200
Jacobs RJ (*see* Berge JJ et al). 2000;31:469-473
Jakins A (*see* Berge JJ et al). 2000;31:469-473
Jalan R (*see* Newby DE et al). 2000;31:1201-1202 (Hepatology *Elsewhere*)
Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis C–infected patients with persistently normal alanine transaminase levels in the southwestern United States. 2000;31:813 (Correction)
James NH (*see* Roberts RA et al). 2000;31:420-427
James OFW (*see* Howel D et al). 2000;31:1055-1060
Jamison SF (*see* Macejak DG et al). 2000;31:769-776
Jarvik GP (*see* Ko CW et al). 2000;31:18-23
Jass JR (*see* Herath NI et al). 2000;31:601-605
Jensen KL (*see* Macejak DG et al). 2000;31:769-776
Jiménez W (*see* Angeli P et al). 2000;31:304-310
Johnson L (*see* Lemon SM et al). 2000;31:800-806 (Meeting Report)
Johnson VD (*see* Brewer GJ et al). 2000;31:364-370
Johnston DE (*see* Jamal MM et al). 2000;31:813 (Correction)
Jolley D (*see* Rodger AJ et al). 2000;31:1029-1030 (Correspondence)
Jonassen TEN, Sørensen A-M, Petersen JS, Andreasen F, Christensen S. Increased natriuretic efficiency of furosemide in rats with carbon tetrachloride–induced cirrhosis. 2000;31:1224-1230
Jones DEJ (*see* Agarwal K et al). 2000;31:49-53
Jonsson JR (*see* Powell EE et al). 2000;31:828-833
Jorgensen RA (*see* Angulo P et al). 2000;31:318-323
Jörnvall H (*see* Borràs E et al). 2000;31:984-989
—(*see* Marschall H-U et al). 2000;31:990-996
Jungermann K, Kietzmann T. Oxygen: Modulator of metabolic zonation and disease of the liver. 2000;31:255-260 (Concise Review)

K

Kaba S (*see* Khan MH et al). 2000;31:513-520
Kamath PS (*see* Malinchoc M et al). 2000;31:864-871
Kamikawa T (*see* Okabe H et al). 2000;31:1073-1079
Kammer AR (*see* Cerny A et al). 2000;31:811-812 (Correspondence)
Kaneda K (*see* Morikawa H et al). 2000;31:83-94
Kaneko S (*see* Honda M et al). 2000;31:1351-1359
Kanel GC (*see* Wang X et al). 2000;31:428-434
Kang SW (*see* Ahn SH et al). 2000;31:1371-1373
Kanno N, LeSage G, Glaser S, Alvaro D, Alpini G. Functional heterogeneity of the intrahepatic biliary epithelium. 2000;31:555-561 (Concise Review)
Karpen SJ (*see* Sturm E et al). 2000;31:124-130
Kasahara A (*see* Tanaka Y et al). 2000;31:890-898
Katayama K (*see* Tanaka Y et al). 2000;31:890-898
Katsura N (*see* Okabe H et al). 2000;31:1073-1079
Kawaguchi T, Sakisaka S, Mitsuyama K, Harada M, Koga H, Taniguchi E, Sasatomi K, Kimura R, Ueno T, Sawada N, Mori M, Sata M. Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis. 2000;31:1285-1295
Kawai H, Suda T, Aoyagi Y, Isokawa O, Mita Y, Waguri N, Kuroiwa T, Igarashi M, Tsukada K, Mori S, Shimizu T, Suzuki Y, Abe Y, Takahashi T, Nomoto M, Asakura H. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: Comparison of loss of heterozygosity and replication error. 2000;31:1246-1250
Kawamura H (*see* Minigawa M et al). 2000;31:907-915
Kawano H (*see* Ito T et al). 2000;31:1080-1085
Kawata S (*see* Ito N et al). 2000;31:544-545 (Correspondence)
Kawut S (*see* Forman L et al). 2000;31:1029 (Correspondence)
Keach JC (*see* Angulo P et al). 2000;31:318-323
Kean JD (*see* Ireland JH et al). 2000;31:1176-1182
Kelly J (*see* Golden-Mason L et al). 2000;31:1251-1256
Kench J (*see* Khan MH et al). 2000;31:513-520
Kenny-Walsh E (*see* Fanning L et al). 2000;31:225-229
—(*see* Fanning LJ et al). 2000;31:1334-1337
Ker C-G (*see* Kuo K-K et al). 2000;31:59-64
Kertesz AE (*see* Adams PC et al). 2000;31:1160-1164
Kew MC (*see* Herath NI et al). 2000;31:601-605
Khan M (*see* Contreras MA et al). 2000;31:446-455
Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Kench J, Kaba S, Crewe E, Liddle C. Which patients with hepatitis C develop liver complications? 2000;31:513-520
Khanna KK (*see* Herath NI et al). 2000;31:601-605
Kietzmann T (*see* Jungermann K et al). 2000;31:255-260 (Concise Review)
Kim DK (*see* Ahn SH et al). 2000;31:1371-1373

Kim H-T, Stoica G, Bazer FW, Ott TL. Interferon tau–induced hepatocyte apoptosis in sheep. 2000;31:1275-1284
Kim S-W (*see* Suh K-S et al). 2000;31:12-17
Kim T-H, Mars WM, Stolz DB, Michalopoulos GK. Expression and activation of Pro-MMP-2 and Pro-MMP-9 during rat liver regeneration. 2000;31:75-82
Kim WR, Poterucha JJ, Gross JB Jr. Cost-effectiveness of interferon alfa-2b and ribavirin in the treatment of chronic hepatitis C. 2000;31:807 (Correspondence)
Kim YS (*see* Ahn SH et al). 2000;31:1371-1373
Kimura R (*see* Kawaguchi T et al). 2000;31:1285-1295
Kirby PA (*see* Schmidt WN et al). 2000;31:737-744
Kisara N (*see* Ueno Y et al). 2000;31:966-974
Kiso S (*see* Ito N et al). 2000;31:544-545 (Correspondence)
Klassen LW (*see* Rolla R et al). 2000;31:878-884
Klein RD (*see* Su GL et al). 2000;31:932-936
Klimpel G (*see* Bertolino P et al). 2000;31:1374-1378 (Meeting Report)
Kluin KJ (*see* Brewer GJ et al). 2000;31:364-370
Knopfel T (*see* Storto M et al). 2000;31:649-655
Ko CW, Beresford SAA, Alderman B, Jarvik GP, Schulte SJ, Calhoun B, Tsuchida AM, Koepsell TD, Lee SP. Apolipoprotein E genotype and the risk of gallbladder disease in pregnancy. 2000;31:18-23
Kobayashi K (*see* Honda M et al). 2000;31:1351-1359
Kobayashi N, Ito M, Nakamura J, Cai J, Gao C, Hammel JM, Fox IJ. Hepatocyte transplantation in rats with decompensated cirrhosis. 2000;31:851-857
Koçak N, Saltik IN, Özen H, Yüce A, Gürakan F. Lamivudine treatment for children with interferon refractory chronic hepatitis B. 2000;31:545 (Correspondence)
Koepsell TD (*see* Ko CW et al). 2000;31:18-23
Koga H (*see* Kawaguchi T et al). 2000;31:1285-1295
Kogure K, Zhang Y-Q, Maeshima A, Suzuki K, Kuwano H, Kojima I. The role of activin and transforming growth factor-β in the regulation of organ mass in the rat liver. 2000;31:916-921
Koh YT (*see* Suh K-S et al). 2000;31:12-17
Kohlhaw KR (*see* Berr F et al). 2000;31:291-298
Kohno H (*see* Nagasue N et al). 2000;31:1107-1114
Kojima I (*see* Kogure K et al). 2000;31:916-921
Kondo T (*see* Terajima H et al). 2000;31:407-415
Kong F (*see* Murphy EL et al). 2000;31:756-762
Konikoff FM, Danino D, Weihs D, Rubin M, Talmon Y. Microstructural evolution of lipid aggregates in nucleating model and human biles visualized by cryogenic transmission electron microscopy. 2000;31:261-268
Kono H (*see* Iimuro Y et al). 2000;31:391-398
Korba BE (*see* Cote PJ et al). 2000;31:190-200
—, Cote P, Hornbuckle W, Tennant BC, Gerin JL. Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (*Marmota monax*) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. 2000;31:1165-1175
Kornetzky (*see* Sarrazin C et al). 2000;31:1360-1370
Kothe MJC (*see* Paulusma CC et al). 2000;31:684-693
Kovalovich K, DeAngelis RA, Li W, Furth EE, Ciliberto G, Taub R. Increased toxin-induced liver injury and fibrosis in interleukin-6–deficient mice. 2000;31:149-159
Krähenbühl S, Brass EP, Hoppel CL. Decreased carnitine biosynthesis in rats with secondary biliary cirrhosis. 2000;31:1217-1223
Kramer L, Tribl B, Gendo A, Zauner C, Schneider B, Ferenci P, Madl C. Partial pressure of ammonia versus ammonia in hepatic encephalopathy. 2000;31:30-34
Krause DS (*see* Thiese ND et al). 2000;31:235-240 (Rapid Communication)
Kresge N (*see* Bauer M et al). 2000;31:937-947
Krisa S (*see* Godichaud S et al). 2000;31:922-931
Krohne TU (*see* Mohr L et al). 2000;31:606-614
Kronenberger B (*see* Sarrazin C et al). 2000;31:1360-1370
Kruckeberg KE (*see* Brandhagen DJ et al). 2000;31:456-460
Krzych U (*see* Guebre-Xabier M et al). 2000;31:633-640
Kubes P (*see* Fox-Robichaud A et al). 2000;31:1123-1127
Kubota H (*see* Nagasue N et al). 2000;31:1107-1114
Kuipers F (*see* Agellon LB et al). 2000;31:543 (Correspondence)
Kuo GC (*see* Tai D-I et al). 2000;31:656-664
Kuo K-K, Sato N, Mizumoto K, Maehara N, Yonemasu H, Ker C-G, Sheen P-C, Tanaka M. Centrosome abnormalities in human carcinomas of the gallbladder and intrahepatic and extrahepatic bile ducts. 2000;31:59-64
Kuroiwa T (*see* Kawai H et al). 2000;31:1246-1250
Kuroki T (*see* Morikawa H et al). 2000;31:83-94
Kurosaki M (*see* Nagayama K et al). 2000;31:745-750
Kuwano H (*see* Kogure K et al). 2000;31:916-921

L

La Corte R (*see* De Vita S et al). 2000;31:182-189
La Villa G (*see* Zignego AL et al). 2000;31:474-479
Labombarda A (*see* De Vita S et al). 2000;31:182-189
LaBrecque DR (*see* Schmidt WN et al). 2000;31:737-744
Laffi G (*see* Carloni V et al). 2000;31:131-140
—(*see* Zignego AL et al). 2000;31:474-479
Laghi L (*see* Roncalli M et al). 2000;31:846-850
Lahme B (*see* Dooley S et al). 2000;31:1094-1106
Lai C-L (*see* Wong W-M et al). 2000;31:201-206
—(*see* Yuen M-F et al). 2000;31:330-335
Lai G-H, Radaeva S, Nakamura T, Sirica AE. Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver. 2000;31:1257-1265
Lam S-K (*see* Yuen M-F et al). 2000;31:330-335
Lanigan A (*see* Rodger AJ et al). 2000;31:1029-1030 (Correspondence)
Larena MG (*see* Macias RIR et al). 2000;31:975-983
LaRusso NF (*see* Marinelli RA et al). 2000;31:1313-1317
Lau GKK (*see* Ireland JH et al). 2000;31:1176-1182
Launder IJ (*see* Yuen M-F et al). 2000;31:330-335
Layden TJ (*see* Lemon SM et al). 2000;31:800-806 (Meeting Report)
Le Breton V (*see* Martinot-Peignoux M et al). 2000;31:726-729
Le Guludec G (*see* Martinot-Peignoux M et al). 2000;31:726-729
Le Moine A (*see* Louis H et al). 2000;31:381-390
Le Moine O (*see* Louis H et al). 2000;31:381-390
—, Louis H, Demols A, Desalle F, Demoor F, Quertinmont E, Goldman M, Devière J. Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice. 2000;31:1266-1274
Leao AAS (*see* Perseghin G et al). 2000;31:694-703

Lecklin A (see Lozeva V et al). 2000;31:336-344
LeClair P (see Fontana RJ et al). 2000;31:730-736
Leduc R (see Villeneuve J-P et al). 2000;31:207-210
Lee AY, Manning WC, Arian CL, Polakos NK, Barajas JL, Ulmer JB, Houghton M, Paliard X. Priming of hepatitis C virus-specific cytotoxic T lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA. 2000;31:1327-1333
Lee CK (see Ahn SH et al). 2000;31:1371-1373
Lee J-H (see Sarrazin C et al). 2000;31:1360-1370
Lee KU (see Suh K-S et al). 2000;31:12-17
Lee SP (see Ko CW et al). 2000;31:18-23
Leggett BA (see Herath NI et al). 2000;31:601-605
Legnani C (see Piscaglia F et al). 2000;31:349-357
Lemon SM (see Bertolino P et al). 2000;31:1374-1378 (Meeting Report)
—(see Honda M et al). 2000;31:1351-1359
—, Layden TJ, Seeff L, Suzuki H, Nishioka K, Mishiro S, Johnson L. The 20th United States–Japan Joint Hepatitis Panel Meeting. 2000;31:800-806 (Meeting Report)
LeSage G (see Kanno N et al). 2000;31:555-561 (Concise Review)
Leung C-C (see Wong W-M et al). 2000;31:201-206
Leung NWY (see Chan HLY et al). 2000;31:763-768
Leung PSC (see Reynoso-Paz S et al). 2000;31:24-29
Levine RAL (see Fontana RJ et al). 2000;31:730-736
Levis J (see Fanning L et al). 2000;31:225-229
—(see Fanning LJ et al). 2000;31:1334-1337
Li W (see Kovalovich K et al). 2000;31:149-159
Li X (see Hui A-M et al). 2000;31:1068-1072
Liaw Y-F (see Tai D-I et al). 2000;31:656-664
—(see Yeh C-T et al). 2000;31:1318-1326
Libera VD (see Angeli P et al). 2000;31:304-310
Liddle C (see Khan MH et al). 2000;31:513-520
Liebert UG (see Wiedman M et al). 2000;31:230-234
Lin HZ (see Guebre-Xabier M et al). 2000;31:633-640
Lin R (see Khan MH et al). 2000;31:513-520
Lindor KD (see Angulo P et al). 2000;31:318-323
—(see Reynoso-Paz S et al). 2000;31:24-29
Ling M-H (see Poynard T et al). 2000;31:211-218
Liu Z-X, Govindarajan S, Okamoto S, Dennert G. Fas- and tumor necrosis factor receptor 1–dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice. 2000;31:665-673
Llach J (see Escorsell A et al). 2000;31:1061-1067
Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: Clues for the best strategy. 2000;31:1019-1021
—, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodés J, Bruix J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. 2000;31:54-58
Locala JA (see Zdilar D et al). 2000;31:1207-1211 (Concise Review)
Lohr HF (see Böcher WO et al). 2000;31:480-487
—(see Rahman F et al). 2000;31:521-527
Lok ASF (see Chan HLY et al). 2000;31:763-768
López-Alcorocho JM (see Cotonat T et al). 2000;31:502-506
Lorenzo A (see Borràs E et al). 2000;31:984-989
Lorenzo-Zúñiga V (see Pardo A et al). 2000;31:858-863
Louis H (see Le Moine O et al). 2000;31:1266-1274
—, Le Moine A, Quertinmont E, Peny M-O, Geerts A, Goldman M, Le Moine O, Devière J. Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis. 2000;31:381-390
Lozeva V, Valjakka A, Lecklin A, Olkkonen H, Hippeläinen M, Itkonen M, Plumed C, Tuomisto L. Effects of the histamine H_1 receptor blocker, pyrilamine, on spontaneous locomotor activity of rats with long-term portacaval anastomosis. 2000;31:336-344
Lucas M (see Fennekohl A et al). 2000;31:1128-1134
Ludwig J (see Brandhagen DJ et al). 2000;31:456-460
Luque T (see Pardo A et al). 2000;31:858-863
Luzi L (see Perseghin G et al). 2000;31:694-703

M

MacDonald GA (see Herath NI et al). 2000;31:601-605
—, Ward PJ, George DK, Powell LW. Iron and fibrosis in nonalcoholic fatty liver disease. 2000;31:549-550 (Correspondence)
Macejak DG, Jensen KL, Jamison SF, Domenico K, Roberts EC, Chaudhary N, von Carlowitz I, Bellon L, Tong MJ, Conrad A, Pavco PA, Blatt LM. Inhibition of hepatitis C virus (HCV)-RNA–dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. 2000;31:769-776
Mach T (see Borràs E et al). 2000;31:984-989
MacHenzie HS (see Angeli P et al). 2000;31:304-310
Macias RIR, Pascual MJ, Bravo A, Alcalde MP, Larena MG, St.-Pierre MV, Serrano MA, Marin JJG. Effect of maternal cholestasis on bile acid transfer across the rat placenta-maternal liver tandem. 2000;31:975-983
Madl C (see Kramer L et al). 2000;31:30-34
Maehara N (see Kuo K-K et al). 2000;31:59-64
Maeshima A (see Kogure K et al). 2000;31:916-921
Maggioni M (see Roncalli M et al). 2000;31:846-850
Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: An outcome-oriented decision analysis. 2000;31:899-906
Makuuchi M (see Hui A-M et al). 2000;31:1068-1072
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. 2000;31:864-871
Mangasser-Stephan K (see Dooley S et al). 2000;31:1094-1106
Manning WC (see Lee AY et al). 2000;31:1327-1333
Manns MP (see Czaja AJ et al). 2000;31:1194-1200 (Meeting Report)
—. Hepatitis C and autoimmune hepatitis. 2000;31:811 (Correspondence)
Mano Y (see Ueno Y et al). 2000;31:966-974
Mansouri A (see Feldmann G et al). 2000;31:674-683
Manzarbeitia F (see Cotonat T et al). 2000;31:502-506
Manzato F (see De Francheschi L et al). 2000;31:997-1004
Marcellin P (see Di Martino V et al). 2000;31:1030-1031 (Correspondence)
—(see Martinot-Peignoux M et al). 2000;31:726-729
Marcus H (see Böcher WO et al). 2000;31:480-487
Margaglione M (see Amitrano L et al). 2000;31:345-348
Margolis HS (see Armstrong GL et al). 2000;31:777-782
Margulies M (see Villeneuve J-P et al). 2000;31:207-210
Marin JJG (see Macias RIR et al). 2000;31:975-983
Marin R (see Merkel C et al). 2000;31:324-329
Marinelli RA, Pharm LD, Tietz PS, LaRusso

NE. Expression of aquaporin-4 water channels in rat cholangiocytes. 2000; 31:1313-1317
Marmo R (*see* Amitrano L et al). 2000;31: 345-348
Marotta PJ (*see* Myers RP et al). 2000;31: 834-839
Marrocchi ME (*see* Zignego AL et al). 2000;31:474-479
Mars WM (*see* Kim T-H et al). 2000;31: 75-82
Marschall H-U, Oppermann UCT, Svensson S, Nordling E, Persson B, Höög J-O, Jörnvall H. Human liver class I alcohol dehydrogenase γγ isozyme: The sole cytosolic 3β-hydroxysteroid dehydrogenase of iso bile acids. 2000; 31:990-996
Martin T (*see* Gournay J et al). 2000;31: 1239-1245
Martinot-Peignoux M, Boyer N, Le Breton V, Le Guludec G, Castelnau C, Akremi R, Marcellin P. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C. 2000;31: 726-729
Marumo F (*see* Nagayama K et al). 2000; 31:745-750
Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, Chiba T. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. 2000;31:488-495
Marzotto A (*see* De Vita S et al). 2000;31: 182-189
Mas A (*see* Sanchez-Fueyo A et al). 2000; 31:496-501
Masliah C (*see* Gournay J et al). 2000;31: 1239-1245
Matsuo K (*see* Okabe H et al). 2000;31: 1073-1079
Matsushita E (*see* Honda M et al). 2000;31: 1351-1359
Matsuzawa Y (*see* Ito N et al). 2000;31: 544-545 (Correspondence)
Mavi G (*see* Greenwel P et al). 2000;31: 109-116
Mazzaferro V (*see* Perseghin G et al). 2000; 31:694-703
Mazzaro C (*see* Merkel C et al). 2000;31: 324-329
Mazzocca A (*see* Zignego AL et al). 2000; 31:474-479
McCashland TM (*see* Chalasani N et al). 2000;31:7-11
McClatchey KD (*see* Gaweco AS et al). 2000;31:1183-1191
McEntee G (*see* Golden-Mason L et al). 2000;31:1251-1256
McFarlane IG (*see* Czaja AJ et al). 2000;31: 1194-1200 (Meeting Report)
McGill JM (*see* Hunt CM et al). 2000;31: 1037-1044
McHutchison J (*see* Poynard T et al). 2000; 31:211-218
—(*see* Younossi et al). 2000;31:807-808 (Correspondence)
McLaren CE (*see* Adams PC et al). 2000; 31:1160-1164
McQuillan GM (*see* Armstrong GL et al). 2000;31:777-782
Mentha G (*see* Majno PE et al). 2000;31: 899-906
Mérillon J-M (*see* Godichaud S et al). 2000; 31:922-931
Merkel C, Marin R, Sacerdoti D, Donada C, Cavallarin G, Torboli P, Amodio P, Sebastianelli G, Bolognesi M, Felder M, Mazzaro C, Gatta A, Gruppo Triveneto per l'Ipertensione Portale (GTIP). Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. 2000; 31:324-329
Messmer K (*see* Terajima H et al). 2000;31: 407-415
Metcalf JV (*see* Howel D et al). 2000;31: 1055-1060
Meyerhoff AS (*see* Berge JJ et al). 2000;31: 469-473
Mezey E. Insulin growth factor 1 and hypogonadism in cirrhosis. 2000;31:783-784 (Editorial)
Michalak A (*see* Rose C et al). 2000;31: 872-877
Michalopoulos GK (*see* Kim T-H et al). 2000;31:75-82
Michel M-L (*see* Pol S et al). 2000;31:548-549 (Correspondence)
Mieli-Vergani G (*see* Bogdanos D-P et al). 2000;31:1380 (Correspondence)
Miller RH (*see* Cote PJ et al). 2000;31:190-200
Minigawa M, Oya H, Yamamoto S, Shimizu T, Bannai M, Kawamura H, Hatakeyama K, Abo T. Intensive expansion of natural killer T cells in the early phase of hepatocyte regeneration after partial hepatectomy in mice and its association with sympathetic nerve activation. 2000;31:907-915
Minola E (*see* Conte D et al). 2000;31:751-755
Mishiro S (*see* Lemon SM et al). 2000;31: 800-806 (Meeting Report)
Mita Y (*see* Kawai H et al). 2000;31:1246-1250
Mitra SK. Herbal products for liver diseases. 2000;31:546 (Correspondence)
Mitros FA (*see* Schmidt WN et al). 2000; 31:737-744
Mitry RR, Sarraf CE, Havlik R, Habib NA. Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-*p53* treatment. 2000;31:885-889
Mitsuyama K (*see* Kawaguchi T et al). 2000;31:1285-1295
Miyasaka Y (*see* Nagayama K et al). 2000; 31:745-750
Mizuhara H (*see* Morikawa H et al). 2000; 31:83-94
Mizumoto K (*see* Kuo K-K et al). 2000;31: 59-64
Mochizuki K (*see* Tanaka Y et al). 2000;31: 890-898
Mohr L, Shankara S, Yoon S-K, Krohne TU, Geissler M, Roberts B, Blum HE, Wands JR. Gene therapy of hepatocellular carcinoma *in vitro* and *in vivo* in nude mice by adenoviral transfer of the *Escherichia coli* purine nucleoside phosphorylase gene. 2000;31:606-614
Moitinho E (*see* Banares R et al). 2000;31: 810-811 (Correspondence)
—(*see* Castaneda B et al). 2000;31:581-586
Momoi H (*see* Okabe H et al). 2000;31: 1073-1079
Monfort P (*see* Hermenegildo C et al). 2000;31:709-715
Monteverde A (*see* De Vita S et al). 2000; 31:182-189
Monti M (*see* Zignego AL et al). 2000;31: 474-479
Moon YM (*see* Ahn SH et al). 2000;31: 1371-1373
Moore SB (*see* Czaja AJ et al). 2000;31: 1231-1238
Moras N (*see* Totsuka E et al). 2000;31: 577-580
Moreau A (*see* Feldmann G et al). 2000;31: 674-683
Morelli A (*see* Santucci L et al). 2000;31: 399-406
Mori M (*see* Kawaguchi T et al). 2000;31: 1285-1295
Mori S (*see* Kawai H et al). 2000;31:1246-1250
Morikawa H, Hachiya K, Mizuhara H, Fujiwara H, Nishiguchi S, Shiomi S, Kuroki T, Kaneda K. Sublobular veins as the main site of lymphocyte adhesion/transmigration and adhesion molecule expression in the porto-sinusoidal-hepatic venous system during concanavalin A–induced hepatitis in mice. 2000;31:83-94
Moriyama M (*see* Ito T et al). 2000;31: 1080-1085
Mörk B (*see* Axelson M et al). 2000;31: 1305-1312
Moshage H (*see* Brown JJ et al). 2000;31: 173-181
Mössner J (*see* Berr F et al). 2000;31:291-298
—(*see* Wiedman M et al). 2000;31:230-234
Mottaran E (*see* Rolla R et al). 2000;31: 878-884
Multicenter Study Group (Necker Hospital, Paris) (*see* Pol S et al). 2000;31: 1338-1344
Munoz A (*see* Reynoso-Paz S et al). 2000; 31:24-29
Muñoz J (*see* Pérez-Paramo M et al). 2000; 31:43-48
Murata H (*see* Tanaka Y et al). 2000;31: 890-898
Muratori L (*see* Bogdanos D-P et al). 2000; 31:1380 (Correspondence)
Muroni MR (*see* De Miglio MR et al). 2000; 31:956-965
Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, Nass

CC, Ownby HE, Schreiber GB, Kong F, Neal KR, Nemo GJ, NHLBI Retrovirus Epidemiology Donor Study. Risk factors for hepatitis C virus infection in United States blood donors. 2000;31: 756-762
Myers RP, Gregor JC, Marotta PJ. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. 2000;31:834-839

N

Nagasue N, Dhar DK, Yamanoi A, Emi Y, Udagawa J, Yamamoto A, Tachibana M, Kubota H, Kohno H, Harada T. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. 2000; 31:1107-1114
Nagata S (see Ueno Y et al). 2000;31:966-974
Nagayama K, Kurosaki M, Enomoto N, Miyasaka Y, Marumo F, Sato C. Characteristics of hepatitis C viral genome associated with disease progression. 2000;31:745-750
Nagler A, Pines M, Abadi U, Pappo O, Zeira M, Rabbani E, Engelhardt D, Ohana M, Chowdhury NR, Chowdhury JR, Ilan Y. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice. 2000;31:641-648
Nakagami M (see Iimuro Y et al). 2000;31: 391-398
Nakajima H (see Ito N et al). 2000;31:544-545 (Correspondence)
Nakamura H (see Tanaka Y et al). 2000;31: 890-898
Nakamura J (see Kobayashi N et al). 2000; 31:851-857
Nakamura M (see Shimoda S et al). 2000; 31:1212-1216
Nakamura N (see Ueno Y et al). 2000;31: 966-974
Nakamura T (see Lai G-H et al). 2000;31: 1257-1265
Nakano T (see Ito T et al). 2000;31:1080-1085
Nalpas B (see Pol S et al). 2000;31:1338-1344
Narumi S (see Totsuka E et al). 2000;31: 577-580
Nass CC (see Murphy EL et al). 2000;31: 756-762
Nath A (see Christ B et al). 2000;31:461-468
Navasa M (see Sanchez-Fueyo A et al). 2000;31:496-501
Neal KR (see Murphy EL et al). 2000;31: 756-762
Nemo GJ (see Murphy EL et al). 2000;31: 756-762
Neuberger J. Urso— Panacea or placebo? 2000;31:1027-1028 (Hepatology *Elsewhere*)
Newby DE, Jalan R. Urotensin II: Better than somatostatin for portal hypertension? 2000;31:1201-1202 (Hepatology *Elsewhere*)
NHLBI Retrovirus Epidemiology Donor Study (REDS) (see Murphy EL et al). 2000;31:756-762
Nicoletti F (see Storto M et al). 2000;31: 649-655
Niederau C (see Erhardt A et al). 2000;31: 716-725
Nishiguchi S (see Morikawa H et al). 2000; 31:83-94
Nishioka K (see Lemon SM et al). 2000;31: 800-806 (Meeting Report)
Nishitai R (see Okabe H et al). 2000;31: 1073-1079
Nolan N (see Golden-Mason L et al). 2000; 31:1251-1256
Nomoto M (see Kawai H et al). 2000;31: 1246-1250
Nordling E (see Marschall H-U et al). 2000; 31:990-996
Noventa F (see De Francheschi L et al). 2000;31:997-1004

O

O'Donnell B (see Ireland JH et al). 2000;31: 1176-1182
O'Farrelly C (see Golden-Mason L et al). 2000;31:1251-1256
Ochiai T, Urata Y, Yamano T, Yamagishi H, Ashihara T. Clonal expansion in evolution of chronic hepatitis to hepatocellular carcinoma as seen at an X-chromosome locus. 2000;31:615-621
Oesen U (see Wiedman M et al). 2000;31: 230-234
Ohana M (see Nagler A et al). 2000;31:641-648
Okabe H, Ikai I, Matsuo K, Satoh S, Momoi H, Kamikawa T, Katsura N, Nishitai R, Takeyama O, Fukumoto M, Yamaoka Y. Comprehensive allelotype study of hepatocellular carcinoma: Potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. 2000;31:1073-1079
Okamoto S (see Liu Z-X et al). 2000;31: 665-673
Olkkonen H (see Lozeva V et al). 2000;31: 336-344
Ooi CG-C (see Yuen M-F et al). 2000;31: 330-335
Opocher E (see Roncalli M et al). 2000;31: 846-850
Oppermann UCT (see Marschall H-U et al). 2000;31:990-996
Orak J (see Contreras MA et al). 2000;31: 446-455
Ortiz-Berrocal J (see Pérez-Paramo M et al). 2000;31:43-48
Oshita M (see Tanaka Y et al). 2000;31: 890-898
Ott TL (see Kim H-T et al). 2000;31:1275-1284
Oue T (see Ito N et al). 2000;31:544-545 (Correspondence)
Ownby HE (see Murphy EL et al). 2000;31: 756-762
Oya H (see Minigawa M et al). 2000;31: 907-915
Ozasa H (see Ito K et al). 2000;31:416-419
Özen H (see Kocak N et al). 2000;31:545 (Correspondence)

P

Palareti G (see Piscaglia F et al). 2000;31: 349-357
Paliard X (see Lee AY et al). 2000;31:1327-1333
Pannunzio M (see Rose C et al). 2000;31: 872-877
Pappo O (see Nagler A et al). 2000;31:641-648
Parashar B (see Brown JJ et al). 2000;31: 173-181
Pardo A, Bartoli R, Lorenzo-Zúñiga V, Planas R, Viñado B, Riba J, Cabré E, Santos J, Luque T, Ausina V, Gassull MA. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis.2000;31: 858-863
Pardo M (see Cotonat T et al). 2000;31: 502-506
Parés X (see Borràs E et al). 2000;31:984-989
—(see Marschall H-U et al). 2000;31:990-996
Park JY (see Ahn SH et al). 2000;31:1371-1373
Park K (see Ahn SH et al). 2000;31:1371-1373
Park Y-H (see Suh K-S et al). 2000;31:12-17
Park YN (see Theise ND et al). 2000;31: 1380-1381 (Correspondence)
Parodi M (see Rolla R et al). 2000;31:878-884
Parola M (see Carloni V et al). 2000;31: 131-140
Pascale RM (see De Miglio MR et al). 2000; 31:956-965
Pascual MJ (see Macias RIR et al). 2000;31: 975-983
Pastorino JG, Hoek JB. Ethanol potentiates tumor necrosis factor-α cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition. 2000;31:1141-1152
Paulusma CC, Kothe MJC, Bakker CTM, Bosma PJ, van Bokhoven I, van Marle J, Bolder U, Tytgat GNJ, Elferink RPJO. Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver. 2000;31:684-693
Pavco PA (see Macejak DG et al). 2000;31: 769-776
Pawlotsky J-M (see Bastie A et al). 2000;31: 547-548 (Correspondence)
—(see Hezode C et al). 2000;31:809 (Correspondence)
Peine CJ (see Malinchoc M et al). 2000;31: 864-871

Peltekian K (*see* Villeneuve J-P et al). 2000; 31:207-210
Peng C-Y (*see* Tai D-I et al). 2000;31:656-664
Peny M-O (*see* Louis H et al). 2000;31:381-390
Perez RG (*see* Zein NN et al). 2000;31:808-809 (Correspondence)
Pérez-del-Pulgar S (*see* Castañeda B et al). 2000;31:581-586
Pérez-Paramo M, Muñoz J, Albillos A, Freile I, Portero F, Santos M, Ortiz-Berrocal J. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. 2000;31:43-48
Perrin D (*see* Gournay J et al). 2000;31: 1239-1245
Perseghin G, Mazzaferro V, Sereni LP, Regalia E, Benedini S, Bazzigaluppi E, Pulvirenti A, Leao AAS, Calori G, Romito R, Baratti D, Luzi L. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation. 2000;31:694-703
Persson B (*see* Marschall H-U et al). 2000; 31:990-996
Pessayre D (*see* Feldmann G et al). 2000; 31:674-683
Petersen JS (*see* Jonassen TEN et al). 2000; 31:1224-1230
Pettenazzo E (*see* Calabrese F et al). 2000; 31:1153-1159
Petzinger E (*see* Honscha W et al). 2000; 31:1296-1304
Pharm LD (*see* Marinelli RA et al). 2000; 31:1313-1317
Phillips MJP (*see* Schmidt WN et al). 2000; 31:737-744
Pien G (*see* Forman L et al). 2000;31:1029 (Correspondence)
Pines M (*see* Nagler A et al). 2000;31:641-648
Ping L (*see* Honda M et al). 2000;31:1351-1359
Pinzani M (*see* Carloni V et al). 2000;31: 131-140
Pinzello G (*see* Belli LS et al). 2000;31: 1345-1350
Piscaglia F, Siringo S, Hermida RC, Legnani C, Valgimigli M, Donati G, Palareti G, Gramantieri L, Gaiani S, Burroughs AK, Bolondi L. Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. 2000; 31:349-357
Pivetta B (*see* De Vita S et al). 2000;31:182-189
Pizcueta P (*see* Castañeda B et al). 2000;31: 581-586
Planas R (*see* Pardo A et al). 2000;31:858-863
Plumed C (*see* Lozeva V et al). 2000;31: 336-344
Pol S, Michel M-L, Bréchot C. Immune therapy of hepatitis B virus chronic infection. 2000;31:548-549 (Correspondence)
—, Nalpas B, Bourlière M, Couzigou P, Tran A, Abergel A, Zarski J-P, Berthelot P, Bréchot C, Multicenter Study Group (Necker Hospital, Paris, France). Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b–related chronic hepatitis C. 2000;31:1338-1344
Polakos NK (*see* Lee AY et al). 2000;31: 1327-1333
Poli F (*see* Belli LS et al). 2000;31:1345-1350
Poli G (*see* Cutrin JC et al). 2000;31:622-632
Pollicino T (*see* Cacciola et al). 2000;31: 507-512
Pomier-Layrargues G (*see* Villeneuve J-P et al). 2000;31:207-210
Pontisso P (*see* Calabrese F et al). 2000;31: 1153-1159
Porayko MK (*see* Gaweco AS et al). 2000; 31:1183-1191
—(*see* Brandhagen DJ et al). 2000;31:456-460
Porst H (*see* Wiedman M et al). 2000;31: 230-234
Portero F (*see* Pérez-Paramo M et al). 2000; 31:43-48
Poterucha JJ (*see* Kim WR et al). 2000;31: 807 (Correspondence)
Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR. Host genetic factors influence disease progression in chronic hepatitis C. 2000; 31:828-833
Powell LW (*see* Herath NI et al). 2000;31: 601-605
—(*see* MacDonald GA et al). 2000;31:549 (Correspondence)
Poynard T, McHutchison J, Goodman Z, Ling M-H, Albrecht J, ALGOVIRC Project Group. Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? 2000;31:211-218
Prati D (*see* Conte D et al). 2000;31:751-755
Press RD. Iron beware: A common *HFE* gene polymorphism may prevent the accurate molecular diagnosis of homozygous hemochromatosis in low-risk, but not high-risk groups. 2000; 31:540-542 (Hepatology *Elsewhere*)
Price D (*see* Galli A et al). 2000;31:101-108
Prieto J (*see* Castilla-Cortazar I et al). 2000; 31:592-600
—(*see* Castilla-Cortazar J et al). 2000;31: 1379 (Correspondence)
Pulvirenti A (*see* Perseghin G et al). 2000; 31:694-703
Purcell RH (*see* Cote PJ et al). 2000;31: 190-200
Purdie DM (*see* Powell EE et al). 2000;31: 828-833
Püschel GP (*see* Fennekohl A et al). 2000; 31:1128-1134

Q

Quattrocchi P (*see* Borràs E et al). 2000;31: 984-989
Quertinmont E (*see* Le Moine O et al). 2000;31:1266-1274
—(*see* Louis H et al). 2000;31:381-390
Quinn PG (*see* Jamal MM et al). 2000;31: 813 (Correction)
Quiroga J (*see* Castilla-Cortazar I et al). 2000;31:592-600
—(*see* Castilla-Cortazar J et al). 2000;31: 1379 (Correspondence)
—(*see* Cotonat T et al). 2000;31:502-506

R

Rabbani E (*see* Brown JJ et al). 2000;31: 173-181
—(*see* Nagler A et al). 2000;31:641-648
Racanelli V (*see* De Vita S et al). 2000;31: 182-189
Radaeva S (*see* Lai G-H et al). 2000;31: 1257-1265
Rahman F, Dahmen A, Herzog-Hauff S, Böcher WO, Galle PR, Löhr HF. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. 2000;31: 521-527
Raimondo G (*see* Cacciola et al). 2000;31: 507-512
Rambaldi A (*see* Rose C et al). 2000;31: 872-877
Rank J (*see* Malinchoc M et al). 2000;31: 864-871
Reddy KR (*see* Chalasani N et al). 2000;31: 7-11
Reeves HL, Thompson MG, Dack CL, Burt AD, Day CP. The role of phosphatidic acid in platelet-derived growth factor–induced proliferation of rat hepatic stellate cells. 2000;31:95-100
Regalia E (*see* Perseghin G et al). 2000;31: 694-703
Reineke U (*see* Erhardt A et al). 2000;31: 716-725
Reisner Y (*see* Böcher WO et al). 2000;31: 480-487
Remick DG (*see* Su GL et al). 2000;31:932-936
Reynoso-Paz S, Leung PSC, Van de Water J, Tanaka A, Munoz A, Bass N, Lindor K, Donald PJ, Coppel RL, Ansari AA, Gershwin ME. Evidence for a locally driven mucosal response and the presence of mitochondrial antigens in saliva in primary biliary cirrhosis. 2000; 31:24-29
Riba J (*see* Pardo A et al). 2000;31:858-863
Ricci D (*see* Roncalli M et al). 2000;31:846-850
Richart C (*see* Borràs E et al). 2000;31:984-989
Richelmi P (*see* Storto M et al). 2000;31: 649-655
Rigotti A, Cohen DE. The Tangier disease gene encodes yet another pathophysi-

ologically relevant ATP-binding cassette protein. 2000;31:538-539 (Hepatology *Elsewhere*)
Rimola A (*see* Sanchez-Fueyo A et al). 2000;31:496-501
Rivas-Estilla AM (*see* Greenwel P et al). 2000;31:109-116
—(*see* Iraburu MJ et al). 2000;31:1086-1093
Roberts B (*see* Mohr L et al). 2000;31:606-614
Roberts EC (*see* Macejak DG et al). 2000;31:769-776
Roberts RA, James NH, Cosulich SC. The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor α-mediated rat hepatocyte survival and apoptosis. 2000;31:420-427
Rodés J (*see* Escorsell A et al). 2000;31:1061-1067
—(*see* Llovet JM et al). 2000;31:54-58
—(*see* Sanchez-Fueyo A et al). 2000;31:496-501
Rodger AJ, Jolley D, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. 2000;31:1029-1030 (Correspondence)
Roh HR (*see* Suh K-S et al). 2000;31:12-17
Rojkind M (*see* Greenwel P et al). 2000;31:109-116
—(*see* Iraburu MJ et al). 2000;31:1086-1093
Rolla R, Vay D, Mottaran E, Parodi M, Traverso N, Aricó S, Sartori M, Bellomo G, Klassen LW, Thiele GM, Tuma DJ, Albano E. Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease. 2000;31:878-884
Romanelli RG (*see* Carloni V et al). 2000;31:131-140
Romito R (*see* Perseghin G et al). 2000;31:694-703
Roncalli M, Bianchi P, Grimaldi GC, Ricci D, Laghi L, Maggioni M, Opocher E, Borzio M, Coggi G. Fractional allelic loss in non–end-stage cirrhosis: Correlations with hepatocellular carcinoma development during follow-up. 2000;31:846-850
—, Borzio M. "Vascular profiles" of regenerative and dysplastic nodules. 2000;31:1381 (Correspondence)
Rondinara G (*see* Belli LS et al). 2000;31:1345-1350
Rose C, Michalak A, Pannunzio M, Chatauret N, Rambaldi A, Butterworth RF. Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure. 2000;31:872-877
Rosell A (*see* Borràs E et al). 2000;31:984-989
Rosen I (*see* Forman L et al). 2000;31:1029 (Correspondence)
Rosenbaum J (*see* Godichaud S et al). 2000;31:922-931
Rosenberg D, Ilic Z, Yin L, Sell S. Proliferation of hepatic lineage cells of normal C57BL and interleukin-6 knockout mice after cocaine-induced periportal injury. 2000;31:948-955
Roth WK (*see* Sarrazin C et al). 2000;31:1360-1370
Roudot-Thoraval F (*see* Bastie A et al). 2000;31:547-548 (Correspondence)
Roy-Chowdhury J (*see* Brown JJ et al). 2000;31:173-181
Roy-Chowdhury N (*see* Brown JJ et al). 2000;31:173-181
Rubin M (*see* Konikoff FM et al). 2000;31:261-268
Rüdiger HA, Clavien P-A. A cytotoxic drug against reperfusion injury? 2000;31:533-535 (Editorial)
Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. 2000;31:299-303
Russo MW, Zacks SL, Sandler RS, Brown RS Jr. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. 2000;31:358-363
Russo-Marie F (*see* de Coupade C et al). 2000;31:371-380
Rüster B (*see* Sarrazin C et al). 2000;31:1360-1370
Rustgi VK (*see* Gaweco AS et al). 2000;31:1183-1191
Rusyn I (*see* Iimuro Y et al). 2000;31:391-398

S

Sacerdoti D (*see* Merkel C et al). 2000;31:324-329
Saeki A (*see* Ito N et al). 2000;31:544-545 (Correspondence)
Sakisaka S (*see* Kawaguchi T et al). 2000;31:1285-1295
Sala M (*see* Llovet JM et al). 2000;31:54-58
Salter KD (*see* Doctor RB et al). 2000;31:1045-1054
Saltik IN (*see* Koçak N et al). 2000;31:545 (Correspondence)
Salzano R (*see* Galli A et al). 2000;31:101-108
Samarasinghe D (*see* Khan MH et al). 2000;31:513-520
—, Tapner M, Farrell GC. Role of oxidative stress in hypoxia-reoxygenation injury to cultured rat hepatic sinusoidal endothelial cells. 2000;31:160-165
Sanada K (*see* Ito K et al). 2000;31:416-419
Sanchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, Cirera I, Sanchez-Tapias JM, Rodés J. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. 2000;31:496-501
Sanchez-Tapias JM (*see* Sanchez-Fueyo A et al). 2000;31:496-501
Sandler RS (*see* Russo MW et al). 2000;31:358-363
Sansonno D (*see* De Vita S et al). 2000;31:182-189
Santantonio T (*see* Cacciola et al). 2000;31:507-512
Santos J (*see* Pardo A et al). 2000;31:858-863
Santos M (*see* Borràs E et al). 2000;31:984-989
—(*see* Pérez-Paramo M et al). 2000;31:43-48
Santrach PJ (*see* Czaja AJ et al). 2000;31:1231-1238
Santucci L, Fiorucci S, Cammilleri F, Servillo G, Federici B, Morelli A. Galectin-1 exerts immunomodulatory and protective effects on concanavalin A–induced hepatitis in mice. 2000;31:399-406
Sarasin FP (*see* Majno PE et al). 2000;31:899-906
Sarraf CE (*see* Mitry RR et al). 2000;31:885-889
Sarrazin C, Kornetzky I, Rüster B, Lee J-H, Kronenberger B, Bruch K, Roth WK, Zeuzem S. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. 2000;31:1360-1370
Sartori M (*see* Rolla R et al). 2000;31:878-884
Sasaki M (*see* Totsuka E et al). 2000;31:577-580
Sasaki Y (*see* Tanaka Y et al). 2000;31:890-898
Sasatomi K (*see* Kawaguchi T et al). 2000;31:1285-1295
Sassa S (*see* Akagi R et al). 2000;31:704-708
Sata M (*see* Kawaguchi T et al). 2000;31:1285-1295
Sato C (*see* Nagayama K et al). 2000;31:745-750
Sato H (*see* Tateno C et al). 2000;31:65-74
Sato N (*see* Kuo K-K et al). 2000;31:59-64
—(*see* Yin M et al). 2000;31:117-123
Satoh S (*see* Okabe H et al). 2000;31:1073-1079
Sawada N (*see* Kawaguchi T et al). 2000;31:1285-1295
Saxena R (*see* Thiese ND et al). 2000;31:235-240 (Rapid Communication)
Scalamogna M (*see* Belli LS et al). 2000;31:1345-1350
Schmidt F (*see* Berr F et al). 2000;31:291-298
Schmidt WN, Stapleton JT, LaBrecque DR, Mitros FA, Kirby PA, Phillips MJP, Brashear DL. Hepatitis C virus (HCV) infection and cryoglobulinemia: Analysis of whole blood and plasma HCV-RNA concentrations and correla-

tion with liver histology. 2000;31:737-744
Schneider B (see Kramer L et al). 2000;31:30-34
Schreiber GB (see Murphy EL et al). 2000;31:756-762
Schroeder S (see Wiedman M et al). 2000;31:230-234
Schulte SJ (see Ko CW et al). 2000;31:18-23
Schuppan D, Hahn EG. Herbal products for liver diseases. 2000;31:546-547 (Correspondence)
Schwenk R (see Guebre-Xabier M et al). 2000;31:633-640
Seabra V (see Yin M et al). 2000;31:117-123
Sebastianelli G (see Merkel C et al). 2000;31:324-329
Sebti SM (see Carloni V et al). 2000;31:131-140
Seeff L (see Lemon SM et al). 2000;31:800-806 (Meeting Report)
Sehayek E. Role of the CDP-choline and the alternative pathway for phosphatidylcholine biosynthesis. 2000;31:543 (Correspondence)
Seitz HK (see Borràs E et al). 2000;31:984-989
—(see Marschall H-U et al). 2000;31:990-996
Sell S (see Rosenberg D et al). 2000;31:948-955
—(see Thiese ND et al). 2000;31:235-240 (Rapid Communication)
Selzner M, Clavien P-A. Failure of regeneration of the steatotic rat liver: Disruption at two different levels in the regeneration pathway. 2000;31:35-42
Sereni LP (see Perseghin G et al). 2000;31:694-703
Serrano MA (see Macias RIR et al). 2000;31:975-983
Servillo G (see Santucci L et al). 2000;31:399-406
Shanahan F (see Fanning L et al). 2000;31:225-229
—(see Fanning LJ et al). 2000;31:1334-1337
Shankara S (see Mohr L et al). 2000;31:606-614
Sharkey KA (see Tjandra K et al). 2000;31:280-290
Sheehan M (see Fanning L et al). 2000;31:225-229
Sheen I-S (see Tai D-I et al). 2000;31:656-664
Sheen P-C (see Kuo K-K et al). 2000;31:59-64
Sherwood KM (see Younossi et al). 2000;31:807-808 (Correspondence)
Shi Y-Z (see Hui A-M et al). 2000;31:1068-1072
Shigematsu H (see Shimoda S et al). 2000;31:1212-1216
Shimazaki T (see Honda M et al). 2000;31:1351-1359
Shimizu R (see Akagi R et al). 2000;31:704-708
Shimizu T (see Kawai H et al). 2000;31:1246-1250
—(see Minigawa M et al). 2000;31:907-915
Shimoda S, Nakamura M, Shigematsu H, Tanimoto H, Gushima T, Gershwin ME, Ishibashi H. Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. 2000;31:1212-1216
Shimosegawa T (see Ueno Y et al). 2000;31:966-974
Shimotohno K (see Marusawa H et al). 2000;31:488-495
Shiomi S (see Morikawa H et al). 2000;31:83-94
Shiraki K (see Ito T et al). 2000;31:1080-1085
Shorthouse C (see Powell EE et al). 2000;31:828-833
Shouval D (see Böcher WO et al). 2000;31:480-487
Silini E (see Belli LS et al). 2000;31:1345-1350
Simile MM (see De Miglio MR et al). 2000;31:956-965
Singer ME (see Younossi ZM et al). 2000;31:807-808 (Correspondence)
Singh AK (see Contreras MA et al). 2000;31:446-455
Singh I (see Contreras MA et al). 2000;31:446-455
Sirica AE (see Lai G-H et al). 2000;31:1257-1265
Siringo S (see Piscaglia F et al). 2000;31:349-357
Smith BT (see Contreras MA et al). 2000;31:446-455
Smith C (see Angulo P et al). 2000;31:318-323
Solero P (see De Francheschi L et al). 2000;31:997-1004
Solito E (see de Coupade C et al). 2000;31:371-380
Soni A (see Jamal MM et al). 2000;31:813 (Correction)
Sonin NV (see Bauer M et al). 2000;31:937-947
Sood G (see Chalasani N et al). 2000;31:7-11
Sørensen A-M (see Jonassen TEN et al). 2000;31:1224-1230
Sorrentino D (see De Vita S et al). 2000;31:182-189
Splendon R (see Carini R et al). 2000;31:166-172
Squadrito G (see Cacciola et al). 2000;31:507-512
St.-Pierre MV (see Macias RIR et al). 2000;31:975-983
Stanley A (see Forrest E et al). 2000;31:809-810
Stanzial AM (see De Francheschi L et al). 2000;31:997-1004
Stapleton JT (see Schmidt WN et al). 2000;31:737-744
Steinstraesser L (see Su GL et al). 2000;31:932-936
Sternlieb I. Wilson's disease and pregnancy. 2000;31:531-532 (Editorial)
Sticca A (see Angeli P et al). 2000;31:304-310
Stoica G (see Kim H-T et al). 2000;31:1275-1284
Stolz DB (see Kim T-H et al). 2000;31:75-82
Storto M, de Grazia U, Knopfel T, Canonico PL, Copani A, Richelmi P, Nicoletti F, Vairetti M. Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage. 2000;31:649-655
Strasberg SM (see Upadhya GA et al). 2000;31:1115-1122
Stremmel W (see Hübner C et al). 2000;31:562-571
Strieter RM (see Colletti LM et al). 2000;31:435-445
Stubblefield W (see Berge JJ et al). 2000;31:469-473
Sturm E, Zimmerman TL, Crawford AR, Svetlov SI, Sundaram P, Ferrara JLM, Karpen SJ, Crawford JM. Endotoxin-stimulated macrophages decrease bile acid uptake in WIF-B cells, a rat hepatoma hybrid cell line. 2000;31:124-130
Su GL, Klein RD, Aminlari A, Zhang HY, Steinstraesser L, Alarcon WH, Remick DG, Wang SC. Kupffer cell activation by lipopolysaccharide in rats: Role for lipopolysaccharide binding protien and Toll-like receptor 4. 2000;31:932-936
Suarez Y (see Llovet JM et al). 2000;31:54-58
Subbotin VM (see Tadic SD et al). 2000;31:1135-1140
Suda T (see Kawai H et al). 2000;31:1246-1250
Suematsu M, Ishimura Y. The heme oxygenase–carbon monoxide system: A regulator of hepatobiliary function. 2000;31:3-6 (Concise Review)
Sugimoto K (see Ito T et al). 2000;31:1080-1085
Suh K-S, Roh HR, Koh YT, Lee KU, Park Y-H, Kim S-W. Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. 2000;31:12-17
Sundaram P (see Sturm E et al). 2000;31:124-130
Surrenti C (see Galli A et al). 2000;31:101-108
Suzuki A (see Ito T et al). 2000;31:1080-1085
Suzuki H (see Lemon SM et al). 2000;31:800-806 (Meeting Report)
Suzuki K (see Kogure K et al). 2000;31:916-921
Suzuki Y (see Kawai H et al). 2000;31:1246-1250
Svensson S (see Marschall H-U et al). 2000;31:990-996
Svetlov SI (see Sturm E et al). 2000;31:124-130

Swain MG (*see* Tjandra K et al). 2000;31: 280-290
Szczepanek M (*see* Borràs E et al). 2000;31: 984-989

T

Tachibana M (*see* Nagasue N et al). 2000; 31:1107-1114
Tadic SD, Elm MS, Subbotin VM, Eagon PK. Hypogonadism precedes liver feminization in chronic alcohol-fed male rats. 2000;31:1135-1140
Tai D-I, Tsai S-L, Chen Y-M, Chuang Y-L, Peng C-Y, Sheen I-S, Yeh C-T, Chang KSS, Huang S-N, Kuo GC, Liaw Y-F. Activation of nuclear factor κB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis. 2000;31:656-664
Taioli E (*see* Belli LS et al). 2000;31:1345-1350
Takahashi K (*see* Totsuka E et al). 2000;31: 577-580
Takahashi T (*see* Kawai H et al). 2000;31: 1246-1250
Takai-Kajihara K (*see* Tateno C et al). 2000;31:65-74
Takase K (*see* Ito T et al). 2000;31:1080-1085
Takayama T (*see* Hui A-M et al). 2000;31: 1068-1072
Takeyama O (*see* Okabe H et al). 2000;31: 1073-1079
Talmon Y (*see* Konikoff FM et al). 2000;31: 261-268
Tam C-M (*see* Wong W-M et al). 2000;31: 201-206
Tamura S (*see* Ito N et al). 2000;31:544-545 (Correspondence)
Tanaka A (*see* Reynoso-Paz S et al). 2000; 31:24-29
Tanaka K (*see* Marusawa H et al). 2000;31: 488-495
Tanaka KE (*see* Brown JJ et al). 2000;31: 173-181
Tanaka M (*see* Kuo K-K et al). 2000;31: 59-64
Tanaka Y, Sasaki Y, Katayama K, Hiramatsu N, Ito A, Murata H, Enomoto N, Oshita M, Mochizuki K, Tsujii M, Tsuji S, Kasahara A, Tomoda K, Nakamura H, Hayashi N, Hori M. Probability of hepatocellular carcinoma of small hepatocellular nodules undetectable by computed tomography during arterial portography. 2000;31:890-898
Taniguchi E (*see* Kawaguchi T et al). 2000; 31:1285-1295
Tanimoto H (*see* Shimoda S et al). 2000;31: 1212-1216
Tannapfel A (*see* Berr F et al). 2000;31: 291-298
Tapner M (*see* Samarasinghe DA et al). 2000;31:160-165
Tateno C, Takai-Kajihara K, Yamasaki C, Sato H, Yoshizato K. Heterogeneity of growth potential of adult rat hepatocytes *in vitro*. 2000;31:65-74
Taub R (*see* Kovalovich K et al). 2000;31: 149-159
Tavill AS (*see* Fontana RJ et al). 2000;31: 730-736
Tennant BC (*see* Cote PJ et al). 2000;31: 190-200
—(*see* Korba BE et al). 2000;31:1165-1175
ter Borg PCJ (*see* Malinchoc M et al). 2000; 31:864-871
Terajima H, Enders G, Thiaener A, Hammer C, Kondo T, Thiery J, Yamamoto Y, Yamaoka Y, Messmer K. Impact of hyperthermic preconditioning on postischemic hepatic microcirculatory disturbances in an isolated perfusion model of the rat liver. 2000;31:407-415
Terkieltaub D (*see* Böcher WO et al). 2000; 31:480-487
Theise ND, Badve S, Saxena R, Henegariu O, Sell S, Crawford JM, Krause DS. Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. 2000;31:235-240 (Rapid Communication)
—, Park YN, Thung SN. "Vascular profiles" of regenerative and dysplastic nodules. 2000;31:1380-1381 (Correspondence)
Therneau TM (*see* Brandhagen DJ et al). 2000;31:456-460
Thevenot T (*see* Di Martino V et al). 2000; 31:1030-1031 (Correspondence)
Thiaener A (*see* Terajima H et al). 2000;31: 407-415
Thibodeau SN (*see* Brandhagen DJ et al). 2000;31:456-460
Thiele GM (*see* Rolla R et al). 2000;31:878-884
Thiery J (*see* Terajima H et al). 2000;31: 407-415
Thiim M (*see* Fontana RJ et al). 2000;31: 730-736
Thio CL, Thomas DL, Carrington M. Chronic viral hepatitis and the human genome. 2000;31:819-827 (Concise Review)
Thomas DL. Hepatitis C epidemiology: Injecting new tools in the field. 2000; 31:790-791 (Editorial)
—(*see* Thio CL et al). 2000;31:819-827 (Concise Review)
Thompson MG (*see* Reeves HL et al). 2000; 31:95-100
Thomsen N (*see* Honscha W et al). 2000; 31:1296-1304
Thomson RA (*see* Murphy EL et al). 2000; 31:756-762
Thung SN (*see* Theise ND et al). 2000;31: 1380-1381 (Correspondence)
Thurman RG (*see* Iimuro Y et al). 2000;31: 391-398
—(*see* Yin M et al). 2000;31:117-123
Tietz PS (*see* Marinelli RA et al). 2000;31: 1313-1317
Tjandra K, Sharkey KA, Swain MG. Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis. 2000;31: 280-290
Tolu P (*see* De Miglio MR et al). 2000;31: 956-965
Tomoda K (*see* Tanaka Y et al). 2000;31: 890-898
Tong MJ (*see* Macejak DG et al). 2000;31: 769-776
Torboli P (*see* Merkel C et al). 2000;31: 324-329
Tortorelli K (*see* Fontana RJ et al). 2000;31: 730-736
Torzilli G (*see* Hui A-M et al). 2000;31: 1068-1072
Totsuka E, Fung JJ, Urakami A, Moras N, Ishii T, Takahashi K, Narumi S, Hakamada K, Sasaki M. Influence of donor cardiopulmonary arrest in human liver transplantation: Possible role of ischemic preconditioning. 2000;31: 577-580
Toyota T (*see* Ueno Y et al). 2000;31:966-974
Tran A (*see* Pol S et al). 2000;31:1338-1344
Traverso N (*see* Rolla R et al). 2000;31:878-884
Traynor O (*see* Golden-Mason L et al). 2000;31:1251-1256
Tribl B (*see* Kramer L et al). 2000;31:30-34
Tsai S-L (*see* Tai D-I et al). 2000;31:656-664
Tsuchida AM (*see* Ko CW et al). 2000;31: 18-23
Tsuji S (*see* Tanaka Y et al). 2000;31:890-898
Tsujii M (*see* Tanaka Y et al). 2000;31:890-898
Tsukada K (*see* Kawai H et al). 2000;31: 1246-1250
Tuma DJ (*see* Rolla R et al). 2000;31:878-884
Tuomisto L (*see* Lozeva V et al). 2000;31: 336-344
Turrini F (*see* De Francheschi L et al). 2000;31:997-1004
Tytgat GNJ (*see* Paulusma CC et al). 2000; 31:684-693

U

Udagawa J (*see* Nagasue N et al). 2000;31: 1107-1114
Ueda Y (*see* Marusawa H et al). 2000;31: 488-495
Uemoto S (*see* Marusawa H et al). 2000;31: 488-495
Ueno T (*see* Kawaguchi T et al). 2000;31: 1285-1295
Ueno Y, Ishii M, Yahagi K, Mano Y, Kisara N, Nakamura N, Shimosegawa T, Toyota T, Nagata S. Fas-mediated cholangiopathy in the murine model of graft versus host disease. 2000;31: 966-974

Ulmer JB (*see* Lee AY et al). 2000;31:1327-1333
Upadhya GA, Strasberg SM. Glutathione, lactobionate, and histidine: Cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions. 2000;31:1115-1122
Urakami A (*see* Totsuka E et al). 2000;31:577-580
Urata Y (*see* Ochiai T et al). 2000;31:615-621

V

Vairetti M (*see* Storto M et al). 2000;31:649-655
Valente M (*see* Calabrese F et al). 2000;31:1153-1159
Valgimigli M (*see* Piscaglia F et al). 2000;31:349-357
Valjakka A (*see* Lozeva V et al). 2000;31:336-344
Valla D (*see* Denninger M-H et al). 2000;31:587-591
Valla D (*see* Di Martino V et al). 2000;31:1030-1031 (Correspondence)
van Bokhoven I (*see* Paulusma CC et al). 2000;31:684-693
Van de Water J (*see* Reynoso-Paz S et al). 2000;31:24-29
van Marle J (*see* Paulusma CC et al). 2000;31:684-693
Van Thiel DH (*see* Gaweco AS et al). 2000;31:1183-1191
Vance DE (*see* Agellon LB et al). 2000;31:543 (Correspondence)
Vargas V (*see* Llovet JM et al). 2000;31:54-58
Vario A (*see* Calabrese F et al). 2000;31:1153-1159
Vay D (*see* Rolla R et al). 2000;31:878-884
Veggian R (*see* Angeli P et al). 2000;31:304-310
Vergani D (*see* Bogdanos D-P et al). 2000;31:1380 (Correspondence)
Verkade HJ (*see* Agellon LB et al). 2000;31:543 (Correspondence)
Vidal F (*see* Borràs E et al). 2000;31:984-989
Vilana R (*see* Llovet JM et al). 2000;31:54-58
Villari D (*see* Cacciola et al). 2000;31:507-512
Villeneuve J-P, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. 2000;31:207-210
Viñado B (*see* Pardo A et al). 2000;31:858-863
Volpin R (*see* Angeli P et al). 2000;31:304-310
von Carlowitz I (*see* Macejak DG et al). 2000;31:769-776

W

Waguri N (*see* Kawai H et al). 2000;31:1246-1250
Walkey CJ (*see* Agellon LB et al). 2000;31:543 (Correspondence)
Wallace LA (*see* Ireland JH et al). 2000;31:1176-1182
Walsh MD (*see* Herath NI et al). 2000;31:601-605
Wands JR (*see* Mohr L et al). 2000;31:606-614
Wang SC (*see* Su GL et al). 2000;31:932-936
Wang X, Kanel GC, DeLeve LD. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. 2000;31:428-434
Wang Y (*see* Ankoma-Sey V et al). 2000;31:141-148
Ward PJ (*see* MacDonald GA et al). 2000;31:549 (Correspondence)
Weihs D (*see* Konikoff FM et al). 2000;31:261-268
Weinberg M (*see* Berge JJ et al). 2000;31:469-473
Weltman M (*see* Khan MH et al). 2000;31:513-520
Westland CE (*see* Xiong X et al). 2000;31:219-224
Wheeler DE (*see* Jamal MM et al). 2000;31:813 (Correction)
Wheeler MD (*see* Yin M et al). 2000;31:117-123
Whelton M (*see* Fanning LJ et al). 2000;31:225-229
—(*see* Fanning LJ et al). 2000;31:1334-1337
Whitehall VLJ (*see* Herath NI et al). 2000;31:601-605
Wiedmann M (*see* Berr F et al). 2000;31:291-298
—, Liebert UG, Oesen U, Porst H, Wiese M, Schroeder S, Halm U, Mössner J, Berr F. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. 2000;31:230-234
Wiese M (*see* Wiedman M et al). 2000;31:230-234
Wiesner RH (*see* Gaweco AS et al). 2000;31:1183-1191
—(*see* Zein NN et al). 2000;31:808-809 (Correspondence)
Willems B (*see* Villeneuve J-P et al). 2000;31:207-210
Williams AE (*see* Murphy EL et al). 2000;31:756-762
Wittekind C (*see* Berr F et al). 2000;31:291-298
Wong F (*see* Villeneuve J-P et al). 2000;31:207-210
Wong ML (*see* Chan HLY et al). 2000;31:763-768
Wong P-C (*see* Wong W-M et al). 2000;31:201-206
Wong W-M, Wu P-C, Yuen M-F, Cheng C-C, Yew W-W, Wong P-C, Tam C-M, Leung C-C, Lai C-L. Antituberculosis drug–related liver dysfunction in chronic hepatitis B infection. 2000;31:201-206
Wright TL (*see* Hirsch KR et al). 2000;31:536-537 (Editorial)
Wu P-C (*see* Wong W-M et al). 2000;31:201-206
Wynne F (*see* Fanning LJ et al). 2000;31:1334-1337

X

Xiong X, Yang H, Westland CE, Zou R, Gibbs CS. *In vitro* evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. 2000;31:219-224

Y

Yahagi K (*see* Ueno Y et al). 2000;31:966-974
Yamagishi H (*see* Ochiai T et al). 2000;31:615-621
Yamamoto A (*see* Nagasue N et al). 2000;31:1107-1114
Yamamoto S (*see* Minigawa M et al). 2000;31:907-915
Yamamoto Y (*see* Terajima H et al). 2000;31:407-415
Yamanaka T (*see* Ito T et al). 2000;31:1080-1085
Yamano T (*see* Ochiai T et al). 2000;31:615-621
Yamanoi A (*see* Nagasue N et al). 2000;31:1107-1114
Yamaoka Y (*see* Okabe H et al). 2000;31:1073-1079
—(*see* Terajima H et al). 2000;31:407-415
Yamasaki C (*see* Tateno C et al). 2000;31:65-74
Yamashina S (*see* Iimuro Y et al). 2000;31:391-398
Yang H (*see* Xiong X et al). 2000;31:219-224
Yang S (*see* Guebre-Xabier M et al). 2000;31:633-640
Yazici E (*see* Christ B et al). 2000;31:461-468
Yeh C-T (*see* Tai D-I et al). 2000;31:656-664
—, Chien R-N, Chu C-M, Liaw Y-F. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. 2000;31:1318-1326
Yen TSB. Nuclear factor κB and hepatitis C—Is there a connection? 2000;31:785-787 (Editorial)
Yew W-W (*see* Wong W-M et al). 2000;31:201-206
Yin L (*see* Rosenberg D et al). 2000;31:948-955
Yin M, Ikejima K, Wheeler MD, Bradford BU, Seabra V, Forman DT, Sato N, Thurman RG. Estrogen is involved in

early alcohol-induced liver injury in a rat enteral feeding model. 2000;31: 117-123
Yokoyama Y (see Bauer M et al). 2000;31: 937-947
Yonemasu H (see Kuo K-K et al). 2000;31: 59-64
Yong S (see Gaweco AS et al). 2000;31: 1183-1191
Yoon S-K (see Mohr L et al). 2000;31:606-614
Yoshizato K (see Tateno C et al). 2000;31: 65-74
Young J (see Herath NI et al). 2000;31:601-605
Younossi ZM (see Zdilar D et al). 2000;31: 1207-1211 (Concise Review)
—, Singer ME, McHutchison JG, Shermock KM. Cost-effectiveness of interferon alfa-2b and ribavirin in the treatment of chronic hepatitis C. 2000;31:807-808 (Correspondence)
Yüce A (see Koçak N et al). 2000;31:545 (Correspondence)
Yuen M-F (see Wong W-M et al). 2000;31: 201-206
—, Cheng C-C, Launder IJ, Lam S-K, Ooi CG-C, Lai C-L. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. 2000;31:330-335

Z

Zacks SL (see Russo MW et al). 2000;31: 358-363
Zaman A (see Chalasani N et al). 2000;31: 7-11
Zarski J-P (see Pol S et al). 2000;31:1338-1344
Zauner C (see Kramer L et al). 2000;31: 30-34
Zavaglia C (see Belli LS et al). 2000;31: 1345-1350
Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. 2000; 31:1207-1211 (Concise Review)
Zein NN, Perez RG, Wiesner RH. Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation. 2000;31:808-809 (Correspondence)
Zeira M (see Nagler A et al). 2000;31:641-648
Zervos X (see Chalasani N et al). 2000;31: 7-11
Zeuzem S (see Sarrazin C et al). 2000;31: 1360-1370
Zhang H (see Honda M et al). 2000;31: 1351-1359
Zhang HY (see Su GL et al). 2000;31:932-936
Zhang JX (see Bauer M et al). 2000;31:937-947
Zhang Y-Q (see Kogure K et al). 2000;31: 916-921
Zignego AL, Giannelli F, Marrocchi ME, Mazzocca A, Ferri C, Giannini C, Monti M, Caini P, La Villa G, Laffi G, Gentilini P. t(14;18) translocation in chronic hepatitis C virus infection. 2000;31:474-479
Zimmerman TL (see Sturm E et al). 2000; 31:124-130
Zingaro B (see Cutrin JC et al). 2000;31: 622-632
Zou R (see Xiong X et al). 2000;31:219-224

Subject Index to Volume 31*

A

AASLD Practice Guidelines
Management of primary biliary cirrhosis (Heathcote). 2000;31:1005-1013 (AASLD Practice Guidelines)

Acetaldehyde
Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease (Rolla et al). 2000;31:878-884
Hydrogen peroxide: A link between acetaldehyde-elicited α1(1) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells (Greenwel et al). 2000;31:109-116

Activin
The role of activin and transforming growth factor-β in the regulation of organ mass in the rat liver (Kogure et al). 2000;31:916-921

Acute liver failure
Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure (Rose et al). 2000;31:872-877

Ad-p53
Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment (Mitry et al). 2000;31:885-889

Adenosine triphosphate (ATP)
ATP depletion in rat cholangiocytes leads to marked internalization of membrane proteins (Doctor et al). 2000;31:1045-1054
The Tangier disease gene encodes yet another pathophysiologically relevant ATP-binding cassette protein (Rigotti and Cohen). 2000;31:538-539 (Hepatology *Elsewhere*)

Adenoviral gene transfer
Gene therapy of hepatocellular carcinoma *in vitro* and *in vivo* in nude mice by adenoviral transfer of the *Escherichia coli* purine nucleoside phosphorylase gene (Mohr et al). 2000;31:606-614

Adenovirus
Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment (Mitry et al). 2000;31:885-889
Fas- and tumor necrosis factor receptor 1-dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice (Liu et al). 2000;31:665-673

Adhesion molecules
Sublobular veins as the main site of lymphocyte adhesion/transmigration and adhesion molecule expression in the porto-sinusoidal-hepatic venous system during concanavalin A–induced hepatitis in mice (Morikawa et al). 2000;31:83-94

Alanine aminotransferase
Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the southwestern United States (Jamal et al). 2000;31:813 (Correction)
Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus–infected patients (Di Martino et al). 2000;31:1030-1031 (Correspondence)

Alcohol dehydrogenase
Genetic polymorphism of alcohol dehydrogenase in Europeans: The *ADH2*2* allele decreases the risk for alcoholism and is associated with *ADH3*1* (Borràs et al). 2000;31:984-989

Alcohol dehydrogenase γγ isozyme
Human liver class I alcohol dehydrogenase γγ isozyme: The sole cytosolic 3-hydroxysteroid dehydrogenase of iso bile acids (Marschall et al). 2000;31:990-996

Alcohol-induced liver injury
Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease (Rolla et al). 2000;31:878-884
Estrogen is involved in early alcohol-induced liver injury in a rat enteral feeding model (Yin et al). 2000;31:117-123
Hypogonadism precedes liver feminization in chronic alcohol-fed male rats (Tadic et al). 2000;31:1135-1140
The glutathione precursor L-2-oxothiazolodine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat (Iimuro et al). 2000;31:391-398

Alcoholism
Genetic polymorphism of alcohol dehydrogenase in Europeans: The *ADH2*2* allele decreases the risk for alcoholism and is associated with *ADH3*1* (Borràs et al). 2000;31:984-989

Allelotypes
Comprehensive allelotype study of hepatocellular carcinoma: Potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors (Okabe et al). 2000;31:1073-1079

Allograft rejection
Update of the international Banff schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection (Demetris et al). 2000;31:792-799 (Meeting Report)

Amino acids
Amino acid sequence of EC2 domain in CD81 is highly conserved in Japanese subjects (Ito et al). 2000;31:544-545 (Correspondence)

δ-Aminolevulinate dehydratase
Novel molecular defects of the δ-aminolevulinate dehydratase gene in a patient with inherited acute hepatic porphyria (Akagi et al). 2000;31:704-708

Ammonia
Partial pressure of ammonia versus ammonia in hepatic encephalopathy (Kramer et al). 2000;31:30-34

Amphetamines
Implication of Bcl-2 family genes in basal and D-amphetamine–induced apoptosis in preneoplastic and neoplastic rat liver lesions (De Miglio et al). 2000;31:956-965

Anastomosis, portacaval
Effects of the histamine H_1 receptor blocker, pyrilamine, on spontaneous locomotor activity of rats with long-term portacaval anastomosis (Lozeva et al). 2000;31:336-344

Annexin I
Annexin I expression and phosphorylation are upregulated during liver regeneration and transformation in antithrombin III SV40 T large antigen transgenic mice (de Coupade et al). 2000;31:371-380

Antituberculosis drugs
Antituberculosis drug–related liver dysfunction in chronic hepatitis B infection (Wong et al). 2000;31:201-206

*January, 1-254; February, 255-554; March, 555-818; April, 818-1036; May, 1037-1206; June, 1207-1426.

Apolipoprotein E
Apolipoprotein E genotype and the risk of gallbladder disease in pregnancy (Ko et al). 2000;31:18-23
Apoptosis
Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment (Mitry et al). 2000;31:885-889
Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells (Honda et al). 2000;31:1351-1359
Implication of Bcl-2 family genes in basal and D-amphetamine–induced apoptosis in preneoplastic and neoplastic rat liver lesions (De Miglio et al). 2000;31:956-965
Interferon tau–induced hepatocyte apoptosis in sheep (Kim et al). 2000;31:1275-1284
Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels (Calabrese et al). 2000;31:1153-1159
Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice (Feldmann et al). 2000;31:674-683
The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor α–mediated rat hepatocyte survival and apoptosis (Roberts et al).
Aquaporin-4
Expression of aquaporin-4 water channels in rat cholangiocytes (Marinelli et al). 2000;31:1313-1317
Arterial portography
Probability of hepatocellular carcinoma of small hepatocellular nodules undetectable by computed tomography during arterial portography (Tanaka et al). 2000;31:890-898
Arterial vasoconstriction
Local arterial vasoconstriction induced by octreotide in patients with cirrhosis (Chatila et al). 2000;31:572-576
Artery, hepatic
The isolated artery: An intrahepatic arterial pathway that can bypass the lobular parenchyma in mammalian livers (Ekataksin). 2000;31:269-279
Ascites
Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites (Angeli et al). 2000;31:304-310
Assays, diagnostic
Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays (Ireland et al). 2000;31:1176-1182
Autoimmune cholangitis
Autoimmune cholangitis within the spectrum of autoimmune liver disease (Czaja et al). 2000;31:1231-1238
Autoimmune liver disease
Autoimmune cholangitis within the spectrum of autoimmune liver disease (Czaja et al). 2000;31:1231-1238
Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis (De Vita et al). 2000;31:182-189
Autoimmune hepatitis
Autoimmune hepatitis: The investigational and clinical challenges (Czaja et al). 2000;31:1194-1200 (Meeting Report)
Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis (Agarwal et al). 2000;31:49-53
Hepatitis C and autoimmune hepatitis (Cerny et al). 2000;31:811-812 (Correspondence)
Hepatitis C virus and autoimmunity (Bogdanos et al). 2000;31:1380 (Correspondence)

B

Bacterial translocation
Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis (Pardo et al). 2000;31:858-863
Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites (Perez-Paramo et al). 2000;31:43-48
Bcl-2 family genes
Implication of Bcl-2 family genes in basal and D-amphetamine–induced apoptosis in preneoplastic and neoplastic rat liver lesions (De Miglio et al). 2000;31:956-965
Beta blockers
Carvediol–A new nonselective beta blocker (Forrest et al). 2000;31:809-810 (Letter); (Banares et al). 2000;31:810-811 (Reply)
Bile acids
Bile acid synthesis in cultured human hepatocytes: Support for an alternative biosynthetic pathway to cholic acid (Axelson et al). 2000;31:1305-1312
Cloning and functional characterization of the bile acid sensitive methotrexate carrier from rat liver cells (Honscha et al). 2000;31:1296-1304
Effect of maternal cholestasis on bile acid transfer across the rat placenta-maternal liver tandem (Macias et al). 2000;31:975-983
Endotoxin-stimulated macrophages decrease bile acid uptake in WIF-B cells, a rat hepatoma hybrid cell line (Sturm et al). 2000;31:124-130
Human liver class I alcohol dehydrogenase γγ isozyme: The sole cytosolic 3-hydroxysteroid dehydrogenase of iso bile acids (Marschall et al). 2000;31:990-996
Bile ducts
Centrosome abnormalities in human carcinomas of the gallbladder and intrahepatic and extrahepatic bile ducts (Kuo et al). 2000;31:59-64
Microstructural evolution of lipid aggregates in nucleating model and human biles visualized by cryogenic transmission electron microscopy (Konikoff et al). 2000;31:261-268
Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival (Berr et al). 2000;31:291-298
Sodium, hydrogen exchange type 1 and bile ductular secretory activity in the guinea pig (Hubner et al). 2000;31:562-571
Biliary cirrhosis, primary
An exploratory population-based case-control study of primary biliary cirrhosis (Howel et al). 2000;31:1055-1060
Evidence for a locally driven mucosal response and the presence of mitochondrial antigens in saliva in primary biliary cirrhosis (Reynoso-Paz et al). 2000;31:24-29
Management of primary biliary cirrhosis (Heathcote). 2000;31:1005-1013 (AASLD Practice Guidelines)
Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis (Shimoda et al). 2000;31:1212-1216
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (Angulo et al). 2000;31:318-323
Urso–Panacea or placebo? (Neuberger). 2000;31:1027-1028 (Hepatology *Elsewhere*)
Biliary cirrhosis, secondary
Decreased carnitine biosynthesis in rats with secondary biliary cirrhosis (Krähenbühl et al). 2000;31:1217-1223
Biliary tract
An exploratory population-based case-control study of primary biliary cirrhosis (Howel et al). 2000;31:1055-1060

Apolipoprotein E genotype and the risk of gallbladder disease in pregnancy (Ko et al). 2000;31:18-23
ATP depletion in rat cholangiocytes leads to marked internalization of membrane proteins (Doctor et al). 2000; 31:1045-1054
Autoimmune cholangitis within the spectrum of autoimmune liver disease (Czaja et al). 2000;31:1231-1238
Bile acid synthesis in cultured human hepatocytes: Support for an alternative biosynthetic pathway to cholic acid (Axelson et al). 2000;31:1305-1312
Centrosome abnormalities in human carcinomas of the gallbladder and intrahepatic and extrahepatic bile ducts (Kuo et al). 2000;31:59-64
Decreased carnitine biosynthesis in rats with secondary biliary cirrhosis (Krähenbühl et al). 2000;31:1217-1223
Functional heterogeneity of the intrahepatic biliary epithelium (Kanno et al). 2000;31:555-561 (Concise Review)
Human liver class I alcohol dehydrogenase γγ isozyme: The sole cytosolic 3-hydroxysteroid dehydrogenase of iso bile acids (Marschall et al). 2000; 31:990-996
Management of primary biliary cirrhosis (Heathcote). 2000;31:1005-1013 (AASLD Practice Guidelines)
Microstructural evolution of lipid aggregates in nucleating model and human biles visualized by cryogenic transmission electron microscopy (Konikoff et al). 2000;31:261-268
Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis (Shimoda et al). 2000;31: 1212-1216
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (Angulo et al). 2000;31:318-323
$p27^{Kip1}$ expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: Association with cancer progression and prognosis (Hui et al). 2000;31:1068-1072
Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival (Berr et al). 2000;31:291-298
Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis (Tjandra et al). 2000;31:280-290
Sodium, hydrogen exchange type 1 and bile ductular secretory activity in the guinea pig (Hubner et al). 2000;31: 562-571
The heme oxygenase–carbon monoxide system: A regulator of hepatobiliary function (Suematsu and Ishimura). 2000;31:3-6 (Concise Review)
The isolated artery: An intrahepatic arterial pathway that can bypass the lobular parenchyma in mammalian livers (Ekataksin). 2000;31:269-279
Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver (Lai et al). 2000; 31:1257-1265

Blood donors
Risk factors for hepatitis C virus infection in United States blood donors (Murphy et al). 2000;31:756-762

Bone marrow
Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation (Thiese et al). 2000;31:235-240 (Rapid Communication)

Brain edema
Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure (Rose et al). 2000;31:872-877

Budesonide
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (Angulo et al). 2000;31:318-323

C

C282Y genotyping
Population screening for hemochromatosis: A comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors (Adams et al). 2000;31:1160-1164

C-peptide
Association of diabetes, serum insulin, and C-peptide with gallbladder disease (Ruhl and Everhart). 2000;31: 299-303

Cancer
Activation of nuclear factor κB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis (Tai et al). 2000;31:656-664
Centrosome abnormalities in human carcinomas of the gallbladder and intrahepatic and extrahepatic bile ducts (Kuo et al). 2000;31:59-64
Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study (Chalasani et al). 2000;31:7-11
Cholangiocarcinoma in primary sclerosing cholangitis: Who is at risk and how do we screen? (de Groen). 2000;31:247-248 (Editorial)
Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma (Suh et al). 2000;31:12-17
Clonal expansion in evolution of chronic hepatitis to hepatocellular carcinoma as seen at an X-chromosome locus (Ochiai et al). 2000;31:615-621
Comprehensive allelotype study of hepatocellular carcinoma: Potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors (Okabe et al). 2000;31:1073-1079
Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment (Mitry et al). 2000;31:885-889
Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver (Golden-Mason et al). 2000;31: 1251-1256
Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience (Yuen et al). 2000;31:330-335
Gene therapy of hepatocellular carcinoma *in vitro* and *in vivo* in nude mice by adenoviral transfer of the *Escherichia coli* purine nucleoside phosphorylase gene (Mohr et al). 2000;31:606-614
Implication of Bcl-2 family genes in basal and D-amphetamine–induced apoptosis in preneoplastic and neoplastic rat liver lesions (De Miglio et al). 2000;31:956-965
$p27^{Kip1}$ expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: Association with cancer progression and prognosis (Hui et al). 2000;31:1068-1072
Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival (Berr et al). 2000;31:291-298
Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: An outcome-oriented decision analysis (Majno et al). 2000;31:899-906
Probability of hepatocellular carcinoma of small hepatocellular nodules undetectable by computed tomography during arterial portography (Tanaka et al). 2000;31:890-898
Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma (Cancer of the Liver Italian Program (CLIP) Investigators). 2000;31:840-845
Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carci-

noma: Comparison of loss of heterozygosity and replication error (Kawai et al). 2000;31:1246-1250
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma (Llovet et al). 2000; 31:54-58
Surgical resection versus transplantation for early hepatocellular carcinoma: Clues for the best strategy (Llovet et al). 2000;31:1019-1021 (Editorial)
Survivin promotes cell proliferation in human hepatocellular carcinoma (Ito et al). 2000;31:1080-1085
Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver (Lai et al). 2000; 31:1257-1265

Carbon monoxide
The heme oxygenase–carbon monoxide system: A regulator of hepatobiliary function (Suematsu and Ishimura). 2000;31:3-6 (Concise Review)

Carbon tetrachloride
Increased natriuretic efficiency of furosemide in rats with carbon tetrachloride–induced cirrhosis (Jonassen et al). 2000;31:1224-1230

Cardiopulmonary arrest
Influence of donor cardiopulmonary arrest in human liver transplantation: Possible role of ischemic preconditioning (Totsuka et al). 2000;31:577-580

Carnitine
Decreased carnitine biosynthesis in rats with secondary biliary cirrhosis (Krähenbühl et al). 2000;31:1217-1223

Carvediol
Carvediol–A new nonselective beta blocker (Forrest et al). 2000;31:809-810 (Letter); (Banares et al). 2000; 31:810-811 (Reply)

CDP-choline
Role of the CDP-choline and the alternative pathway for phosphatidylcholine biosynthesis (Sehayek). 2000; 31:543 (Letter); (Agellon et al). 2000;31:543 (Reply)

Centrosomes
Centrosome abnormalities in human carcinomas of the gallbladder and intrahepatic and extrahepatic bile ducts (Kuo et al). 2000;31:59-64

Chemiluminescence
In situ determination by surface chemiluminescence of temporal relationships between evolving warm ischemia-reperfusion injury in rat liver and phagocyte activation and recruitment (Cutrin et al). 2000;31: 622-631

Chemokines
The ratio of ELR+ to ELR− CXC chemokines affects the lung and liver injury following hepatic ischemia/reperfusion in the rat (Colletti et al). 2000;31:435-445

Cholangiocarcinoma
Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study (Chalasani et al). 2000;31:7-11
Cholangiocarcinoma in primary sclerosing cholangitis: Who is at risk and how do we screen? (de Groen). 2000;31:247-248 (Editorial)
Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma (Suh et al). 2000;31:12-17

Cholangiocytes
ATP depletion in rat cholangiocytes leads to marked internalization of membrane proteins (Doctor et al). 2000; 31:1045-1054
Expression of aquaporin-4 water channels in rat cholangiocytes (Marinelli et al). 2000;31:1313-1317

Cholangiopathy
Fas-mediated cholangiopathy in the murine model of graft versus host disease (Ueno et al). 2000;31:966-974

Cholangitis
Autoimmune cholangitis within the spectrum of autoimmune liver disease (Czaja et al). 2000;31:1231-1238
Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study (Chalasani et al). 2000;31:7-11
Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis (Tjandra et al). 2000;31:280-290

Cholelithiasis
Cholelithiasis and the insulin resistance syndrome (Diehl). 2000;31:528-530 (Editorial)

Cholestasis
Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis (Kawaguchi et al). 2000;31:1285-1295
Effect of maternal cholestasis on bile acid transfer across the rat placenta-maternal liver tandem (Macias et al). 2000;31:975-983

Cholic acid
Bile acid synthesis in cultured human hepatocytes: Support for an alternative biosynthetic pathway to cholic acid (Axelson et al). 2000;31:1305-1312

Chronic liver disease
A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts (Malinchoc et al). 2000;31:864-871
Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors (Denninger et al). 2000;31:587-591
Chronic viral hepatitis and the human genome (Thio et al). 2000;31:819-827 (Concise Review)
Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients (Das). 2000;31:311-317
Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis (Agarwal et al). 2000;31: 49-53
Effects of the histamine H_1 receptor blocker, pyrilamine, on spontaneous locomotor activity of rats with long-term portacaval anastomosis (Lozeva et al). 2000;31:336-344
Failure of regeneration of the steatotic rat liver: Disruption at two different levels in the regeneration pathway (Selzner and Clavien). 2000;31:35-42
Hepatocyte transplantation in rats with decompensated cirrhosis (Kobayashi et al). 2000;31:851-857
Host genetic factors influence disease progression in chronic hepatitis C (Powell et al). 2000;31:828-833
Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites (Angeli et al). 2000; 31:304-310
Increased natriuretic efficiency of furosemide in rats with carbon tetrachloride–induced cirrhosis (Jonassen et al). 2000;31:1224-1230
Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis (Amitrano et al). 2000; 31:345-348
Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? (Poynard et al). 2000;31:211-218
Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding (Gournay et al). 2000;31:1239-1245
Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels (Calabrese et al). 2000;31:1153-1159
Partial pressure of ammonia versus ammonia in hepatic encephalopathy (Kramer et al). 2000;31:30-34
Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension (Escoresell et al). 2000;31:1061-1067
The past incidence of hepatitis C virus infection: Implications for the future

burden of chronic liver disease in the United States (Armstrong et al). 2000;31:777-782
The role of portal pressure in the severity of bleeding in portal hypertensive rats (Castaneda et al). 2000;31:581-586
Treatment of Wilson's disease with zinc. XVII: Treatment during pregnancy (Brewer et al). 2000;31:364-370
Wilson's disease and pregnancy (Sternlieb). 2000;31:531-532

Cirrhosis
An exploratory population-based case-control study of primary biliary cirrhosis (Howel et al). 2000;31:1055-1060
Carvediol—A new nonselective beta blocker (Forrest et al). 2000;31:809-810 (Letter); (Banares et al). 2000; 31:810-811 (Reply)
Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding (Russo et al). 2000;31:358-363
Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices (Piscaglia et al). 2000;31:349-357
Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis (Pardo et al). 2000; 31:858-863
Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites (Perez-Paramo et al). 2000;31:43-48
Evidence for a locally driven mucosal response and the presence of mitochondrial antigens in saliva in primary biliary cirrhosis (Reynoso-Paz et al). 2000;31:24-29
Hepatocyte transplantation in rats with decompensated cirrhosis (Kobayashi et al). 2000;31:851-857
Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites (Angeli et al). 2000; 31:304-310
Increased natriuretic efficiency of furosemide in rats with carbon tetrachloride–induced cirrhosis (Jonassen et al). 2000;31:1224-1230
Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis (Amitrano et al). 2000; 31:345-348
Insulin growth factor 1 and hypogonadism in cirrhosis (Mezey). 2000;31: 783-784 (Editorial)
Insulin-like growth factor-1, liver function, and hypogonadism in rats with experimentally induced cirrhosis. (Castilla-Cortazar et al). 2000;31: 1379 (Correspondence)
Insulin-like growth factor-1 reverts testicular atrophy in rats with advanced cirrhosis (Castilla-Cortazar et al). 2000;31:592-600
Iron overload in cirrhosis—*HFE* genotypes and outcome after liver transplantation (Brandhagen et al). 2000; 31:456-460
Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding (Gournay et al). 2000;31:1239-1245
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B (Villeneuve et al). 2000;31:207-210
Local arterial vasoconstriction induced by octreotide in patients with cirrhosis (Chatila et al). 2000;31:572-576
Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis (Merkel et al). 2000;31:324-329
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (Angulo et al). 2000;31:318-323
Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension (Escoresell et al). 2000;31:1061-1067
Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis (Nagasue et al). 2000;31:1107-1114
Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma (Cancer of the Liver Italian Program (CLIP) Investigators). 2000;31:840-845
Urso—Panacea or placebo? (Neuberger). 2000;31:1027-1028 (Hepatology *Elsewhere*)

Cisapride
Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis (Pardo et al). 2000; 31:858-863

CLIP score
Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma (Cancer of the Liver Italian Program (CLIP) Investigators). 2000;31:840-845

Cloning
Cloning and functional characterization of the bile acid sensitive methotrexate carrier from rat liver cells (Honscha et al). 2000;31:1296-1304

Coagulation disorders
Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis (Amitrano et al). 2000; 31:345-348

Cocaine
Proliferation of hepatic lineage cells of normal C57BL and interleukin-6 knockout mice after cocaine-induced periportal injury (Rosenberg et al). 2000;31:948-955

Colitis
Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis (Kawaguchi et al). 2000;31:1285-1295

Collagen
Hydrogen peroxide: A link between acetaldehyde-elicited α1(1) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells (Greenwel et al). 2000;31:109-116
Tumor necrosis factor α down-regulates expression of the α1(1) collagen gene in rat hepatic stellate cells through a P20C/EBP- and C/EBP-dependent mechanism (Iraburu et al). 2000;31:1086-1093

Coma
Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure (Rose et al). 2000;31:872-877

Computed tomography
Probability of hepatocellular carcinoma of small hepatocellular nodules undetectable by computed tomography during arterial portography (Tanaka et al). 2000;31:890-898

Concanavalin A
Galectin-1 exerts immunomodulatory and protective effects on concanavalin A–induced hepatitis in mice (Santucci et al). 2000;31:399-406
Repeated concanavalin A challenge in mice induces an interleukin 10–producing phenotype and liver fibrosis (Louis et al). 2000;31:381-390
Sublobular veins as the main site of lymphocyte adhesion/transmigration and adhesion molecule expression in the porto-sinusoidal-hepatic venous system during concanavalin A–induced hepatitis in mice (Morikawa et al). 2000;31:83-94

Concise Reviews
Chronic viral hepatitis and the human genome (Thio et al). 2000;31:819-827
Clinical relevance of hepatitis B viral mutations (Hunt et al). 2000;31:1037-1044
Functional heterogeneity of the intrahepatic biliary epithelium (Kanno et al). 2000;31:555-561
Hepatitis C, interferon alfa, and depression (Zdilar et al). 2000;31:1207-1211
Oxygen: Modulator of metabolic zonation and disease of the liver (Junger-

mann and Kietzmann). 2000;31: 255-260
The heme oxygenase–carbon monoxide system: A regulator of hepatobiliary function (Suematsu and Ishimura). 2000;31:3-6

Correction
1998 and 1999 Referees. 2000;31:813
Clinical features of hepatitis C–infected patients with persistently normal alanine transaminase levels in the southwestern United States (Jamal et al). 2000;31:813

Correspondence
Amino acid sequence of EC2 domain in CD81 is highly conserved in Japanese subjects (Ito et al). 2000;31: 544-545 (Letter)
Carvediol–A new nonselective beta blocker (Forrest et al). 2000;31:809-810 (Letter); (Banares et al). 2000; 31:810-811 (Reply)
Cost-effectiveness of interferon alfa-2b and ribavirin in the treatment of chronic hepatitis C (Younossi et al). 2000;31:807-808 (Letter)
Hepatitis C and autoimmune hepatitis (Cerny et al). 2000;31:811-812 (Letter)
Hepatitis C virus and autoimmunity (Bogdanos et al). 2000;31:1380 (Letter)
Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation (Zein et al). 2000;31: 808-809 (Letter)
Herbal products for liver diseases (Schuppan and Hahn). 2000;31:546-547 (Letter)
Immune therapy of hepatitis B virus chronic infection (Pol et al). 2000; 31:548-549 (Letter)
Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: A wrong track (Bastie et al). 2000;31:547-548 (Letter)
Insulin-like growth factor-1, liver function, and hypogonadism in rats with experimentally induced cirrhosis. (Castilla-Cortazar et al). 2000;31: 1379 (Letter)
Iron and fibrosis in nonalcoholic fatty liver disease (MacDonald et al). 2000;31:549 (Letter)
Lamivudine treatment for children with interferon refractory chronic hepatitis B (Kocak et al). 2000;31:545 (Letter)
Role of the CDP-choline and the alternative pathway for phosphatidylcholine biosynthesis (Sehayek). 2000; 31:543 (Letter); (Agellon et al). 2000;31:543 (Reply)
Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus–infected patients (Di Martino et al). 2000;31:1030-1031 (Letter)
"Vascular profiles" of regenerative and dysplastic nodules (Theise et al). 2000;31:1380-1381 (Letter); (Roncallir et al). 2000;31:1381 (Reply)

Cost-effectiveness studies
Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding (Russo et al). 2000;31:358-363
Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients (Das). 2000;31:311-317
Cost-effectiveness of interferon alfa-2b and ribavirin in the treatment of chronic hepatitis C (Kim et al). 2000;31:807 (Letter); (Younossi et al). 2000;31:807-808 (Reply)
The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C (Myers et al). 2000;31: 834-839
The cost of hepatitis A infections in American adolescents and adults in 1997 (Berge et al). 2000;31:469-473

Cryogenic transmission electron microscopy
Microstructural evolution of lipid aggregates in nucleating model and human biles visualized by cryogenic transmission electron microscopy (Konikoff et al). 2000;31:261-268

Cryoglobulinemia
Hepatitis C virus (HCV) infection and cryoglobulinemia: Analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology (Schmidt et al). 2000; 31:737-744

Cyclooxygenase pathway
Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: A wrong track (Bastie et al). 2000;31:547-548 (Correspondence)

Cytokines
Induction by interleukin 6 of G_S-coupled prostaglandin E_2 receptors in rat hepatocytes mediating a prostaglandin E_2-dependent inhibition of the hepatocytes' acute phase response (Fennekohl et al). 2000;31:1128-1134
Molecular mechanisms of tumor necrosis factor α–stimulated leukocyte recruitment into the murine hepatic circulation (Fox-Robichaud and Kubes). 2000;31:1123-1127
Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice (Nagler et al). 2000;31:641-648
Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis (Tjandra et al). 2000;31:280-290

Cytomegalovirus prophylaxis
Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients (Das). 2000;31:311-317

Cytotoxic T lymphocytes
Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis (Agarwal et al). 2000;31: 49-53
Priming of hepatitis C virus-specific cytotoxic T lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA (Lee et al). 2000;31:1327-1333

D

Decompensated cirrhosis
Hepatocyte transplantation in rats with decompensated cirrhosis (Kobayashi et al). 2000;31:851-857
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B (Villeneuve et al). 2000;31:207-210

Depression
Hepatitis C, interferon alfa, and depression (Zdilar et al). 2000;31:1207-1211 (Concise Review)

Diabetes
Association of diabetes, serum insulin, and C-peptide with gallbladder disease (Ruhl and Everhart). 2000;31: 299-303
Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation (Perseghin et al). 2000;31:694-703

Diagnostic assays
Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays (Ireland et al). 2000;31:1176-1182

Donor, liver
Influence of donor cardiopulmonary arrest in human liver transplantation: Possible role of ischemic preconditioning (Totsuka et al). 2000;31:577-580

Doxorubicin
A cytotoxic drug against reperfusion injury? (Rudiger and Clavien). 2000; 31:533-535 (Editorial)
Doxorubicin preconditioning: A protection against rat hepatic ischemia-reperfusion injury (Ito et al). 2000; 31:416-419

Dysplasia
"Vascular profiles" of regenerative and dysplastic nodules (Theise et al). 2000;31:1380-1381 (Letter); (Roncallir et al). 2000;31:1381 (Reply)

E

E2
Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response (Sarrazin et al). 2000;31:1360-1370
Editorials
A cytotoxic drug against reperfusion injury? (Rudiger and Clavien). 2000; 31:533-535
Cholangiocarcinoma in primary sclerosing cholangitis: Who is at risk and how do we screen? (de Groen). 2000;31:247-248
Cholelithiasis and the insulin resistance syndrome (Diehl). 2000;31:528-530
Do natural T cells promote liver regeneration? (Crispie). 2000;31:1022-1024
Hepatitis C epidemiology: Injecting new tools in the field (Thomas). 2000;31: 790-791
Insulin growth factor 1 and hypogonadism in cirrhosis (Mezey). 2000;31: 783-784
Nuclear factor κB and hepatitis C–Is there a connection? (Yen). 2000;31: 785-787
Screening for hemochromatosis (Crawford and Hickman). 2000;31:1192-1193
"Silent killer: or benign disease? The dilemma of hepatitis C virus outcomes (Hirsch and Wright). 2000;31:536-537
Standardization of hepatitis C virus-RNA quantification: Advances and unfinished business (Gretch). 2000;31: 788-789
Surgical resection versus transplantation for early hepatocellular carcinoma: Clues for the best strategy (Llovet et al). 2000;31:1019-1021
The dual play of endothelin receptors in hepatic vasoregulation (Housset). 2000;31:1025-1026
Wilson's disease and pregnancy (Sternlieb). 2000;31:531-532
Editor's Report
Brave new millennium (Bissell). 2000; 31:1-2
Encephalopathy, hepatic
Partial pressure of ammonia versus ammonia in hepatic encephalopathy (Kramer et al). 2000;31:30-34
Endoscopic therapy
Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding (Russo et al). 2000;31:358-363
Endothelins
Functional significance of endothelin B receptors in mediating sinusoidal and extrasinusoidal effects of endothelins in the intact rat liver (Bauer et al). 2000;31:937-947
Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis (Nagasue et al). 2000;31:1107-1114
The dual play of endothelin receptors in hepatic vasoregulation (Housset). 2000;31:1025-1026 (Editorial)
Endotoxin
Endotoxin induces structure-function alterations of rat liver peroxisomes: Kupffer cells released factors as possible modulators (Contreras et al). 2000;31:446-455
Endotoxin-stimulated macrophages decrease bile acid uptake in WIF-B cells, a rat hepatoma hybrid cell line (Sturm et al). 2000;31:124-130
Epidemiology
Hepatitis C epidemiology: Injecting new tools in the field (Thomas). 2000;31: 790-791 (Editorial)
Epidermal growth factor
The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor α–mediated rat hepatocyte survival and apoptosis (Roberts et al).
Epithelial cells
Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver (Lai et al). 2000; 31:1257-1265
Escherichia coli
Gene therapy of hepatocellular carcinoma *in vitro* and *in vivo* in nude mice by adenoviral transfer of the *Escherichia coli* purine nucleoside phosphorylase gene (Mohr et al). 2000;31:606-614
Esophageal varices
Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding (Russo et al). 2000;31:358-363
Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding (Gournay et al). 2000;31:1239-1245
Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis (Merkel et al). 2000;31:324-329
Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices (Piscaglia et al). 2000;31:349-357
Estrogen
Estrogen is involved in early alcohol-induced liver injury in a rat enteral feeding model (Yin et al). 2000;31: 117-123

F

Famciclovir
In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance (Xiong et al). 2000;31:219-224
Fas stimulation
Fas- and tumor necrosis factor receptor 1-dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice (Liu et al). 2000;31: 665-673
Fas-mediated cholangiopathy in the murine model of graft versus host disease (Ueno et al). 2000;31:966-974
Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice (Feldmann et al). 2000;31:674-683
Fatty liver disease
Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: Potential mechanism for sensitization to liver damage (Guebre-Xabier et al). 2000;31:633-640
Iron and fibrosis in nonalcoholic fatty liver disease (MacDonald et al). 2000;31:549 (Correspondence)
Feminization, liver
Hypogonadism precedes liver feminization in chronic alcohol-fed male rats (Tadic et al). 2000;31:1135-1140
Fibrinolysis
Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices (Piscaglia et al). 2000;31:349-357
Fibrosis
Deactivation of cultured human myofibroblasts by *trans*-reservatrol, a grapevine-derived polyphenol (Godichaud et al). 2000;31:922-931
Increased toxin-induced liver injury and fibrosis in interleukin-6–deficient mice (Kovalovich et al). 2000;31: 149-159
Iron and fibrosis in nonalcoholic fatty liver disease (MacDonald et al). 2000;31:549 (Correspondence)
Modulation of transforming growth factor-β response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts (Dooley et al). 2000;31:1094-1106
Repeated concanavalin A challenge in mice induces an interleukin 10–producing phenotype and liver fibrosis (Louis et al). 2000;31:381-390
Focal adhesion kinase
Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on Ras in human hepatic stellate

cells (Carloni et al). 2000;31:131-140

Furosemide

Increased natriuretic efficiency of furosemide in rats with carbon tetrachloride–induced cirrhosis (Jonassen et al). 2000;31:1224-1230

G

Galactin-1

Galectin-1 exerts immunomodulatory and protective effects on concanavalin A–induced hepatitis in mice (Santucci et al). 2000;31:399-406

Gallbladder

Apolipoprotein E genotype and the risk of gallbladder disease in pregnancy (Ko et al). 2000;31:18-23

Association of diabetes, serum insulin, and C-peptide with gallbladder disease (Ruhl and Everhart). 2000;31:299-303

Centrosome abnormalities in human carcinomas of the gallbladder and intrahepatic and extrahepatic bile ducts (Kuo et al). 2000;31:59-64

$p27^{Kip1}$ expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: Association with cancer progression and prognosis (Hui et al). 2000;31:1068-1072

Gastric disorders

Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis (De Vita et al). 2000;31:182-189

Gene therapy

Gene therapy of hepatocellular carcinoma *in vitro* and *in vivo* in nude mice by adenoviral transfer of the *Escherichia coli* purine nucleoside phosphorylase gene (Mohr et al). 2000;31:606-614

Genetic diseases

Genetic polymorphism of alcohol dehydrogenase in Europeans: The *ADH2*2* allele decreases the risk for alcoholism and is associated with *ADH3*3* (Borràs et al). 2000;31:984-989

Iron beware: A common *HFE* gene polymorphism may prevent the accurate molecular diagnosis of homozygous hemochromatosis in low-risk, but not high-risk groups (Press). 2000;31:540-542 (Hepatology *Elsewhere*)

Iron overload in cirrhosis— *HFE* genotypes and outcome after liver transplantation (Brandhagen et al). 2000;31:456-460

Population screening for hemochromatosis: A comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors (Adams et al). 2000;31:1160-1164

Screening for hemochromatosis (Crawford and Hickman). 2000;31:1192-1193 (Editorial)

Genetics

Chronic viral hepatitis and the human genome (Thio et al). 2000;31:819-827 (Concise Review)

Comprehensive allelotype study of hepatocellular carcinoma: Potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors (Okabe et al). 2000;31:1073-1079

Host genetic factors influence disease progression in chronic hepatitis C (Powell et al). 2000;31:828-833

Genome, human

Characteristics of hepatitis C viral genome associated with disease progression (Nagayama et al). 2000;31:745-750

Chronic viral hepatitis and the human genome (Thio et al). 2000;31:819-827 (Concise Review)

Genomic instability

Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: Comparison of loss of heterozygosity and replication error (Kawai et al). 2000;31:1246-1250

Glutamate

Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure (Rose et al). 2000;31:872-877

Glutamate receptors

Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage (Storto et al). 2000;31:649-655

Glutathione

Glutathione, lactobionate, and histidine: Cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions (Upadhya and Strasberg). 2000;31:1115-1122

Support of sinusoidal endothelial cell glutathione prevents hepatic venoocclusive disease in the rat (Wang et al). 2000;31:428-434

The glutathione precursor L-2-oxothiazolodine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat (Iimuro et al). 2000;31:391-398

Glycoproteins

Amino acid sequence of EC2 domain in CD81 is highly conserved in Japanese subjects (Ito et al). 2000;31:544-545 (Correspondence)

Graft versus host disease

Fas-mediated cholangiopathy in the murine model of graft versus host disease (Ueno et al). 2000;31:966-974

Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice (Nagler et al). 2000;31:641-648

Growth factors

Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells (Ankoma-Sey et al). 2000;31:141-148

Modulation of transforming growth factor-β response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts (Dooley et al). 2000;31:1094-1106

Peroxisome proliferator-activated receptor γ transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells (Galli et al). 2000;31:101-108

The role of activin and transforming growth factor-β in the regulation of organ mass in the rat liver (Kogure et al). 2000;31:916-921

The role of phosphatidic acid in platelet-derived growth factor–induced proliferation of rat hepatic stellate cells (Reeves et al). 2000;31:95-100

The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor α–mediated rat hepatocyte survival and apoptosis (Roberts et al).

Growth regulation

Expression and activation of Pro-MMP-2 and Pro-MMP-9 during rat liver regeneration (Kim et al). 2000;31:75-82

Heterogeneity of growth potential of adult rat hepatocytes in vitro (Tateno et al). 2000;31:65-74

The role of activin and transforming growth factor-β in the regulation of organ mass in the rat liver (Kogure et al). 2000;31:916-921

Guanosine 3'-5'-cyclic monophosphate phosphodiesterase

Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites (Angeli et al). 2000;31:304-310

H

Hematopoietic stem cells

Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver (Golden-Mason et al). 2000;31:1251-1256

Heme oxygenase
The heme oxygenase–carbon monoxide system: A regulator of hepatobiliary function (Suematsu and Ishimura). 2000;31:3-6 (Concise Review)
Hemochromatosis
Iron beware: A common *HFE* gene polymorphism may prevent the accurate molecular diagnosis of homozygous hemochromatosis in low-risk, but not high-risk groups (Press). 2000; 31:540-542 (Hepatology *Elsewhere*)
Population screening for hemochromatosis: A comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors (Adams et al). 2000;31:1160-1164
Screening for hemochromatosis (Crawford and Hickman). 2000;31:1192-1193 (Editorial)
Hemolytic anemia
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage (De Francheschi et al). 2000;31:997-1004
Hepatectomy
Intensive expansion of natural killer T cells in the early phase of hepatocyte regeneration after partial hepatectomy in mice and its association with sympathetic nerve activation (Minigawa et al). 2000;31:907-915
Hepatic artery
The isolated artery: An intrahepatic arterial pathway that can bypass the lobular parenchyma in mammalian livers (Ekataksin). 2000;31:269-279
Hepatic encephalopathy
Partial pressure of ammonia versus ammonia in hepatic encephalopathy (Kramer et al). 2000;31:30-34
Hepatic vein thrombosis
Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors (Denninger et al). 2000;31:587-591
Hepatitis
Chronic viral hepatitis and the human genome (Thio et al). 2000;31:819-827 (Concise Review)
Clonal expansion in evolution of chronic hepatitis to hepatocellular carcinoma as seen at an X-chromosome locus (Ochiai et al). 2000;31:615-621
Galectin-1 exerts immunomodulatory and protective effects on concanavalin A–induced hepatitis in mice (Santucci et al). 2000;31:399-406
Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond (Brunt). 2000;31:241-246 (Hepatology at the Millennium)
Sublobular veins as the main site of lymphocyte adhesion/transmigration and adhesion molecule expression in the porto-sinusoidal-hepatic venous system during concanavalin A–induced hepatitis in mice (Morikawa et al). 2000;31:83-94
Hepatitis A
The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C (Myers et al). 2000;31: 834-839
The cost of hepatitis A infections in American adolescents and adults in 1997 (Berge et al). 2000;31:469-473
Hepatitis B
A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2–deficient mice (Brown et al). 2000;31:173-181
Antituberculosis drug–related liver dysfunction in chronic hepatitis B infection (Wong et al). 2000;31:201-206
Association between hepatitis B virus infection and HLA-DR type in Korea (Ahn et al). 2000;31:1371-1373
Chronic viral hepatitis and the human genome (Thio et al). 2000;31:819-827 (Concise Review)
Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy (Yeh et al). 2000;31:1318-1326
Clinical relevance of hepatitis B viral mutations (Hunt et al). 2000;31:1037-1044 (Concise Review)
Comprehensive allelotype study of hepatocellular carcinoma: Potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors (Okabe et al). 2000;31:1073-1079
Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C (Weidman et al). 2000; 31:230-234
Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong (Chan et al). 2000;31:763-768
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation (Sanchez-Fuego et al). 2000;31:496-501
Immune therapy of hepatitis B virus chronic infection (Pol et al). 2000; 31:548-549 (Correspondence)
In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance (Xiong et al). 2000;31:219-224
Lamivudine treatment for children with interferon refractory chronic hepatitis B (Kocak et al). 2000;31:545 (Correspondence)
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B (Villeneuve et al). 2000;31:207-210
Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen (Marusawa et al). 2000;31:488-495
Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B (Erhardt et al). 2000;31:716-725
Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B E antibody-positive patients (Cotonat et al). 2000;31:502-506
Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays (Ireland et al). 2000;31:1176-1182
Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse (Bocher et al). 2000; 31:480-487
Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus–infected patients (Di Martino et al). 2000;31:1030-1031 (Correspondence)
Hepatitis B core antigen
Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen (Marusawa et al). 2000;31:488-495
Hepatitis B surface antigen
Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen (Rahman et al). 2000;31:521-527
Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays (Ireland et al). 2000;31:1176-1182
Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse (Bocher et al). 2000; 31:480-487
Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (*Marmota monax*) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans (Korba et al). 2000;31:1165-1175
Hepatitis C
Activation of nuclear factor κB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis (Tai et al). 2000;31:656-664
Amino acid sequence of EC2 domain in CD81 is highly conserved in Japa-

nese subjects (Ito et al). 2000;31:544-545 (Correspondence)
A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C (Martinot-Peignoux et al). 2000;31:726-729
Characteristics of hepatitis C viral genome associated with disease progression (Nagayama et al). 2000;31:745-750
Chronic viral hepatitis and the human genome (Thio et al). 2000;31:819-827 (Concise Review)
Clinical features of hepatitis C–infected patients with persistently normal alanine transaminase levels in the southwestern United States (Jamal et al). 2000;31:813 (Correction)
Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b–related chronic hepatitis C (Pol et al). 2000;31:1338-1344
Cost-effectiveness of interferon alfa-2b and ribavirin in the treatment of chronic hepatitis C (Kim et al). 2000;31:807 (Letter); (Younossi et al). 2000;31:807-808 (Reply)
Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C (Weidman et al). 2000;31:230-234
Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis (De Vita et al). 2000;31:182-189
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage (De Francheschi et al). 2000;31:997-1004
Hepatitis C and autoimmune hepatitis (Cerny et al). 2000;31:811-812 (Correspondence)
Hepatitis C epidemiology: Injecting new tools in the field (Thomas). 2000;31:790-791 (Editorial)
Hepatitis C virus and autoimmunity (Bogdanos et al). 2000;31:1380 (Correspondence)
Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells (Honda et al). 2000;31:1351-1359
Hepatitis C virus (HCV) infection and cryoglobulinemia: Analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology (Schmidt et al). 2000;31:737-744
Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation (Zein et al). 2000;31:808-809 (Correspondence)
Host genetic factors influence disease progression in chronic hepatitis C (Powell et al). 2000;31:828-833
Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation (Belli et al). 2000;31:1345-1350
Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes (Macejak et al). 2000;31:769-776
Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: A wrong track (Bastie et al). 2000;31:547-548 (Correspondence)
Intragraft localization of activated nuclear factor κB in recurrent hepatitis C virus disease following liver transplantation (Gaweco et al). 2000;31:1183-1191
Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial (Fontana et al). 2000;31:730-736
Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? (Poynard et al). 2000;31:211-218
Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels (Calabrese et al). 2000;31:1153-1159
Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response (Sarrazin et al). 2000;31:1360-1370
Natural fluctuations of hepatitis C viral load in a homogeneous patient population: A prospective study (Fanning et al). 2000;31:225-229
Natural history of hepatitis C: Its impact on clinical management (Di Bisceglie). 2000;31:1014-1018 (Hepatology at the Millennium)
Nuclear factor κB and hepatitis C–Is there a connection? (Yen). 2000;31:785-787 (Editorial)
Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women (Conte et al). 2000;31:751-755
Priming of hepatitis C virus–specific cytotoxic T lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA (Lee et al). 2000;31:1327-1333
Risk factors for hepatitis C virus infection in United States blood donors (Murpy et al). 2000;31:756-762
"Silent killer: or benign disease? The dilemma of hepatitis C virus outcomes (Hirsch and Wright). 2000;31:536-537 (Editorial)
Standardization of hepatitis C virus-RNA quantification: Advances and unfinished business (Gretch). 2000;31:788-789 (Editorial)
t(14;18) translocation in chronic hepatitis C virus infection (Zignego et al). 2000;31:474-479
The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C (Myers et al). 2000;31:834-839
The impact of diagnosis of hepatitis C on quality of life (Forman et al). 2000;31:1029 (Letter);(Rodger et al). 2000;31:1029-1030 (Reply)
The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States (Armstrong et al). 2000;31:777-782
Viral clearance in hepatitis C (1b) infection: Relationship with human leukocyte antigen class II in a homogeneous population (Fanning et al). 2000;31:1334-1337
Which patients with hepatitis C develop liver complications? (Khan et al). 2000;31:513-520

Hepatocarcinogenesis

Activation of nuclear factor κB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis (Tai et al). 2000;31:656-664
Clonal expansion in evolution of chronic hepatitis to hepatocellular carcinoma as seen at an X-chromosome locus (Ochiai et al). 2000;31:615-621

Hepatocellular carcinoma

Activation of nuclear factor κB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis (Tai et al). 2000;31:656-664
Clonal expansion in evolution of chronic hepatitis to hepatocellular carcinoma as seen at an X-chromosome locus (Ochiai et al). 2000;31:615-621
Comprehensive allelotype study of hepatocellular carcinoma: Potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors (Okabe et al). 2000;31:1073-1079
Detection of adenovirus and initiation of apoptosis in hepatocellular carcinoma cells after Ad-p53 treatment (Mitry et al). 2000;31:885-889
Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience (Yuen et al). 2000;31:330-335
Fractional allelic loss in non-end-stage cirrhosis: Correlations with hepato-

cellular carcinoma development during follow-up (Roncalli et al). 2000; 31:846-850
Gene therapy of hepatocellular carcinoma *in vitro* and *in vivo* in nude mice by adenoviral transfer of the *Escherichia coli* purine nucleoside phosphorylase gene (Mohr et al). 2000;31:606-614
Probability of hepatocellular carcinoma of small hepatocellular nodules undetectable by computed tomography during arterial portography (Tanaka et al). 2000;31:890-898
Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma (Cancer of the Liver Italian Program (CLIP) Investigators). 2000;31:840-845
Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: Comparison of loss of heterozygosity and replication error (Kawai et al). 2000;31:1246-1250
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma (Llovet et al). 2000; 31:54-58
Surgical resection versus transplantation for early hepatocellular carcinoma: Clues for the best strategy (Llovet et al). 2000;31:1019-1021 (Editorial)
Survivin promotes cell proliferation in human hepatocellular carcinoma (Ito et al). 2000;31:1080-1085

Hepatocyte growth factor
Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver (Lai et al). 2000; 31:1257-1265

Hepatocytes
A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2–deficient mice (Brown et al). 2000;31:173-181
Bile acid synthesis in cultured human hepatocytes: Support for an alternative biosynthetic pathway to cholic acid (Axelson et al). 2000;31:1305-1312
Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis (Kawaguchi et al). 2000;31:1285-1295
Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation (Thiese et al). 2000;31:235-240 (Rapid Communication)
Ethanol potentiates tumor necrosis factor-α cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition (Pastorino and Hoek). 2000;31:1141-1152
Hepatocyte transplantation in rats with decompensated cirrhosis (Kobayashi et al). 2000;31:851-857
Heterogeneity of growth potential of adult rat hepatocytes in vitro (Tateno et al). 2000;31:65-74
Induction by interleukin 6 of G_s-coupled prostaglandin E_2 receptors in rat hepatocytes mediating a prostaglandin E_2-dependent inhibition of the hepatocytes' acute phase response (Fennekohl et al). 2000;31:1128-1134
Intensive expansion of natural killer T cells in the early phase of hepatocyte regeneration after partial hepatectomy in mice and its association with sympathetic nerve activation (Minigawa et al). 2000;31:907-915
Interferon tau–induced hepatocyte apoptosis in sheep (Kim et al). 2000;31: 1275-1284
Ischemic preconditioning reduces Na^+ accumulation and cell killing in isolated rat hepatocytes exposed to hypoxia (Carini et al). 2000;31:166-172
Phosphatidylinositol 3-kinase and protein kinase C contribute to the inhibition by interleukin 6 of phosphoenolpyruvate carboxykinase gene expression in cultured rat hepatocytes (Christ et al). 2000;31:461-468
Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: An outcome-oriented decision analysis (Majno et al). 2000;31:899-906
Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage (Storto et al). 2000;31:649-655
The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor α–mediated rat hepatocyte survival and apoptosis (Roberts et al).

Hepatogenous diabetes
Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation (Perseghin et al). 2000;31:694-703

Hepatology at the Millennium
Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond (Brunt). 2000;31:241-246
Natural history of hepatitis C: Its impact on clinical management (Di Bisceglie). 2000;31:1014-1018

Hepatology *Elsewhere*
Iron beware: A common *HFE* gene polymorphism may prevent the accurate molecular diagnosis of homozygous hemochromatosis in low-risk, but not high-risk groups (Press). 2000; 31:540-542
The Tangier disease gene encodes yet another pathophysiologically relevant ATP-binding cassette protein (Rigotti and Cohen). 2000;31:538-539
Urso–Panacea or placebo? (Neuberger). 2000;31:1027-1028
Urotensin II: Better than somatostatin for portal hypertension? (Newby and Jalan). 2000;31:1201-1202

Hepatoma
Endotoxin-stimulated macrophages decrease bile acid uptake in WIF-B cells, a rat hepatoma hybrid cell line (Sturm et al). 2000;31:124-130
Ethanol potentiates tumor necrosis factor-α cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition (Pastorino and Hoek). 2000;31:1141-1152

Herbal products
Herbal products for liver diseases (Schuppan and Hahn). 2000;31:546-547 (Correspondence)

***HFE* gene**
Iron beware: A common *HFE* gene polymorphism may prevent the accurate molecular diagnosis of homozygous hemochromatosis in low-risk, but not high-risk groups (Press). 2000; 31:540-542 (Hepatology *Elsewhere*)
Iron overload in cirrhosis–*HFE* genotypes and outcome after liver transplantation (Brandhagen et al). 2000; 31:456-460

Histamine H_1 receptor
Effects of the histamine H_1 receptor blocker, pyrilamine, on spontaneous locomotor activity of rats with long-term portacaval anastomosis (Lozeva et al). 2000;31:336-344

Histidine
Glutathione, lactobionate, and histidine: Cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions (Upadhya and Strasberg). 2000;31:1115-1122

Histologic activity
Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond (Brunt). 2000;31:241-246 (Hepatology at the Millennium)

Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels (Calabrese et al). 2000;31:1153-1159

Histology
Hepatitis C virus (HCV) infection and cryoglobulinemia: Analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology (Schmidt et al). 2000; 31:737-744

Histopathologic staging
Update of the international Banff schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection (Demetris et al). 2000;31:792-799 (Meeting Report)

HLA-DR type
Association between hepatitis B virus infection and HLA-DR type in Korea (Ahn et al). 2000;31:1371-1373

Human genome
Chronic viral hepatitis and the human genome (Thio et al). 2000;31:819-827 (Concise Review)

Human immunodeficiency virus
Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus–infected patients (Di Martino et al). 2000;31:1030-1031 (Correspondence)

Human leukocyte antigen
Viral clearance in hepatitis C (1b) infection: Relationship with human leukocyte antigen class II in a homogeneous population (Fanning et al). 2000;31:1334-1337

Hydrogen
Sodium, hydrogen exchange type 1 and bile ductular secretory activity in the guinea pig (Hubner et al). 2000;31: 562-571

Hydrogen peroxide
Hydrogen peroxide: A link between acetaldehyde-elicited α1(1) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells (Greenwel et al). 2000;31:109-116

Hypertension, portal
Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension (Escoresell et al). 2000;31:1061-1067
Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis (Nagasue et al). 2000;31:1107-1114
The role of portal pressure in the severity of bleeding in portal hypertensive rats (Castaneda et al). 2000;31:581-586
Urotensin II: Better than somatostatin for portal hypertension? (Newby and Jalan). 2000;31:1201-1202 (Hepatology *Elsewhere*)

Hyperthermic preconditioning
Impact of hyperthermic preconditioning on postischemic hepatic microcirculatory disturbances in an isolated perfusion model of the rat liver (Terajima et al). 2000;31:407-415

Hypogonadism
Hypogonadism precedes liver feminization in chronic alcohol-fed male rats (Tadic et al). 2000;31:1135-1140
Insulin growth factor 1 and hypogonadism in cirrhosis (Mezey). 2000;31: 783-784 (Editorial)
Insulin-like growth factor-1, liver function, and hypogonadism in rats with experimentally induced cirrhosis. (Castilla-Cortazar et al). 2000;31: 1379 (Correspondence)
Insulin-like growth factor-1 reverts testicular atrophy in rats with advanced cirrhosis (Castilla-Cortazar et al). 2000;31:592-600

Hypothermia
Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure (Rose et al). 2000;31:872-877

Hypoxia
Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells (Ankoma-Sey et al). 2000;31:141-148
Ischemic preconditioning reduces Na^+ accumulation and cell killing in isolated rat hepatocytes exposed to hypoxia (Carini et al). 2000;31:166-172
Role of oxidative stress in hypoxia-reoxygenation injury to cultured rat hepatic sinusoidal endothelial cells (Samarsinghe et al). 2000;31:160-165
Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage (Storto et al). 2000;31:649-655

I

Immune system
Hepatic imflammation and immunity: A summary of a conference on the function of the immune system within the liver (Bertolini et al). 2000;31:1374-1378 (Meeting Report)

Immune therapy
Immune therapy of hepatitis B virus chronic infection (Pol et al). 2000; 31:548-549 (Correspondence)

Immunogenetics
Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation (Belli et al). 2000;31:1345-1350

Inflammation
Hepatic imflammation and immunity: A summary of a conference on the function of the immune system within the liver (Bertolini et al). 2000;31:1374-1378 (Meeting Report)

Inflammatory bowel disease
Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis (Kawaguchi et al). 2000;31:1285-1295

Injury, liver cell
Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: Potential mechanism for sensitization to liver damage (Guebre-Xabier et al). 2000;31:633-640
Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice (Le Moine et al). 2000;31:1266-1274
Doxorubicin preconditioning: A protection against rat hepatic ischemia-reperfusion injury (Ito et al). 2000; 31:416-419
Endotoxin induces structure-function alterations of rat liver peroxisomes: Kupffer cells released factors as possible modulators (Contreras et al). 2000;31:446-455
Estrogen is involved in early alcohol-induced liver injury in a rat enteral feeding model (Yin et al). 2000;31: 117-123
Ethanol potentiates tumor necrosis factor-α cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition (Pastorino and Hoek). 2000;31:1141-1152
Fas- and tumor necrosis factor receptor 1–dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice (Liu et al). 2000; 31:665-673
Fas-mediated cholangiopathy in the murine model of graft versus host disease (Ueno et al). 2000;31:966-974
Impact of hyperthermic preconditioning on postischemic hepatic microcirculatory disturbances in an isolated perfusion model of the rat liver (Terajima et al). 2000;31:407-415
Proliferation of hepatic lineage cells of normal C57BL and interleukin-6 knockout mice after cocaine-induced periportal injury (Rosenberg et al). 2000;31:948-955
Role of oxidative stress in hypoxia-reoxygenation injury to cultured rat

hepatic sinusoidal endothelial cells (Samarsinghe et al). 2000;31:160-165
Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage (Storto et al). 2000;31:649-655
Support of sinusoidal endothelial cell glutathione prevents hepatic venoocclusive disease in the rat (Wang et al). 2000;31:428-434
The glutathione precursor L-2-oxothiazolodine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat (Iimuro et al). 2000;31:391-398
The ratio of ELR+ to ELR− CXC chemokines affects the lung and liver injury following hepatic ischemia/reperfusion in the rat (Colletti et al). 2000;31:435-445

Insulin
Association of diabetes, serum insulin, and C-peptide with gallbladder disease (Ruhl and Everhart). 2000;31:299-303
Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: Effect of liver transplantation (Perseghin et al). 2000;31:694-703

Insulin-like growth factor-1
Insulin-like growth factor-1, liver function, and hypogonadism in rats with experimentally induced cirrhosis. (Castilla-Cortazar et al). 2000;31:1379 (Correspondence)
Insulin-like growth factor-1 reverts testicular atrophy in rats with advanced cirrhosis (Castilla-Cortazar et al). 2000;31:592-600
Insulin growth factor 1 and hypogonadism in cirrhosis (Mezey). 2000;31:783-784 (Editorial)

Insulin resistance syndrome
Cholelithiasis and the insulin resistance syndrome (Diehl). 2000;31:528-530 (Editorial)

Interferon
Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial (Fontana et al). 2000;31:730-736
Lamivudine treatment for children with interferon refractory chronic hepatitis B (Kocak et al). 2000;31:545 (Correspondence)
Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B (Erhardt et al). 2000;31:716-725
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma (Llovet et al). 2000;31:54-58

Interferon alfa
Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b–related chronic hepatitis C (Pol et al). 2000;31:1338-1344
Cost-effectiveness of interferon alfa-2b and ribavirin in the treatment of chronic hepatitis C (Kim et al). 2000;31:807 (Letter); (Younossi et al). 2000;31:807-808 (Reply)
Hepatitis C, interferon alfa, and depression (Zdilar et al). 2000;31:1207-1211 (Concise Review)
Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: A wrong track (Bastie et al). 2000;31:547-548 (Correspondence)
Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? (Poynard et al). 2000;31:211-218
Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B E antibody-positive patients (Cotonat et al). 2000;31:502-506
Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus–infected patients (Di Martino et al). 2000;31:1030-1031 (Correspondence)

Interferon tau
Interferon tau–induced hepatocyte apoptosis in sheep (Kim et al). 2000;31:1275-1284

Interleukin-6
Increased toxin-induced liver injury and fibrosis in interleukin-6–deficient mice (Kovalovich et al). 2000;31:149-159
Induction by interleukin 6 of G_S-coupled prostaglandin E_2 receptors in rat hepatocytes mediating a prostaglandin E_2-dependent inhibition of the hepatocytes' acute phase response (Fennekohl et al). 2000;31:1128-1134
Proliferation of hepatic lineage cells of normal C57BL and interleukin-6 knockout mice after cocaine-induced periportal injury (Rosenberg et al). 2000;31:948-955

Interleukin-10
Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice (Le Moine et al). 2000;31:1266-1274
Repeated concanavalin A challenge in mice induces an interleukin 10–producing phenotype and liver fibrosis (Louis et al). 2000;31:381-390

Intestinal bacteria
Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis (Pardo et al). 2000;31:858-863

Intestinal metaplasia
Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver (Lai et al). 2000;31:1257-1265

Iron
Iron and fibrosis in nonalcoholic fatty liver disease (MacDonald et al). 2000;31:549 (Correspondence)

Iron-binding capacity
Population screening for hemochromatosis: A comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors (Adams et al). 2000;31:1160-1164

Iron overload
Iron overload in cirrhosis—*HFE* genotypes and outcome after liver transplantation (Brandhagen et al). 2000;31:456-460

Iron reduction
Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial (Fontana et al). 2000;31:730-736

Ischemia/reperfusion
A cytotoxic drug against reperfusion injury? (Rudiger and Clavien). 2000;31:533-535
Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice (Le Moine et al). 2000;31:1266-1274
Doxorubicin preconditioning: A protection against rat hepatic ischemia-reperfusion injury (Ito et al). 2000;31:416-419
Impact of hyperthermic preconditioning on postischemic hepatic microcirculatory disturbances in an isolated perfusion model of the rat liver (Terajima et al). 2000;31:407-415
In situ determination by surface chemiluminescence of temporal relationships between evolving warm ischemia-reperfusion injury in rat liver and phagocyte activation and recruitment (Cutrin et al). 2000;31:622-631
The ratio of ELR+ to ELR– CXC chemokines affects the lung and liver injury following hepatic ischemia/reperfusion in the rat (Colletti et al). 2000;31:435-445

Ischemic preconditioning
Influence of donor cardiopulmonary arrest in human liver transplantation: Possible role of ischemic precondi-

tioning (Totsuka et al). 2000;31:577-580
Ischemic preconditioning reduces Na^+ accumulation and cell killing in isolated rat hepatocytes exposed to hypoxia (Carini et al). 2000;31:166-172

Isosorbide mononitrate
Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding (Gournay et al). 2000;31:1239-1245
Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis (Merkel et al). 2000;31:324-329

K

Ketoglutarate
Glutathione, lactobionate, and histidine: Cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions (Upadhya and Strasberg). 2000;31:1115-1122

Knodell histologic activity index
Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond (Brunt). 2000;31:241-246 (Hepatology at the Millennium)

Kupffer cells
Endotoxin induces structure-function alterations of rat liver peroxisomes: Kupffer cells released factors as possible modulators (Contreras et al). 2000;31:446-455
Kupffer cell activation by lipopolysaccharide in rats: Role for lipopolysaccharide binding protein and Toll-like receptor 4 (Su et al). 2000;31:932-936

L

Lactobionate
Glutathione, lactobionate, and histidine: Cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions (Upadhya and Strasberg). 2000;31:1115-1122

Lamivudine
Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy (Yeh et al). 2000;31:1318-1326
Lamivudine treatment for children with interferon refractory chronic hepatitis B (Kocak et al). 2000;31:545 (Correspondence)
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B (Villeneuve et al). 2000;31:207-210

Leukocytes
Molecular mechanisms of tumor necrosis factor α–stimulated leukocyte recruitment into the murine hepatic circulation (Fox-Robichaud and Kubes). 2000;31:1123-1127

Lipids
Microstructural evolution of lipid aggregates in nucleating model and human biles visualized by cryogenic transmission electron microscopy (Konikoff et al). 2000;31:261-268

Lipopolysaccharide binding protein
Kupffer cell activation by lipopolysaccharide in rats: Role for lipopolysaccharide binding protein and Toll-like receptor 4 (Su et al). 2000;31:932-936

Lipoxygenase pathway
Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: A wrong track (Bastie et al). 2000;31:547-548 (Correspondence)

Liver cell injury
Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: Potential mechanism for sensitization to liver damage (Guebre-Xabier et al). 2000;31:633-640
Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice (Le Moine et al). 2000;31:1266-1274
Doxorubicin preconditioning: A protection against rat hepatic ischemia-reperfusion injury (Ito et al). 2000;31:416-419
Endotoxin induces structure-function alterations of rat liver peroxisomes: Kupffer cells released factors as possible modulators (Contreras et al). 2000;31:446-455
Estrogen is involved in early alcohol-induced liver injury in a rat enteral feeding model (Yin et al). 2000;31:117-123
Ethanol potentiates tumor necrosis factor-α cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition (Pastorino and Hoek). 2000;31:1141-1152
Fas- and tumor necrosis factor receptor 1–dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice (Liu et al). 2000;31:665-673
Fas-mediated cholangiopathy in the murine model of graft versus host disease (Ueno et al). 2000;31:966-974
Impact of hyperthermic preconditioning on postischemic hepatic microcirculatory disturbances in an isolated perfusion model of the rat liver (Terajima et al). 2000;31:407-415
Proliferation of hepatic lineage cells of normal C57BL and interleukin-6 knockout mice after cocaine-induced periportal injury (Rosenberg et al). 2000;31:948-955
Role of oxidative stress in hypoxia-reoxygenation injury to cultured rat hepatic sinusoidal endothelial cells (Samarsinghe et al). 2000;31:160-165
Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage (Storto et al). 2000;31:649-655
Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat (Wang et al). 2000;31:428-434
The glutathione precursor L-2-oxothiazolodine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat (Iimuro et al). 2000;31:391-398
The ratio of ELR+ to ELR− CXC chemokines affects the lung and liver injury following hepatic ischemia/reperfusion in the rat (Colletti et al). 2000;31:435-445

Liver failure, acute
Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure (Rose et al). 2000;31:872-877

Liver regeneration
Annexin I expression and phosphorylation are upregulated during liver regeneration and transformation in antithrombin III SV40 T large antigen transgenic mice (de Coupade et al). 2000;31:371-380
Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation (Thiese et al). 2000;31:235-240 (Rapid Communication)
Do natural T cells promote liver regeneration? (Crispie). 2000;31:1022-1024 (Editorial)
Expression and activation of Pro-MMP-2 and Pro-MMP-9 during rat liver regeneration (Kim et al). 2000;31:75-82
Failure of regeneration of the steatotic rat liver: Disruption at two different levels in the regeneration pathway (Selzner and Clavien). 2000;31:35-42
Intensive expansion of natural killer T cells in the early phase of hepatocyte regeneration after partial hepatectomy in mice and its association

with sympathetic nerve activation (Minigawa et al). 2000;31:907-915

Liver transplantation
Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients (Das). 2000;31:311-317
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation (Sanchez-Fuego et al). 2000;31:496-501
Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation (Zein et al). 2000;31:808-809 (Correspondence)
Influence of donor cardiopulmonary arrest in human liver transplantation: Possible role of ischemic preconditioning (Totsuka et al). 2000;31:577-580
Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation (Belli et al). 2000;31:1345-1350
Intragraft localization of activated nuclear factor κB in recurrent hepatitis C virus disease following liver transplantation (Gaweco et al). 2000;31:1183-1191
Iron overload in cirrhosis– *HFE* genotypes and outcome after liver transplantation (Brandhagen et al). 2000;31:456-460
Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: An outcome-oriented decision analysis (Majno et al). 2000;31:899-906
Surgical resection versus transplantation for early hepatocellular carcinoma: Clues for the best strategy (Llovet et al). 2000;31:1019-1021 (Editorial)
Update of the international Banff schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection (Demetris et al). 2000;31:792-799 (Meeting Report)

Lymphocyte adhesion
Sublobular veins as the main site of lymphocyte adhesion/transmigration and adhesion molecule expression in the porto-sinusoidal-hepatic venous system during concanavalin A–induced hepatitis in mice (Morikawa et al). 2000;31:83-94

Lymphocytes
Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: Potential mechanism for sensitization to liver damage (Guebre-Xabier et al). 2000;31:633-640

Lymphoid markers
Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver (Golden-Mason et al). 2000;31:1251-1256

Lymphoma
Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis (De Vita et al). 2000;31:182-189

Lymphoproliferative disorders
Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation (Zein et al). 2000;31:808-809 (Correspondence)

M

Macrophages
Endotoxin-stimulated macrophages decrease bile acid uptake in WIF-B cells, a rat hepatoma hybrid cell line (Sturm et al). 2000;31:124-130

Malondialdehyde
Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease (Rolla et al). 2000;31:878-884

Mass, liver
The role of activin and transforming growth factor-β in the regulation of organ mass in the rat liver (Kogure et al). 2000;31:916-921

Matrix metalloproteinases
Expression and activation of Pro-MMP-2 and Pro-MMP-9 during rat liver regeneration (Kim et al). 2000;31:75-82
Glutathione, lactobionate, and histidine: Cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions (Upadhya and Strasberg). 2000;31:1115-1122

Meeting Reports
Autoimmune hepatitis: The investigational and clinical challenges (Czaja et al). 2000;31:1194-1200
Hepatic imflammation and immunity: A summary of a conference on the function of the immune system within the liver (Bertolini et al). 2000;31:1374-1378 (Meeting Report)
The 20th United States-Japan Joint Hepatitis Panel Meeting (Lemon et al). 2000;31:800-806
Update of the international Banff schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection (Demetris et al). 2000;31:792-799

Metabolism
Oxygen: Modulator of metabolic zonation and disease of the liver (Jungermann and Kietzmann). 2000;31:255-260 (Concise Review)

Metaplasia
Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver (Lai et al). 2000;31:1257-1265

Methotrexate
Cloning and functional characterization of the bile acid sensitive methotrexate carrier from rat liver cells (Honscha et al). 2000;31:1296-1304

mGlu5 receptor
Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage (Storto et al). 2000;31:649-655

Mimicry peptides
Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis (Shimoda et al). 2000;31:1212-1216

Mitochondria membrane
Ethanol potentiates tumor necrosis factor-α cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition (Pastorino and Hoek). 2000;31:1141-1152
Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice (Feldmann et al). 2000;31:674-683

Mitochondrial antigens
Evidence for a locally driven mucosal response and the presence of mitochondrial antigens in saliva in primary biliary cirrhosis (Reynoso-Paz et al). 2000;31:24-29

Mitogen-activated protein kinase
The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor α–mediated rat hepatocyte survival and apoptosis (Roberts et al).

Molecular genetics
Chronic viral hepatitis and the human genome (Thio et al). 2000;31:819-827 (Concise Review)

Multidrug resistance protein 2
Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat

liver (Paulusma et al). 2000;31:684-693

Multispecific organic anion transporter
Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis (Kawaguchi et al). 2000;31:1285-1295

Myeloid markers
Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver (Golden-Mason et al). 2000;31:1251-1256

Myofibroblasts
Deactivation of cultured human myofibroblasts by *trans*-reservatrol, a grapevine-derived polyphenol (Godichaud et al). 2000;31:922-931
Modulation of transforming growth factor-β response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts (Dooley et al). 2000;31:1094-1106

N

Nadolol
Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis (Merkel et al). 2000;31:324-329

Natriuretic efficicency
Increased natriuretic efficiency of furosemide in rats with carbon tetrachloride–induced cirrhosis (Jonassen et al). 2000;31:1224-1230

Natural killer T cells
Intensive expansion of natural killer T cells in the early phase of hepatocyte regeneration after partial hepatectomy in mice and its association with sympathetic nerve activation (Minigawa et al). 2000;31:907-915

Nodules
"Vascular profiles" of regenerative and dysplastic nodules (Theise et al). 2000;31:1380-1381 (Letter); (Roncallir et al). 2000;31:1381 (Reply)

NS5A protein
Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response (Sarrazin et al). 2000;31:1360-1370

Nuclear factor κB
Activation of nuclear factor κB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis (Tai et al). 2000;31:656-664
Intragraft localization of activated nuclear factor κB in recurrent hepatitis C virus disease following liver transplantation (Gaweco et al). 2000;31:1183-1191
Nuclear factor κB and hepatitis C–Is there a connection? (Yen). 2000;31:785-787 (Editorial)

Nucleoside analogues
Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (*Marmota monax*) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans (Korba et al). 2000;31:1165-1175

O

Obesity
Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: Potential mechanism for sensitization to liver damage (Guebre-Xabier et al). 2000;31:633-640

Octreotide
Local arterial vasoconstriction induced by octreotide in patients with cirrhosis (Chatila et al). 2000;31:572-576

Oral tolerization
Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice (Nagler et al). 2000;31:641-648

Orthotopic liver transplantation
Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients (Das). 2000;31:311-317

Oxidative damage
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage (De Francheschi et al). 2000;31:997-1004

Oxidative stress
Hydrogen peroxide: A link between acetaldehyde-elicited α1(1) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells (Greenwel et al). 2000;31:109-116
Role of oxidative stress in hypoxia-reoxygenation injury to cultured rat hepatic sinusoidal endothelial cells (Samarsinghe et al). 2000;31:160-165

L-2-Oxothiazolodine-4-carboxylic acid
The glutathione precursor L-2-oxothiazolodine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat (Iimuro et al). 2000;31:391-398

Oxygen
Oxygen: Modulator of metabolic zonation and disease of the liver (Jungermann and Kietzmann). 2000;31:255-260 (Concise Review)

P

PDC-E2 163-176 peptide
Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis (Shimoda et al). 2000;31:1212-1216

Pediatrics
Lamivudine treatment for children with interferon refractory chronic hepatitis B (Kocak et al). 2000;31:545 (Correspondence)

Peptides
Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis (Shimoda et al). 2000;31:1212-1216

Perforin
Fas- and tumor necrosis factor receptor 1-dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice (Liu et al). 2000;31:665-673

Peroxisome proliferator-activated receptor γ
Peroxisome proliferator-activated receptor γ transcriptional regulation is involved in platelet-derived growth factor–induced proliferation of human hepatic stellate cells (Galli et al). 2000;31:101-108

Peroxisomes
Endotoxin induces structure-function alterations of rat liver peroxisomes: Kupffer cells released factors as possible modulators (Contreras et al). 2000;31:446-455

Phagocytes
In situ determination by surface chemiluminescence of temporal relationships between evolving warm ischemia-reperfusion injury in rat liver and phagocyte activation and recruitment (Cutrin et al). 2000;31:622-631

Phosphatidylcholine
Role of the CDP-choline and the alternative pathway for phosphatidylcholine biosynthesis (Sehayek). 2000;31:543 (Letter); (Agellon et al). 2000;31:543 (Reply)

Phosphatidylinositol 3-kinase
Phosphatidylinositol 3-kinase and protein kinase C contribute to the inhibition by interleukin 6 of phosphoenolpyruvate carboxykinase gene expression in cultured rat hepatocytes (Christ et al). 2000;31:461-468

Phosphoenolpyruvate carboxykinase
Phosphatidylinositol 3-kinase and protein kinase C contribute to the inhibition by interleukin 6 of phosphoenolpyruvate carboxykinase gene expression in cultured rat hepatocytes (Christ et al). 2000;31:461-468

Photodynamic therapy
Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival (Berr et al). 2000;31:291-298
Plasmid DNA
Priming of hepatitis C virus-specific cytotoxic T lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA (Lee et al). 2000;31:1327-1333
Platelet-derived growth factor
Peroxisome proliferator-activated receptor γ transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells (Galli et al). 2000;31:101-108
The role of phosphatidic acid in platelet-derived growth factor–induced proliferation of rat hepatic stellate cells (Reeves et al). 2000;31:95-100
Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on Ras in human hepatic stellate cells (Carloni et al). 2000;31:131-140
Phosphatidic acid
The role of phosphatidic acid in platelet-derived growth factor-induced proliferation of rat hepatic stellate cells (Reeves et al). 2000;31:95-100
Poliovirus
Inhibition of hepatitis C virus (HCV)-RNA–dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes (Macejak et al). 2000;31:769-776
Porphyria
Novel molecular defects of the δ-aminolevulinate dehydratase gene in a patient with inherited acute hepatic porphyria (Akagi et al). 2000;31:704-708
Portacaval anastomosis
Effects of the histamine H_1 receptor blocker, pyrilamine, on spontaneous locomotor activity of rats with long-term portacaval anastomosis (Lozeva et al). 2000;31:336-344
Portal hypertension
Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension (Escoresell et al). 2000;31:1061-1067
Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis (Nagasue et al). 2000;31:1107-1114
The role of portal pressure in the severity of bleeding in portal hypertensive rats (Castaneda et al). 2000;31:581-586
Urotensin II: Better than somatostatin for portal hypertension? (Newby and Jalan). 2000;31:1201-1202 (Hepatology *Elsewhere*)
Portal vein thrombosis
Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors (Denninger et al). 2000;31:587-591
Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis (Amitrano et al). 2000;31:345-348
Portography, arterial
Probability of hepatocellular carcinoma of small hepatocellular nodules undetectable by computed tomography during arterial portography (Tanaka et al). 2000;31:890-898
Practice Guidelines
Management of primary biliary cirrhosis (Heathcote). 2000;31:1005-1013 (AASLD Practice Guidelines)
Precancerous conditions
Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver (Lai et al). 2000;31:1257-1265
Pregnancy
Apolipoprotein E genotype and the risk of gallbladder disease in pregnancy (Ko et al). 2000;31:18-23
Effect of maternal cholestasis on bile acid transfer across the rat placenta-maternal liver tandem (Macias et al). 2000;31:975-983
Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women (Conte et al). 2000;31:751-755
Treatment of Wilson's disease with zinc, XVII: Treatment during pregnancy (Brewer et al). 2000;31:364-370
Wilson's disease and pregnancy (Sternlieb). 2000;31:531-532 (Editorial)
Preservation solutions
Glutathione, lactobionate, and histidine: Cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions (Upadhya and Strasberg). 2000;31:1115-1122
Primary biliary cirrhosis
An exploratory population-based case-control study of primary biliary cirrhosis (Howel et al). 2000;31:1055-1060
Evidence for a locally driven mucosal response and the presence of mitochondrial antigens in saliva in primary biliary cirrhosis (Reynoso-Paz et al). 2000;31:24-29
Management of primary biliary cirrhosis (Heathcote). 2000;31:1005-1013 (AASLD Practice Guidelines)
Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis (Shimoda et al). 2000;31:1212-1216
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (Angulo et al). 2000;31:318-323
Urso–Panacea or placebo? (Neuberger). 2000;31:1027-1028 (Hepatology *Elsewhere*)
Primary sclerosing cholangitis
Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study (Chalasani et al). 2000;31:7-11
Cholangiocarcinoma in primary sclerosing cholangitis: Who is at risk and how do we screen? (de Groen). 2000;31:247-248 (Editorial)
Prognosis
$p27^{Kip1}$ expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: Association with cancer progression and prognosis (Hui et al). 2000;31:1068-1072
Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma (Cancer of the Liver Italian Program (CLIP) Investigators). 2000;31:840-845
Propranolol
Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites (Perez-Paramo et al). 2000;31:43-48
Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding (Gournay et al). 2000;31:1239-1245
Prostaglandin E_2
Induction by interleukin 6 of G_S-coupled prostaglandin E_2 receptors in rat hepatocytes mediating a prostaglandin E_2-dependent inhibition of the hepatocytes' acute phase response (Fennekohl et al). 2000;31:1128-1134
Protein kinases
Phosphatidylinositol 3-kinase and protein kinase C contribute to the inhibition by interleukin 6 of phosphoenolpyruvate carboxykinase gene expression in cultured rat hepatocytes (Christ et al). 2000;31:461-468
The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor -mediated rat hepatocyte survival and apoptosis (Roberts et al).

Pyrilamine
Effects of the histamine H_1 receptor blocker, pyrilamine, on spontaneous locomotor activity of rats with long-term portacaval anastomosis (Lozeva et al). 2000;31:336-344

Q

Quality of life
The impact of diagnosis of hepatitis C on quality of life (Forman et al). 2000; 31:1029 (Letter); (Rodger et al). 2000;31:1029-1030 (Reply)
Quantification, virus-RNA
Standardization of hepatitis C virus-RNA quantification: Advances and unfinished business (Gretch). 2000;31: 788-789 (Editorial)

R

Radiation-induced injury
Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation (Thiese et al). 2000;31:235-240 (Rapid Communication)
Rapid Communications
Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation (Thiese et al). 2000;31:235-240
Host genetic factors influence disease progression in chronic hepatitis C (Powell et al). 2000;31:828-833
Referees
1998 and 1999 referees (volumes 29 and 30). 2000;31:251-254
Regeneration, liver
Annexin I expression and phosphorylation are upregulated during liver regeneration and transformation in antithrombin III SV40 T large antigen transgenic mice (de Coupade et al). 2000;31:371-380
Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation (Thiese et al). 2000;31:235-240 (Rapid Communication)
Do natural T cells promote liver regeneration? (Crispie). 2000;31:1022-1024 (Editorial)
Expression and activation of Pro-MMP-2 and Pro-MMP-9 during rat liver regeneration (Kim et al). 2000;31:75-82
Failure of regeneration of the steatotic rat liver: Disruption at two different levels in the regeneration pathway (Selzner and Clavien). 2000;31:35-42
Intensive expansion of natural killer T cells in the early phase of hepatocyte regeneration after partial hepatectomy in mice and its association with sympathetic nerve activation (Minigawa et al). 2000;31:907-915
Rejection, allograft
Update of the international Banff schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection (Demetris et al). 2000;31:792-799 (Meeting Report)
Reperfusion injury
A cytotoxic drug against reperfusion injury? (Rudiger and Clavien). 2000; 31:533-535 (Editorial)
Resection, liver
Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: An outcome-oriented decision analysis (Majno et al). 2000;31:899-906
Surgical resection versus transplantation for early hepatocellular carcinoma: Clues for the best strategy (Llovet et al). 2000;31:1019-1021 (Editorial)
***Trans*-reservatrol**
Deactivation of cultured human myofibroblasts by *trans*-reservatrol, a grapevine-derived polyphenol (Godichaud et al). 2000;31:922-931
Ribavirin
Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b–related chronic hepatitis C (Pol et al). 2000;31:1338-1344
Cost-effectiveness of interferon alfa-2b and ribavirin in the treatment of chronic hepatitis C (Kim et al). 2000;31:807 (Letter); (Younossi et al). 2000;31:807-808 (Reply)
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage (De Francheschi et al). 2000;31:997-1004
Is an "à la carte" combination interferon alfa-2B plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? (Poynard et al). 2000;31:211-218
Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients (Cotonat et al). 2000;31:502-506
Ribozymes
Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes (Macejak et al). 2000;31: 769-776

S

Saliva
Evidence for a locally driven mucosal response and the presence of mitochondrial antigens in saliva in primary biliary cirrhosis (Reynoso-Paz et al). 2000;31:24-29
Scatter factor
Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated "intestinal-type" biliary cancer chemically induced in rat liver (Lai et al). 2000; 31:1257-1265
Sclerosing cholangitis, primary
Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study (Chalasani et al). 2000;31:7-11
Cholangiocarcinoma in primary sclerosing cholangitis: Who is at risk and how do we screen? (de Groen). 2000;31:247-248 (Editorial)
Screening
Population screening for hemochromatosis: A comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors (Adams et al). 2000;31:1160-1164
Screening for hemochromatosis (Crawford and Hickman). 2000;31:1192-1193 (Editorial)
Secondary biliary cirrhosis
Decreased carnitine biosynthesis in rats with secondary biliary cirrhosis (Krähenbühl et al). 2000;31:1217-1223
Sex hormones
Hypogonadism precedes liver feminization in chronic alcohol-fed male rats (Tadic et al). 2000;31:1135-1140
Sinusoidal endothelial cells
Role of oxidative stress in hypoxia-reoxygenation injury to cultured rat hepatic sinusoidal endothelial cells (Samarsinghe et al). 2000;31:160-165
Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat (Wang et al). 2000;31:428-434
Sodium
Ischemic preconditioning reduces Na^+ accumulation and cell killing in isolated rat hepatocytes exposed to hypoxia (Carini et al). 2000;31:166-172
Sodium, hydrogen exchange type 1 and bile ductular secretory activity in the guinea pig (Hubner et al). 2000;31: 562-571
Somatostatin
Urotensin II: Better than somatostatin for portal hypertension? (Newby and

Jalan). 2000;31:1201-1202 (Hepatology *Elsewhere*)

Steatosis
Failure of regeneration of the steatotic rat liver: Disruption at two different levels in the regeneration pathway (Selzner and Clavien). 2000;31:35-42

Stellate cells
Hydrogen peroxide: A link between acetaldehyde-elicited α1(1) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells (Greenwel et al). 2000;31:109-116
Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells (Ankoma-Sey et al). 2000;31:141-148
Modulation of transforming growth factor-β response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts (Dooley et al). 2000;31:1094-1106
The role of phosphatidic acid in platelet-derived growth factor–induced proliferation of rat hepatic stellate cells (Reeves et al). 2000;31:95-100
Tumor necrosis factor α down-regulates expression of the α1(1) collagen gene in rat hepatic stellate cells through a P20C/EBP- and C/EBP-dependent mechanism (Iraburu et al). 2000;31:1086-1093
Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on Ras in human hepatic stellate cells (Carloni et al). 2000;31:131-140

Stem cells
Differential expression of lymphoid and myeloid markers on differentiating hematopoietic stem cells in normal and tumor-bearing adult human liver (Golden-Mason et al). 2000;31:1251-1256

Survivin
Survivin promotes cell proliferation in human hepatocellular carcinoma (Ito et al). 2000;31:1080-1085

Sympathetic nerve activation
Intensive expansion of natural killer T cells in the early phase of hepatocyte regeneration after partial hepatectomy in mice and its association with sympathetic nerve activation (Minigawa et al). 2000;31:907-915

T

t(14;18)
t(14;18) translocation in chronic hepatitis C virus infection (Zignego et al). 2000;31:474-479

T cells
Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice (Le Moine et al). 2000;31:1266-1274
Do natural T cells promote liver regeneration? (Crispie). 2000;31:1022-1024 (Editorial)

T helper (Th) cells
Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis (Tjandra et al). 2000;31:280-290

Tangier disease gene
The Tangier disease gene encodes yet another pathophysiologically relevant ATP-binding cassette protein (Rigotti and Cohen). 2000;31:538-539 (Hepatology *Elsewhere*)

Testicular atrophy
Hypogonadism precedes liver feminization in chronic alcohol-fed male rats (Tadic et al). 2000;31:1135-1140
Insulin-like growth factor-1 reverts testicular atrophy in rats with advanced cirrhosis (Castilla-Cortazar et al). 2000;31:592-600

Th1 helper cells
Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse (Bocher et al). 2000;31:480-487

Thrombosis
Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors (Denninger et al). 2000;31:587-591
Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis (Amitrano et al). 2000;31:345-348

Tight junctions
Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis (Kawaguchi et al). 2000;31:1285-1295

Toll-like receptor
Kupffer cell activation by lipopolysaccharide in rats: Role for lipopolysaccharide binding protein and Toll-like receptor 4 (Su et al). 2000;31:932-936

Transferrin
Population screening for hemochromatosis: A comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors (Adams et al). 2000;31:1160-1164

Transforming growth factor-β
Modulation of transforming growth factor-β response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts (Dooley et al). 2000;31:1094-1106
The role of activin and transforming growth factor-β in the regulation of organ mass in the rat liver (Kogure et al). 2000;31:916-921

Transjugular intrahepatic portosystemic shunt
A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts (Malinchoc et al). 2000;31:864-871
Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding (Russo et al). 2000;31:358-363

Transmission electron microscopy
Microstructural evolution of lipid aggregates in nucleating model and human biles visualized by cryogenic transmission electron microscopy (Konikoff et al). 2000;31:261-268

Transplantation, liver
Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic tiver transplant recipients (Das). 2000;31:311-317
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation (Sanchez-Fuego et al). 2000;31:496-501
Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation (Zein et al). 2000;31:808-809 (Correspondence)
Influence of donor cardiopulmonary arrest in human liver transplantation: Possible role of ischemic preconditioning (Totsuka et al). 2000;31:577-580
Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation (Belli et al). 2000;31:1345-1350
Intragraft localization of activated nuclear factor κB in recurrent hepatitis C virus disease following liver transplantation (Gaweco et al). 2000;31:1183-1191
Iron overload in cirrhosis–*HFE* genotypes and outcome after liver transplantation (Brandhagen et al). 2000;31:456-460
Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: An outcome-oriented decision analysis (Majno et al). 2000;31:899-906
Surgical resection versus transplantation for early hepatocellular carcinoma:

Clues for the best strategy (Llovet et al). 2000;31:1019-1021 (Editorial)
Update of the international Banff schema for liver allograft rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection (Demetris et al). 2000;31:792-799 (Meeting Report)

Transport
Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis (Kawaguchi et al). 2000;31:1285-1295
Cloning and functional characterization of the bile acid sensitive methotrexate carrier from rat liver cells (Honscha et al). 2000;31:1296-1304
Effect of maternal cholestasis on bile acid transfer across the rat placenta-maternal liver tandem (Macias et al). 2000;31:975-983
Expression of aquaporin-4 water channels in rat cholangiocytes (Marinelli et al). 2000;31:1313-1317
Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver (Paulusma et al). 2000;31:684-693

***Trans*-reservatrol**
Deactivation of cultured human myofibroblasts by *trans*-reservatrol, a grapevine-derived polyphenol (Godichaud et al). 2000;31:922-931

Tryptophan
Glutathione, lactobionate, and histidine: Cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions (Upadhya and Strasberg). 2000;31:1115-1122

Tuberculosis treatment
Antituberculosis drug–related liver dysfunction in chronic hepatitis B infection (Wong et al). 2000;31:201-206

Tumor necrosis factor-α
Ethanol potentiates tumor necrosis factor-α cytotoxicity in hepatoma cells and primary rat hepatocytes by promoting induction of the mitochondrial permeability transition (Pastorino and Hoek). 2000;31:1141-1152
Fas- and tumor necrosis factor receptor 1-dependent but not perforin-dependent pathways cause injury in livers infected with an adenovirus construct in mice (Liu et al). 2000;31:665-673
Molecular mechanisms of tumor necrosis factor -stimulated leukocyte recruitment into the murine hepatic circulation (Fox-Robichaud and Kubes). 2000;31:1123-1127
The role of protein kinase B and mitogen-activated protein kinase in epidermal growth factor and tumor necrosis factor -mediated rat hepatocyte survival and apoptosis (Roberts et al). 2000;31:420-427
Tumor necrosis factor α down-regulates expression of the α1(1) collagen gene in rat hepatic stellate cells through a P20C/EBP- and C/EBP-dependent mechanism (Iraburu et al). 2000;31:1086-1093

Tyrosine
Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on Ras in human hepatic stellate cells (Carloni et al). 2000;31:131-140

U

Urotensin II
Urotensin II: Better than somatostatin for portal hypertension? (Newby and Jalan). 2000;31:1201-1202 (Hepatology *Elsewhere*)

Ursodeoxycholic acid
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid (Angulo et al). 2000;31:318-323
Urso–Panacea or placebo? (Neuberger). 2000;31:1027-1028 (Hepatology *Elsewhere*)

V

Vaccines
Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen (Rahman et al). 2000;31:521-527
Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C (Weidman et al). 2000;31:230-234
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation (Sanchez-Fuego et al). 2000;31:496-501
The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C (Myers et al). 2000;31:834-839

Varices, esophageal
Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding (Russo et al). 2000;31:358-363
Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices (Piscaglia et al). 2000;31:349-357
Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding (Gournay et al). 2000;31:1239-1245
Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis (Merkel et al). 2000;31:324-329
Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension (Escoresell et al). 2000;31:1061-1067

Vascular endothelial growth factor
Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells (Ankoma-Sey et al). 2000;31:141-148

Vasoconstriction
Local arterial vasoconstriction induced by octreotide in patients with cirrhosis (Chatila et al). 2000;31:572-576

Vasoregulation
The dual play of endothelin receptors in hepatic vasoregulation (Housset). 2000;31:1025-1026 (Editorial)

Veno-occlusive disease
Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat (Wang et al). 2000;31:428-434

Venous thrombosis
Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors (Denninger et al). 2000;31:587-591

Viral hepatitis
A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2–deficient mice (Brown et al). 2000;31:173-181
Amino acid sequence of EC2 domain in CD81 is highly conserved in Japanese subjects (Ito et al). 2000;31:544-545 (Correspondence)
A new step toward standardization of serum hepatitis C virus–RNA quantification in patients with chronic hepatitis C (Martinot-Peignoux et al). 2000;31:726-729
Activation of nuclear factor κB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis (Tai et al). 2000;31:656-664
Antituberculosis drug–related liver dysfunction in chronic hepatitis B infection (Wong et al). 2000;31:201-206
Association between hepatitis B virus infection and HLA-DR type in Korea (Ahn et al). 2000;31:1371-1373

Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen (Rahman et al). 2000;31:521-527
Characteristics of hepatitis C viral genome associated with disease progression (Nagayama et al). 2000;31:745-750
Chronic viral hepatitis and the human genome (Thio et al). 2000;31:819-827 (Concise Review)
Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy (Yeh et al). 2000;31:1318-1326
Clinical features of hepatitis C–infected patients with persistently normal alanine transaminase levels in the southwestern United States (Jamal et al). 2000;31:813 (Correction)
Clinical relevance of hepatitis B viral mutations (Hunt et al). 2000;31:1037-1044 (Concise Review)
Clonal expansion in evolution of chronic hepatitis to hepatocellular carcinoma as seen at an X-chromosome locus (Ochiai et al). 2000;31:615-621
Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b–related chronic hepatitis C (Pol et al). 2000;31:1338-1344
Comprehensive allelotype study of hepatocellular carcinoma: Potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors (Okabe et al). 2000;31:1073-1079
Cost-effectiveness of interferon alfa-2b and ribavirin in the treatment of chronic hepatitis C (Kim et al). 2000;31:807 (Letter); (Younossi et al). 2000;31:807-808 (Reply)
Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C (Weidman et al). 2000;31:230-234
Galectin-1 exerts immunomodulatory and protective effects on concanavalin A–induced hepatitis in mice (Santucci et al). 2000;31:399-406
Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis (De Vita et al). 2000;31:182-189
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage (De Francheschi et al). 2000;31:997-1004
Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong (Chan et al). 2000;31:763-768
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation (Sanchez-Fuego et al). 2000;31:496-501
Hepatitis C epidemiology: Injecting new tools in the field (Thomas). 2000;31:790-791 (Editorial)
Hepatitis C, interferon alfa, and depression (Zdilar et al). 2000;31:1207-1211 (Concise Review)
Hepatitis C virus and autoimmunity (Bogdanos et al). 2000;31:1380 (Correspondence)
Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells (Honda et al). 2000;31:1351-1359
Hepatitis C virus (HCV) infection and cryoglobulinemia: Analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology (Schmidt et al). 2000;31:737-744
Hepatitis C virus infection and lymphoproliferative disorders after liver transplantation (Zein et al). 2000;31:808-809 (Correspondence)
Host genetic factors influence disease progression in chronic hepatitis C (Powell et al). 2000;31:828-833 (Rapid Communication)
Immune therapy of hepatitis B virus chronic infection (Pol et al). 2000;31:548-549 (Correspondence)
Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation (Belli et al). 2000;31:1345-1350
Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes (Macejak et al). 2000;31:769-776
Inhibition of the cyclooxygenase/lipoxygenase pathways to improve interferon alfa efficacy in chronic hepatitis C: A wrong track (Bastie et al). 2000;31:547-548 (Correspondence)
In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance (Xiong et al). 2000;31:219-224
Intragraft localization of activated nuclear factor κB in recurrent hepatitis C virus disease following liver transplantation (Gaweco et al). 2000;31:1183-1191
Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial (Fontana et al). 2000;31:730-736
Is an "à la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? (Poynard et al). 2000;31:211-218
Lamivudine treatment for children with interferon refractory chronic hepatitis B (Kocak et al). 2000;31:545 (Correspondence)
Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B (Villeneuve et al). 2000;31:207-210
Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen (Marusawa et al). 2000;31:488-495
Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels (Calabrese et al). 2000;31:1153-1159
Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B (Erhardt et al). 2000;31:716-725
Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response (Sarrazin et al). 2000;31:1360-1370
Natural fluctuations of hepatitis C viral load in a homogeneous patient population: A prospective study (Fanning et al). 2000;31:225-229
Natural history of hepatitis C: Its impact on clinical management (Di Bisceglie). 2000;31:1014-1018 (Hepatology at the Millennium)
Nuclear factor κB and hepatitis C–Is there a connection? (Yen). 2000;31:785-787 (Editorial)
Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B E antibody-positive patients (Cotonat et al). 2000;31:502-506
Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women (Conte et al). 2000;31:751-755
Priming of hepatitis C virus-specific cytotoxic T lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA (Lee et al). 2000;31:1327-1333
Reactivity of 13 in vitro expressed hepatitis B surface antigen variants in 7 commercial diagnostic assays (Ireland et al). 2000;31:1176-1182

Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse (Bocher et al). 2000; 31:480-487
Risk factors for hepatitis C virus infection in United States blood donors (Murpy et al). 2000;31:756-762
Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus–infected patients (Di Martino et al). 2000;31:1030-1031 (Correspondence)
"Silent killer: or benign disease? The dilemma of hepatitis C virus outcomes (Hirsch and Wright). 2000;31:536-537 (Editorial)
Standardization of hepatitis C virus-RNA quantification: Advances and unfinished business (Gretch). 2000;31: 788-789 (Editorial)
Sublobular veins as the main site of lymphocyte adhesion/transmigration and adhesion molecule expression in the porto-sinusoidal-hepatic venous system during concanavalin A–induced hepatitis in mice (Morikawa et al). 2000;31:83-94
t(14;18) translocation in chronic hepatitis C virus infection (Zignego et al). 2000;31:474-479
The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C (Myers et al). 2000;31: 834-839
The cost of hepatitis A infections in American adolescents and adults in 1997 (Berge et al). 2000;31:469-473
The impact of diagnosis of hepatitis C on quality of life (Forman et al). 2000; 31:1029 (Letter); (Rodger et al). 2000;31:1029-1030 (Reply)
The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States (Armstrong et al). 2000;31:777-782
Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (*Marmota monax*) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans (Korba et al). 2000;31:1165-1175
Viral clearance in hepatitis C (1b) infection: Relationship with human leukocyte antigen class II in a homogeneous population (Fanning et al). 2000;31:1334-1337
Which patients with hepatitis C develop liver complications? (Khan et al). 2000;31:513-520

Viral load quantification

A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C (Martinot-Peignoux et al). 2000;31:726-729
Standardization of hepatitis C virus-RNA quantification: Advances and unfinished business (Gretch). 2000;31: 788-789 (Editorial)

W

Water channels

Expression of aquaporin-4 water channels in rat cholangiocytes (Marinelli et al). 2000;31:1313-1317

Wilson's disease

Treatment of Wilson's disease with zinc. XVII: Treatment during pregnancy (Brewer et al). 2000;31:364-370
Wilson's disease and pregnancy (Sternlieb). 2000;31:531-532 (Editorial)

Woodchuck hepatitis virus

Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection (Cote et al). 2000;31:190-200
Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (*Marmota monax*) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans (Korba et al). 2000;31:1165-1175

X

X-chromosome

Clonal expansion in evolution of chronic hepatitis to hepatocellular carcinoma as seen at an X-chromosome locus (Ochiai et al). 2000;31:615-621

Y

YMDD-motif

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy (Yeh et al). 2000;31:1318-1326

Z

Zinc

Treatment of Wilson's disease with zinc. XVII: Treatment during pregnancy (Brewer et al). 2000;31:364-370